NOTE: The compliance officer (or, the center CSO/Scientist, if the action was center-initiated) assigned to the administrative action should diligently pursue and actively monitor the progress of the case through the Agency review process to its conclusion. The Office of Strategic Planning and Operational Policy (OSPOP), Division of Enforcement (DE) can assist in situations where significant delays are experienced or assistance is needed to resolve technical, scientific, or policy issues. See also section on Ad Hoc Committees in Chapter 10.

For actions resulting from a Current Good Manufacturing Practice (CGMP) or Quality System (QS) inspection of a domestic or foreign drug, biologics, or medical device facility, the firm’s profile status information in the Field Accomplishment and Compliance Tracking System (FACTS) should be appropriately updated at each stage in the review process. See “Firm Profile Updates in FACTS” in Chapter 4 for more information.

This chapter contains the following sections.

Section Topic

5-1 CITATIONS ..................................................................................................................................... 4
5-1-1 Purpose ........................................................................................................................................ 4
5-1-2 Legal Authority .......................................................................................................................... 4
5-1-3 Citation Under Multiple Laws .................................................................................................... 4
5-1-4 Criteria For Citation ................................................................................................................ 4
5-1-5 Determining The Need For Citation ......................................................................................... 5
5-1-6 Time Frames ................................................................................................................................ 6
5-1-7 Citation Procedures .................................................................................................................. 6
5-1-8 Determination Of Citees ........................................................................................................... 8
5-1-9 Setting Date For Meeting .......................................................................................................... 8
5-1-10 Preparation Of Citation Documents ....................................................................................... 9
5-1-11 Distribution Of Citation Documents ....................................................................................... 11
5-1-12 Transfer of Meeting ................................................................................................................ 12
5-1-13 Correspondence With Attorneys ............................................................................................. 13
5-1-14 Drug Advertising Citations .................................................................................................... 13
5-2 SECTION 305 MEETING ........................................................................................................ 14
5-2-1 Purpose ............................................................................................................................... 14
5-2-2 Authority ............................................................................................................................. 14
5-2-3 Preparation ......................................................................................................................... 14
5-2-4 Respondents’ Request For Special Information................................................................. 15
5-2-5 Conducting The 305 Meeting .............................................................................................. 15
5-2-6 Procedures After Meeting ................................................................................................... 23
5-3ADMINISTRATIVE DETENTION OF FOODS ................................................................................... 24
5-3-1 Purpose ............................................................................................................................... 24
5-3-2 Background ......................................................................................................................... 24
5-3-3 Issuing and Terminating Detention Orders ......................................................................... 26
5-3-4 Appeal of a Detention Order ............................................................................................... 36
5-3-5 Informal Hearing on Appeal of a Detention Order ............................................................. 43
5-3-6 Issuing the Decision on an Appeal ...................................................................................... 46
5-3-7 Administrative Record and FOIA Requests ......................................................................... 48
5-4 DETENTION OF FOODS – OTHER STATUTORY AUTHORITY ......................................................... 48
5-4-1 Purpose ............................................................................................................................... 48
5-4-2 Authority ............................................................................................................................. 49
5-4-3 Criteria For Effecting And Terminating Detentions ............................................................ 50
5-5 ADMINISTRATIVE DETENTION OF DRUGS ................................................................................... 51
5-5-1 Purpose ............................................................................................................................... 51
5-5-2 Background ......................................................................................................................... 51
5-5-3 Issuing and Terminating Detention Orders ......................................................................... 53
5-5-4 Appeal of a Detention Order ............................................................................................... 63
5-5-5 Informal Hearing on Appeal of a Detention Order ............................................................. 69
5-5-6 Issuing the Decision on an Appeal ...................................................................................... 72
5-5-7 Administrative Record and FOIA Requests ......................................................................... 73
5-6 ADMINISTRATIVE DETENTION OF DEVICES ................................................................................. 74
5-6-1 Purpose ............................................................................................................................... 74
5-6-2 Detention of Devices ........................................................................................................... 75
5-6-3 Appeal Of A Detention Order ............................................................................................. 81
5-6-4 Informal Hearing On Appeal Of A Detention Order ........................................................... 85
5-6-5 Requirements After A Hearing On Appeal Of A Detention Order ..................................... 87
5-7 LICENSE REVOCATION OR SUSPENSION ..................................................................................... 89
5-7-1 Purpose ............................................................................................................................... 89
5-7-2 General ............................................................................................................................... 89
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-7-3</td>
<td>General Considerations for Revocation</td>
<td>90</td>
</tr>
<tr>
<td>5-7-4</td>
<td>Issues Not Supporting License Revocation</td>
<td>91</td>
</tr>
<tr>
<td>5-7-5</td>
<td>Revocation Procedures</td>
<td>92</td>
</tr>
<tr>
<td>5-7-6</td>
<td>General Considerations For Suspension</td>
<td>94</td>
</tr>
<tr>
<td>5-7-7</td>
<td>Suspension Procedures</td>
<td>95</td>
</tr>
<tr>
<td>5-8</td>
<td>ORDERS OF RETENTION, RECALL, DESTRUCTION AND CESSATION OF MANUFACTURING RELATED TO HUMAN CELL, TISSUE AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps)</td>
<td>97</td>
</tr>
<tr>
<td>5-8-1</td>
<td>Purpose</td>
<td>97</td>
</tr>
<tr>
<td>5-8-2</td>
<td>Background</td>
<td>97</td>
</tr>
<tr>
<td>5-8-3</td>
<td>General Considerations</td>
<td>99</td>
</tr>
<tr>
<td>5-8-4</td>
<td>Procedures for Orders of Retention, Recall, or Destruction of HCT/Ps</td>
<td>99</td>
</tr>
<tr>
<td>5-8-5</td>
<td>Follow-Up to Orders of Retention, Recall, or Destruction</td>
<td>101</td>
</tr>
<tr>
<td>5-8-6</td>
<td>Procedures for Orders of Cessation of Manufacturing</td>
<td>102</td>
</tr>
<tr>
<td>5-8-7</td>
<td>Follow Up to Orders of Cessation of Manufacturing</td>
<td>104</td>
</tr>
<tr>
<td>5-8-8</td>
<td>Part 16 Hearing</td>
<td>104</td>
</tr>
<tr>
<td>5-9</td>
<td>CIVIL MONEY PENALTIES AND NO-TOBACCO-SALE ORDERS</td>
<td>105</td>
</tr>
<tr>
<td>5-9-1</td>
<td>Civil Money Penalty Authorities</td>
<td>105</td>
</tr>
<tr>
<td>5-9-2</td>
<td>Reduction Of Civil Money Penalties For Small Entities</td>
<td>112</td>
</tr>
<tr>
<td>5-9-3</td>
<td>Civil Money Penalty Recommendations</td>
<td>112</td>
</tr>
<tr>
<td>5-10</td>
<td>DISQUALIFICATION OF CLINICAL INVESTIGATORS</td>
<td>113</td>
</tr>
<tr>
<td>5-10-1</td>
<td>Purpose</td>
<td>113</td>
</tr>
<tr>
<td>5-10-2</td>
<td>Criteria for Initiating Disqualification Proceedings</td>
<td>114</td>
</tr>
<tr>
<td>5-10-3</td>
<td>Initiating the Disqualification Process</td>
<td>114</td>
</tr>
<tr>
<td>5-10-4</td>
<td>Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE)</td>
<td>115</td>
</tr>
<tr>
<td>5-10-5</td>
<td>Consent Agreements</td>
<td>116</td>
</tr>
<tr>
<td>5-10-6</td>
<td>Informal Conference with the Clinical Investigator</td>
<td>116</td>
</tr>
<tr>
<td>5-10-7</td>
<td>The Notice of Opportunity for Hearing (NOOH)</td>
<td>117</td>
</tr>
<tr>
<td>5-11</td>
<td>EXHIBITS</td>
<td>120</td>
</tr>
</tbody>
</table>
5-1 CITATIONS

5-1-1 Purpose
This section describes the Food and Drug Administration's (FDA) procedures for issuing Section 305 Notices (21 USC 335).

5-1-2 Legal Authority
FDA issues Citations under Section 305 of the Federal Food, Drug, and Cosmetic Act (the Act or the FFDCA), which states:

"Before any violation of this Act is reported by the Secretary to any United States attorney for institution of a criminal proceeding, the person against whom such proceeding is contemplated shall be given appropriate notice and an opportunity to present his views, either orally or in writing, with regard to such contemplated proceeding."

21 CFR 7.84 provides requirements about the issuance of such notice and opportunity.

NOTE: Citation is to be used only when a prosecution recommendation is contemplated. Do not use a Citation for warning purposes.

5-1-3 Citation Under Multiple Laws
On occasion, the same or related conduct that violates the Act may also constitute a violation of one or more other federal laws, such as the licensing provisions for biologics under the Public Health Service Act (42 U.S.C. Section 262), 18 U.S.C. Section 1001 (Fraud and False Statements), and 18 U.S.C. Section 371 (Conspiracy to commit offense or to defraud United States).

In such a case, identify the section of each law under which action is contemplated, and the specific actions considered to violate that law.

5-1-4 Criteria For Citation
The basic criteria for consideration of citation are as follows:

- A violation of the law has been established and the Agency has evidence in its possession to support the case in court.
- The violation is significant in terms of consumer protection.

Except in cases involving a health hazard, fraud, or extremely gross violations, prior warning must have been given to the firm and each individual involved. This prior warning may be in the form of conferences, previous meetings, letters, or discussions of FDA 483s at the conclusion of inspections or previous court actions. See RPM Chapter...
for a discussion of Prior Notice. In instances where the prior warning was in the form of letters or a Section 305 Notice involving past violations, copies must have been directed to each individual to be cited.

NOTE: Additional, more specific criteria in many areas may be found in Compliance Policy Guides (CPGs) and the Compliance Program Guidance Manual (CPGM).

### 5-1-5 Determining The Need For Citation

The division compliance branch is responsible for deciding whether citation is warranted. The compliance officer assigned to the case should ensure that all samples and other evidence have been considered. The search for other samples and evidence may include:

1. Searching the Field Accomplishments and Compliance Tracking System (FACTS) for further information on the firm;
2. Checking with the laboratory to find out if there are other samples that are in-process and need to be analyzed;
3. Checking the collection report (C/R) on the initial sample to ensure that all related samples are attached; and,
4. Checking outstanding sample assignments in FACTS.

If there are other samples to be analyzed or the establishment inspection report has not been completed, and seizure has not yet been considered, you may wish to defer action until the entire case can be considered at one time. In such instances, discuss the matter with investigations branch and/or the laboratory to expedite processing of the report or the samples.

Conduct a thorough review of the evidence. For example, review the firm's regulatory history to determine who was responsible for the violations and whether prior warning has been given. Review inspection reports to ensure that any inspectional observations that are inconsistent with analytical results are addressed. Ensure that reserve samples are available, where required. In labeling violations, search the file to determine whether the firm has revised the labeling since the shipment of the samples in question.

A citation may be based solely on establishment inspection evidence. A minimum of two documentary samples covering violative products is desirable.

**NOTE:** Under normal circumstances, notice and an opportunity to present information and views will always be given before violations are reported for criminal prosecution. However, there are certain circumstances under which notice and opportunity need not be provided. Notice and opportunity need not be given when there is reason to believe that alerting the prospective defendants by a Section 305 Notice may result in the destruction of evidence or cause the proposed defendants to flee to avoid prosecution.
(21 CFR 7.84(a)(2)). In addition, notice and opportunity need not be given when further investigation by the Department of Justice is contemplated. (21 CFR 7.84(a)(3)).

Such situations are infrequent and should be approved on a case-by-case basis. Submit the facts to the center and request concurrence from the center, Office of Strategic Planning and Operational Policy (OSPOP), and the Office of Chief Counsel (OCC) when you do not believe providing notice and an opportunity for presentation of views is appropriate.

5-1-6 Time Frames

All timeframes are in calendar days unless specified otherwise.

The following time frames apply to citations:

1. Division: fifteen (15) working days after analysis of most recent sample involved in case.
2. Center: fifteen (15) working days after receipt of the recommendation.

There may be good reasons for exceeding these timeframes in a particular case. For example, analytical procedures may be lengthy, or there may be a need to obtain assistance from other divisions to establish responsibility. Document the reasons for delays in the case file.

5-1-7 Citation Procedures

1. Prior Consultation with the Office of Criminal Investigations (OCI)

   The Office of Criminal Investigations (OCI) is responsible for reviewing all matters in FDA for which a criminal investigation is recommended, and is the focal point for all criminal matters.

   FDA personnel must refer all criminal matters, regardless of their complexity or breadth, to OCI. This includes criminal search warrants, misdemeanor prosecutions, and citations.

   Division management must communicate with its local OCI office before pursuing any criminal matter. This communication is absolutely essential to preclude potential interference with other on-going criminal investigations and to prevent confusion among the components of OCC and the Department of Justice that are responsible for handling FDA’s criminal cases. During this communication, OCI is to be provided with all the facts of the potential case and any additional information that is relevant to, or could impact, the case in any way. OCI will decide promptly whether or not it is interested in pursuing the case and will communicate that decision to the division.
If OCI chooses not to pursue a criminal matter, the division office, after considering the reasons for the declination, is at liberty to proceed with the case in accordance with the procedures in this chapter.

2. Authorization To Cite

Citation may issue either on a direct basis or after the submission of a recommendation to the appropriate center and receipt of concurrence to issue the Section 305 Notice.

It is incumbent upon the office issuing the Section 305 Notice to ensure that the firm and each individual to be cited have received prior warning, unless such warning is not required.

a. Direct Citation

CPGs give division offices authority to issue Section 305 Notices in cases where specific criteria are met. Most of these guidelines involve filth violations or noncompliance with standards. Check the CPG manual each time the division office believes citation is the action of choice to preclude submitting unnecessary recommendations to a center.

b. Citation Recommendation

Where the division office does not have direct citation authority, it should submit a citation recommendation to the appropriate center for approval.

The recommendation should include:

- the full background of the case,
- the history of notification,
- the facts supporting the violation(s) for which prosecution is being considered,
- the names and responsibilities of each individual to be cited,
- the proposed charges,
- the supporting samples,
- any labels, worksheets, and pertinent inspection reports, and
- any issues, concerns, discrepancies, or other problems with the case.

The recommendation package should be well-organized, tabbed, and indexed. The recommendation should identify the location of supporting information it discusses. Interstate (IS) documentation remains the responsibility of the divisions and need not be submitted. However, the center may request IS documentation if there is a special need to review it.
c. Citation Recommendation After or Concurrently with Seizure

When the division follows a seizure action with a citation recommendation based on the same underlying violations, it is acceptable to submit a memorandum that references information in the seizure recommendation, provided that the center has all of the labeling and other documents necessary to consider the citation.

When the division office is recommending citation at the same time it is recommending seizure, flag the recommendation memorandum as "Seizure and Citation Recommendation."

5-1-8 Determination Of Citees

1. Corporations, Partnerships, and Associations

Corporations, partnerships, and associations are "persons" under the Act, and may be prosecuted as separate legal entities. They should always be included in the citation.

2. Individuals

In every case, carefully consider citing individuals. Prior warning is a prerequisite except where the violation involves a danger to health, fraud, or where the violation is extremely gross.

It is FDA procedure to cite officers of corporations and members of partnerships and associations, when the available evidence establishes that the individual stood in a "responsible relationship" to the violation. As the U.S. Supreme Court stated in U.S. v. Park: "The Act imposes not only a positive duty to seek out and remedy violations when they occur but also, and primarily, a duty to implement measures that will insure that violations will not occur."

Persons who have the power and authority, and therefore the responsibility, to carry out these duties and fail to do so are logical candidates for citation. Obtain the type of information needed to demonstrate responsibility from observations reported by the investigators, through correspondence and/or memoranda of conferences with the individuals, or through other means. In addition, if there is a need, obtain information from officers and individuals located at a parent plant, as well as persons at the inspected plant.

5-1-9 Setting Date For Meeting

If the firm and individuals to be cited are located within a reasonable proximity of the office in which the meeting is to be held, schedule the meeting for approximately ten (10) days after issuing the Section 305 Notice. If the citees must travel extensive
distances or wish to have a corporate attorney in attendance, or the violations involved are complex, schedule the meeting approximately twenty (20) days after issuing the Section 305 Notice.

When there are multiple citees, schedule a separate meeting for any citee who requests one in writing. The meeting may be held at a separate time on the same date or on a separate date. The citee must submit the request to the office that issued the Section 305 Notice, and the request must be received at least three (3) working days before the date set in the notice.

5-1-10 Preparation Of Citation Documents

1. Section 305 Notice (Exhibit 5-1)

Insert the division address under the printed heading "Food and Drug Administration." Under the caption at the right, "In reply refer to," insert the key or file reference sample number for the action, and "et. al." if there are several samples involved. If there is only one product or class of products, such as "drugs," bakery products," etc., identify the product directly below the reference sample number. The complete list of samples will appear on the Charge Sheet along with the respective products. See Exhibits 5-2 and 5-3 for examples of charge sheets.

Enter the date that Notice issues directly above the rectangle on "Section 305 Notice" or centered under the city and state of the division's address.

In the space for addressee, insert the name and address of the firm or sole owner cited (primary citee). When the citation also names responsible individuals, address it in the following manner:

Standard Pharmaceutical Co.
and Mr. Henry Jones
and Mr. John Doe
125 Main Street
Canton, Ohio 28531

(Do not show titles of individuals listed as citees.)

In the body of the Notice, following the phrase "with respect to the following," enter clear, concise statements identifying the specific interstate shipment and product for each sample on which citation is issuing. In each statement include

- the name of the product,
- sufficient quotation from the label to identify the brand, size, etc.,
- the date of shipment,
- where the shipment originated, and
- where and to whom it was consigned.
When there is more than one sample, show sample numbers in parenthesis following the description of each shipment. If there is insufficient space on the form to enter the samples and shipments involved, enter the notation "See Page 2" conspicuously in the body of the Notice and continue the additional information regarding the samples on a separate page captioned as follows: "Page 2 - Section 305 Notice".

**NOTE:** When charging violations involving items other than shipments, include a concise factual statement of the violations. See Exhibits.

Following the words, "A meeting has been scheduled for," insert the day, date, specific time and location of the meeting. Add any other information that may facilitate the citee's appearance in parentheses following this statement (e.g., availability of parking near the building).

Type the name of the Compliance Officer who will conduct the meeting at the bottom of the form and have that individual sign the copies mailed to the firm and each individual cited.

If individuals have been cited along with the firm, show distribution on all copies of the Notice under the parenthetical statement: "(IMPORTANT: NOTE ALL ENCLOSURES CAREFULLY)" such as: 1 cc to Mr. John Doe and to Mr. Robert Roe each with Charge Sheet and Information Sheet.

2. Charge Sheet (Form FDA 1854) ([Exhibit 5-2](Exhibit 5-2))

Use Form FDA 1854 (Model Charge Sheet [Exhibit 5-2](Exhibit 5-2)). Under the title, list each sample and product in ascending numerical order. If the list of samples is long, arrange it in two columns.

Under the heading "PROHIBITED ACT" state the section(s) of the law(s) violated and the statutory description from the law. In charges involving Title 18 or Title 42, cite those laws.

At the left of the sheet, following the above paragraph type the word "CHARGES". If only one sample and charge are involved, enter the statement "The article is violative in that" followed by the non-legal description of the violation. In the case of multiple charges, enter the statement: "The article is violative in the following respects:" and list each charge separately, numbered as "1," "2," "3," etc.

When a number of samples and charges are involved, use the statement "The articles are violative in the following respects:" and list the charges as described above. Show the sample numbers involved at the left of each charge.
State the charges in "lay language." There is no need to reference specific sections of the Act (other than the "Prohibited Act") or the regulations. Exhibit 5-3 contains examples of charges.

3. Legal Status Sheet (Form FDA 454) (Exhibit 5-4)

Use Form FDA 454. Exhibit 5-4 Legal Status Sheet. Enter the sample numbers involved in the citation in the upper right hand side of the form following the caption "Sample No."; and the date(s) of the alleged violations over the "(Date)" caption following line "A." If more than two dates are involved, show the earliest and latest dates only; for example, "3/3/94 thru 4/12/94." The division office makes no other entries.

4. Information Sheet (Form FDA 466a) (Exhibit 5-5)

Use Form FDA 466 (Exhibit 5-5 Information Sheet) This form describes the purpose and nature of the meeting. It is not necessary to type any information on the form; however, it is mandatory that this form accompany the Section 305 Notice sent to each individual cited.

5-1-11 Distribution Of Citation Documents

1. Distribute the Section 305 Notice, Charge Sheet, Legal Status Sheet, and Information Sheet as follows:

   a. Send a signed, original copy of the Section 305 Notice, a Charge Sheet, an Information Sheet, and a Legal Status Sheet to the primary citee (generally the firm).

   b. Send a signed copy of the Section 305 Notice, a copy of the Charge Sheet, and an Information Sheet, to each of the other citees, if it is a joint citation.

   c. Forward one copy of the Section 305 Notice, together with one copy of the Charge Sheet, to the factory file, the reading file, and, if applicable, to the division resident post.

   d. Retain three copies of the Section 305 Notice and the Charge Sheet in the Division Sample File for use when making a recommendation for disposition of the charges.

2. Mailing Instructions

   Mail the Section 305 Notice in a regular, letter size envelope with the typed name and address of the citee. Do not use window envelopes. When individuals are cited along with a firm, circle or underline their names on their respective copies and mail each citee's copy in a separate envelope. Where the interests of the individual citees may be at odds, you may send the individual notices to the home addresses of the citees.
Send the Section 305 Notice by certified mail with return receipt requested or by other method with proof of receipt.

3. Postponement of Meetings

Divisions may grant a reasonable postponement of a meeting upon written request by a citee or person representing a citee (see exception below). The length of the postponement will depend on particular circumstances but should avoid excessive delay. Confirm the new date by a letter to the citee or representative who requested the postponement. Provide an information file copy to the center.

**Exception:** If an office in headquarters directed that the meeting be scheduled within a certain time frame, do not agree to postponements without first consulting with that office.

5-1-12 Transfer of Meeting

Occasionally citees will request a transfer of the scheduled meeting to another city in the division area, to another division office, or to Washington headquarters. The citee also has the option of answering by other means when personal appearance at the division headquarters is impractical.

1. Transfer Within Division Area

Do not grant requests for transfer of the meeting to another city in the division area. The cost to the public of holding the meeting in another city outweighs any benefit or convenience to the citee.

2. Transfer to Another Division

A request to transfer a meeting to another division may be granted if reasonable grounds are presented, the request is addressed to the office that issued the Section 305 Notice, and the request is received in that office at least three (3) working days prior to the date set in the notice. See 21 CFR 7.84(e). However, before granting the request to transfer the meeting, check with the division involved to make sure it agrees to the meeting.

Once the request is granted, verify the transfer by letter to the citee. Send copies of the letter to the new division with these attachments:

- a. complete file on the samples involved
- b. pertinent Establishment Inspection Reports (EIRs)
- c. a FACTS printout of firm's record, if pertinent to the case

The home division should establish a temporary jacket as a record of the transfer. The transferee division will reschedule the meeting promptly and advise accordingly. This may be done by letter with reference to the original
Section 305 Notice and to the letter approving transfer from the original division. Forward copies to the home division.

After the meeting, send the Record and any exhibits to the home division along with the original files.

Prepare a skeleton sample jacket or electronic file containing a copy of the Record, transcripts (if any), and copies of any collateral correspondence that may have issued on the case.

3. Transfer to Headquarters

Discourage requests by citees, before or during the meeting, to transfer the meeting to headquarters.

If, however, the citee insists that the meeting be held at headquarters, refer the request to the center involved. If granted, the center will inform the citee and home division of the new date set for the meeting. The division should then promptly forward the case file to the center for review and use during the meeting. The center will return the case file with the Record to the home division for disposition of the charges.

5-1-13 Correspondence With Attorneys

Attorneys representing clients who received a Section 305 Notice will often correspond with the division compliance officer regarding the Section 305 Notice. Because the issuance of a Section 305 Notice is confidential and generally not releasable to the public until all potential criminal matters are resolved, division compliance officers are responsible for ensuring that representatives of the citee provide appropriate documentation regarding their authorization. See 21 CFR 7.84(g).

It is not necessary to send citees copies of correspondence from their attorneys. However, when a citee is identified as having received a copy of the citee’s attorney’s correspondence, and we have responded to that correspondence, you may wish to send the citee a copy of our response.

5-1-14 Drug Advertising Citations

Due to the specialized nature of medical advertising, the Office of Prescription Drug Promotion (OPDP), Center for Drug Evaluation and Research (CDER) is the primary reviewer of drug advertisements. With few exceptions, OPDP will initiate citations based on violative drug advertisements.

After determining that an advertisement is violative and that citation is warranted, OPDP may initiate a request for samples to support an action. Samples that are obtained are routed to the home division of the responsible firm.
OPDP will prepare citation instructions for issuance by the appropriate division. The instructions will specify whether the meeting is to be held at the division office or at headquarters. In most cases, meetings are held at headquarters.

The division will issue the Section 305 Notice in the normal manner, with a copy to OPDP. Following the meeting, OPDP will make a decision on the disposition of the charges and notify the division of that decision.

5-2 SECTION 305 MEETING

5-2-1 Purpose

This section summarizes the authority and procedures pertaining to the opportunity, under Section 305 of the Act, for a person to present their views before criminal prosecution is recommended to a United States Attorney.

5-2-2 Authority

The Secretary of Health and Human Services delegates broad authority to the Commissioner of Food and Drugs, and, unless specifically prohibited, gives the Commissioner the authority to redelegate this authority. Division Directors, Program Directors, and Directors and Deputy Directors of the centers, are authorized under the redelegations to designate officials to hold hearings under section 305 of the Act.1 A Compliance Officer has authority to hold Section 305 meetings by such designation.

21 CFR 7.85 provides requirements about the conduct of such meetings.

5-2-3 Preparation

Except in unusual circumstances, the Compliance Officer who holds the meeting is the individual who issued the Section 305 Notice. As there is normally a time lapse between the issuance of the Section 305 Notice and the meeting date, the Compliance Officer should review the case immediately prior to the meeting. The Compliance Officer will need to be completely familiar with the charges, the law and regulations, and fully understand any analytical results and methodology that are part of the case (if necessary, through discussion with the analyst).

The Compliance Officer should assemble any necessary references, such as the Act, regulations, official compendia, etc. The Compliance Officer may also wish to mark or photocopy pertinent information in the files to avoid searches for data during the meeting. Such information may include records relating to samples, EIRs, and FDA

1 Delegation of authority information is available on the Internet at [www.fda.gov/aboutfda/reportsmanualsforms/staffmanualguides](http://www.fda.gov/aboutfda/reportsmanualsforms/staffmanualguides).
483s, and documents relating to prior warnings to the firm or individuals in the form of citations, seizures, prosecutions, office interviews, letters, etc. To avoid the need to reread all of the material, it is best to organize this information at the time of the initial review, when preparing the Section 305 Notice.

5-2-4 Respondents’ Request For Special Information

Respondents, their attorneys, and others occasionally attempt to obtain detailed information concerning the government’s case. Such requests constitute requests for information under the Freedom of Information Act (FOIA). Point out that under the FOIA, they must submit requests in writing to the Director of FDA's Division of FOI. Refer the requester to FDA’s Freedom of Information page and mention that the request must be processed according to law and FDA’s procedures. For example, FDA’s Associate Commissioner for External Affairs might determine that some or all of the information about FDA’s case may be withheld from disclosure under 21 CFR 20.62 (pre-decisional information, attorney work product, etc.) and/or 21 CFR. 20.64 (open investigatory, personal privacy, confidential source, etc.).

NOTE: If a respondent requests a portion of a sample, follow the procedures set forth in 21 CFR 2.10(d) and 2.10(c).

5-2-5 Conducting The 305 Meeting

Respondents are occasionally quite upset due to the receipt of the Section 305 Notice and may tend to be discourteous or argumentative. The 305 meeting is not a debate and nothing can be gained by the Compliance Officer losing objectivity or by the respondent becoming abusive. The Compliance Officer should politely point out that the proceedings are not a trial but rather an opportunity for the respondents to give their side of the story and discuss any mitigating circumstances, corrective actions taken or planned, etc., and that FDA will consider this information when deciding whether or not to forward the case to the Department of Justice for the institution of criminal proceedings.

Do not make an unofficial audio or video recording of the meeting or permit any attendee to make an audio or video recording, without obtaining documentation from OCC that it is permissible. If an official transcript is desired, see 11(c) below.

The Compliance Officer should strive for continuity and relevancy. Some respondents may digress into time-consuming, irrelevant or repetitious discussion unless there is a diplomatic effort to focus upon relevant matters. Listed below is a suggested routine format for achieving orderly progress during the meeting:

1. Identification of Respondents

   After the respondents have been introduced and seated, make notes showing the name, address, position, and business connection of each respondent.
The notes are for ready reference during the meeting and useful during the dictation of the record.

2. Failure of Respondent To Appear

Frequently, a cited individual does not attend the meeting. Determine if anyone present purports to represent such respondent and enter any responses into the record.

Designated representative(s) must have a signed written statement of authorization for each respondent for whom he/she has authority to act. If a representative appears without written authorization, the meeting may proceed with respect to any respondent for whom the representative appears, only if the Compliance Officer first verifies by telephone, or other appropriate means, the authenticity of the representative’s authority. See 21 CFR 7.84(g).

3. Attendance by Individuals Not Cited

Occasionally, an individual who was not named in the Section 305 Notice will appear and, during the course of the meeting, it will become apparent that the person shares the responsibility for the violation. In such instances, request a short delay and have the legal clerk prepare a supplemental Section 305 Notice including the individual's name, present it to him/her, and proceed with the meeting.

Respondents may arrive at a meeting accompanied by adherents. When this situation occurs, the Compliance Officer should have each person identify themselves by name, state their relationship to the respondent, and, for the record, state that they are attending on behalf of the respondent. The Compliance Officer should then announce to the group that the meeting is not open to the public, that it concerns only the respondent, and that the only legitimate business other persons have in being there is that they are there at the request of, and on behalf of, the respondent; otherwise, they may not be present.

Afterwards, the Compliance Officer will hear comments from all persons remaining present.

If these actions are not taken, the respondent may claim that FDA deprived him/her of his/her rights to fully respond and explain.

4. More Than One Respondent

Requests for separate meetings should be in writing and should be received at least three (3) working days before the date set in the notice. 21 CFR
7.84(e). However, if there is more than one respondent, advise the respondents in advance that they are entitled to separate meetings if they so wish.

5. Legal Status Sheet, Form FDA 454 *(Exhibit 5-4)*

Ask for the Legal Status Sheet. The respondent may complete the sheet before or at the meeting. However, you may not demand completion or submittal of the sheet since there is no legal requirement that respondents furnish the sheet.

6. Explain The Purpose Of The Meeting And The Charges

Although the Information Sheet (*Exhibit 5-5*), which accompanies the Section 305 Notice and Charge Sheet, contains information concerning the reason for the notice, the Compliance Officer should reiterate the purpose of the notice prior to the discussion of the charges and advise the respondents that:

a. The meeting is being held in accordance with Section 305 of the Act to give them an opportunity to present any facts they believe are relevant prior to the FDA making its decision whether to recommend prosecution to the Department of Justice; and

b. The purpose of the meeting is not to resolve conclusively whether violations occurred, and therefore FDA will not present either witnesses or evidence at the meeting.

The Compliance Officer should briefly state the information in the FDA's possession, which indicates that violations of the Act (and other laws, if pertinent) occurred and that the individuals listed in the Section 305 Notice were responsible, either through their actions or their failure to take action. This may be by reference to the pertinent inspections, FDA 483s, warning letters etc., to provide a brief summary of the relevant time and acts. Request that the respondents follow their copies of the Section 305 Notice and Charge Sheet as the Compliance Officer either reads verbatim or summarizes the pertinent information concerning the shipment or receipt of each product and the charges pertaining to it, or the acts that constitute violations.

The Compliance Officer should ask the respondents whether they understand the charges. If the response is negative, answer any questions to ensure that the respondent understands the basis of the allegations. If the respondent indicates that the shipping or receiving dates are incorrect, clarify the discrepancies. If they indicate that they will make no admissions with regard to the shipment or receipt of the products, do not pursue the matter.
7. Miranda Warning

In the past, there were questions regarding whether the Compliance Officer needs to give the "Miranda Warnings" prior to conducting a Section 305 meeting. They are not to be given.

In *Miranda v. Arizona*, the court ruled that when an individual is taken into custody or otherwise deprived of his freedom and subjected to questioning, the person must be notified of his right to remain silent, that anything he says may be used against him, and that he has the right to an attorney. This warning does not apply to Section 305 meetings because a respondent to a Section 305 Notice is not "taken into custody or otherwise deprived of his freedom." In addition, even though not required, FDA notifies the respondents (Exhibit 5-5) that they are not compelled to answer and that an attorney may represent them. In 1976, in *Beckwith v. United States*, the Supreme Court held that even when the investigation has "focused" on an individual, he is not entitled to Miranda warnings unless he is in custody. In *Oregon v. Mathiason*, decided in January 1977, the Supreme Court held that a meeting at which the individual was free to leave did not require Miranda warnings.

8. Respondents' Statement

After discussing the purpose for the meeting and the charges, the Compliance Officer should invite the respondents to state their views with respect to the alleged violations. Take notes regarding the various points covered by the respondents to ensure that pertinent comments are not inadvertently omitted when the summary is dictated.

Occasionally respondents appearing at a meeting present a prepared written response. In such instances the Compliance Officer should, if practical, read the written response aloud while the respondents follow their copies. The Compliance Officer should ask questions regarding any points that need clarification. In the dictation of the meeting summary, refer to the written response, which will be attached to the record as an exhibit, indicate that it was read aloud in the presence of the respondents, and include in the dictation only information concerning the points discussed for clarification.

Each respondent may present any information bearing upon the issues. This may consist of proposed or revised labeling, letters, laboratory data, sanitation contracts, etc. Identify each exhibit submitted by respondents at the meeting with the related sample number, date received, and the Compliance Officer’s initials. Place the identification at the top right hand corner of the exhibit, if it is possible to do so without obscuring any material.

Respondents may request that the Compliance Officer comment on the adequacy of the proposed corrections. Unless headquarters provided specific
instruction, refrain from commenting, and explain that comments may be provided after careful consideration of the submitted material and that it may involve headquarters review. Advise the respondents that the information will be included in the record as an exhibit.

9. Ensure Scope of Respondents' Responsibility

Usually respondents demonstrate their responsibilities while expressing their views with respect to the alleged violations. Normally, they express responsibilities in the form of comments such as "I hired extra men for sanitation" or "I ordered the destruction of the merchandise" etc.

If there are any doubts about the responsibility of any of the respondents, ask questions to ensure that you are not including individuals in a criminal proceeding who lack the authority to detect, prevent or correct violations. For example, ask who had the authority to change pest control firms or consulting laboratories, who hires or discharges employees for sanitation or quality control work, who directs labeling changes, and who expends monies for structural repairs and the purchase of new equipment, etc.

In addition to the responsibility of those who appear, the Compliance Officer may need to make inquiries regarding the responsibilities of an individual listed in the Section 305 Notice who does not appear. This could be particularly important in cases where officials of a company at a location other than the one inspected have been cited, but do not appear at the meeting.

10. Guaranties

Unless a respondent voluntarily includes as part of his presentation a guaranty related to the violations, explore thoroughly the question of whether one exists. Otherwise, the respondent may overlook the fact that he/she had a guaranty, until he/she or his/her attorney eventually presents it as a defense at trial.

If a respondent requests information regarding guaranties so that he/she may obtain them in the future, furnish a copy of 21 CFR 7.13.

If the respondent presents a guaranty at the meeting, do not comment upon its validity. Tell the respondents that the validity of the guarantee will be reviewed after the meeting.

11. Summary

At the conclusion of the meeting, the Compliance Officer will create an accurate summary of the meeting in the presence of the respondents, or at
their option, immediately after their departure. The respondents, for a variety of reasons, may wish to leave the meeting before the summary is completed, and should be afforded that option. In that event, a draft copy of the summary should be forwarded to the respondents, requesting their comments within ten (10) days, and explaining that without benefit of comment the record will stand as drafted. In the event respondents remain, they should be offered an opportunity to provide additional comments or corrections. Inform the respondents that if they disagree with, or wish to clarify, any of the statements they may do so after completion of the summary.

If respondents undertake to have long or irrelevant statements included in the summary, tactfully suggest that they may wish to submit a statement after the meeting, and that the statement will be included as an attachment to the Record. 21 CFR 7.85(g).

a. Required Statements

The Summary should always contain statements to the effect that:

i. The purpose of the meeting was discussed with the respondents and they understood that it was being held pursuant to Section 305 of the Act;

ii. The charges were discussed with the respondents and they understood them;

iii. The respondents indicated that the shipments had been made, or received, as alleged. (If not admitted, or they have reservations, this information should be included);

iv. Information concerning the statements each respondent made concerning his scope of authority (responsibility) at the firm;

v. The respondents were asked if they had any corrections or comments to make (followed by their statements or a comment in the record that they had none);

vi. Copies of the Summary will be forwarded to the respondents; and,

vii. (In the final section of the record) that the Summary was dictated in the presence of the respondents and when asked if they felt that it accurately and fairly summarized the discussion they indicated that it did (or did not in the following respect). If the respondents elected not to remain for the finalization of the summary, the final section of the draft should reflect that fact.

A copy of the typed summary should be provided to each respondent, and should be accompanied by a cover letter, which states that the firm and individuals have an opportunity to make any additions or corrections in writing within ten (10) days after receipt.
b. Addendum to the Summary

Occasionally after the respondents have left the premises, the Compliance Officer will realize that significant information was omitted from the Summary. In such a case, an addendum to the Summary should be created and mailed to the respondents along with the Summary created in their presence. A cover letter should accompany the Summary and addendum pointing out the inadvertent omission. Request a letter from the respondents within ten (10) days indicating that the additional information had been discussed as recorded in the addendum.

A respondent may request that the meeting be reopened in order to submit new information for the record. Such a request must be timely, in writing, state the nature of the new information, the reason it was not previously available at the time of the original meeting and why the information cannot be submitted in documentary form. If the division concludes that the meeting should be reopened to receive the new information, it may do so.

On occasion, respondents will request an additional meeting at headquarters to discuss the matter further. Such meetings are an extension of the Section 305 meeting and are governed by the procedures of this chapter.

c. Verbatim Transcript of Meeting

The respondent has the right to a verbatim transcript, at his expense. If exercising this right, the respondent must provide the necessary person or equipment to make the transcript. The respondent must submit a copy of such transcription to the division at no cost with an opportunity to make corrections and obtain agreement as to its accuracy. Under these circumstances, the Compliance Officer need dictate only a brief in-house summary after departure of the respondents, explaining the circumstances under which the verbatim transcript was made, who was present, etc. In this case, FDA does not prepare a "Summary".

The Compliance Officer may also order the meeting transcribed at FDA’s expense. In this case, a copy of the transcription is provided to each respondent See 21 CFR 7.85(e).

d. Handling of Electronic Recording

If the meeting statement has been recorded, after transcribing, appropriately identify the recording medium with the date of the meeting, the name of firm cited, the sample numbers, and the transcriber’s name. File the recording in the lead sample jacket and retain it until the ten
(10) -day period for review by the respondent has expired, then remove and destroy, or erase the recording.

e. Preparation of Summary

i. Method of Preparation

• Prepare the summary as a separate document, using the format in Exhibit 5-6 as an example.
• Include the following statement at the bottom of the copy provided to each respondent: "Copy of this Summary (or transcript) furnished to (respondent)."
• Include the transmittal letter advising respondents of the ten (10) -day period for additions or corrections.

ii. Number of Copies - Make sufficient copies for the following distribution:

• Original + 1 copy for center (hold for submission with case)
• One copy for division case file
• One copy for division establishment file on firm
• One copy for Resident Investigator, if desired
• One copy for division reading file
• One copy for each respondent

12. Multi-Session Meetings

The intent of the regulations is to limit multi-session meetings. Requests for changes in time and place of the meeting must be made in accordance with 21 CFR 7.84(e). New evidence may be submitted in accordance with 21 CFR 7.85(g). Nevertheless, a respondent may appear for a meeting, but claim he/she has further evidence to submit. If the request is reasonable, recess the meeting until a mutually agreeable date. Prepare only one Record covering both meetings.

When the respondent merely requests an opportunity to submit supplemental documentary evidence without further personal appearance, he/she may do as provided in 21 CFR 7.85(g). Mark additional information and/or documentation that is received within ten (10) calendar days after respondents received their copy of the summary or transcription of the meeting as an exhibit and add it to the Record.

13. Response By Mail

Frequently, respondents elect to respond in writing in lieu of making a personal appearance. It is not necessary to acknowledge receipt of a written response. However, it may be desirable to acknowledge a written response
when you also need to clarify some point of misunderstanding or oversight on the part of the respondent.

Hold correspondence to a minimum to avoid "holding a meeting by mail."

5-2-6 Procedures After Meeting

After the meeting (or written response, if any), a decision must be made as to disposition of the charges for each sample involved. The charges are disposed of by one or a combination of the following actions: Permanent Abeyance, Temporary Abeyance, or Prosecution.

1. Reporting Permanent Abeyance And Temporary Abeyance Cases

The division should process cases designated as in abeyance within seven (7) days after the meeting, with notification to the appropriate center, as described below.

a. Permanent Abeyance

Prepare a memorandum to the appropriate center(s) compliance office, headed "PA after CITATION" which provides the reason for placing the case in permanent abeyance (PA) and the planned division follow-up. Attachments should include a copy of the Section 305 Notice endorsed "PA (date and initials)"; a copy of the Charge Sheet, a copy of the Summary, and any relevant information. Hold all copies of the above documents in the division case file.

Forward a copy of the memorandum to the center(s), an endorsed "PA (date and initials)" copy of the Section 305 Notice, and a copy of the Charge Sheet to the division establishment file.

The Home Division’s Compliance Branch should update the Sample Disposition record(s) in FACTS with the appropriate information about the status of the samples.

a. Temporary Abeyance

Prepare assignments for necessary follow-up and forward copies to the appropriate center(s) compliance office. Hold the file in the Division Compliance Branch. A case in TA is not considered closed.

2. Notification Of Non-Prosecution

When the Agency makes a final determination that prosecution will not be recommended for any of the persons named in a notice (i.e., the case is closed), the division that issued the 305 Notice will advise each person in writing of that fact. 21 CFR 7.85(h)(1).
After the Agency decides to decline prosecution, that decision must be communicated to the office (generally a division office) that originated the citation recommendation to ensure that notification of non-prosecution issues in accordance with regulations. The FDA unit to which the recommendation was made, e.g., center, OSPOP/DE, OCC, is responsible for issuance of the declination to the originating office/division. Upon receipt of the declination, and absent a request for reconsideration of the recommendation, the originating office/division should issue the notification of non-prosecution within ten (10) working days.

When it is determined that one of several persons named in a notice will not be included in a recommendation for criminal prosecution, OCC will determine when that person will be notified (21 CFR 7.85(h)(2)). OCC will notify the division of this fact, and the district will issue the letter. The latter procedure applies when the Department of Justice declines to proceed with the entire case (21 CFR 7.85(h)(3)) or declines to proceed against an individual (21 CFR 7.85(h)(4)). See Exhibit 5-7 for the model letter to use.

5-3 ADMINISTRATIVE DETENTION OF FOODS

5-3-1 Purpose

This section provides procedures for the administrative detention of articles of food.

5-3-2 Background

The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 provided FDA with the authority to administratively detain articles of food and made it a prohibited act to move a detained article or to remove or alter any mark or label required by a detention order. In 2011, the FDA Food Safety Modernization Act amended the criteria for administrative detention to provide that an article of food may be detained when FDA has reason to believe that the article of food is adulterated or misbranded.

Further, administrative detention protects the public by preventing movement of an article of food while FDA institutes appropriate action, which may include seizure under section 304(a) of the Act, injunction under section 302 of the Act, or other administrative actions, such as emergency permit control, mandatory recall, or food facility registration suspension. Administrative detention is implemented to gain immediate control over food when there is reason to believe the food is adulterated or misbranded. Administrative detention is designed for swift and immediate action to ensure that adulterated or misbranded products do not enter commerce or, if they are already in commerce, to stop them from reaching consumers. As such, administrative
detention is a tool that can be used to achieve immediate public health protection. FDA’s administrative detention authority applies to articles of food in interstate and intrastate commerce, and food that is outside a United States Department of Agriculture regulated facility. See the Investigations Operations Manual (IOM), Section 2.7 for further information on detention of food authorities under the FD&C Act and under the Federal Meat Inspection Act, the Poultry Products Inspection Act, or the Egg Products Inspection Act.

Administrative detention of food requires prior approval by the Division Director of the Division where the detained article of food is located or an official senior to the Division Director (hereinafter referred to as the Division Director) (21 CFR 1.391). When ordering an administrative detention, the Division will need to act quickly to protect the public health. However, in situations where FDA has reason to believe the food is adulterated within the meaning of section 402(a)(4) of the FD&C Act (e.g., failure to have and implement a seafood or juice HACCP plan when required, or other critical violations of risk-based preventive control standards), the Division should immediately initiate a preliminary assessment (PA) call to consult with and obtain the concurrence of the appropriate Center compliance office, OCC, and OSPOP/DE prior to issuing an administrative detention order. In most situations of misbranding, the Division should immediately initiate a PA call, as well.

The period of the detention must be for a reasonable period, not to exceed twenty (20) calendar days. However, the period of detention may be extended up to a total of thirty (30) calendar days, if necessary to provide sufficient time to institute a seizure, injunction or other administrative enforcement action.

Any person, who would be entitled to claim the detained article of food, if seized, may appeal the administrative detention and may also request a hearing on the appeal. The appeal and request for a hearing must be submitted to the Division Director that issued the detention order. If requested by the individual entitled to claim the detained article of food and granted by the presiding officer, the hearing must be held within two (2) calendar days after the appeal is filed. The presiding officer’s decision to affirm or revoke the detention must be made within five (5) calendar days after the appeal is filed.

Articles of food offered for import into the U.S. can be administratively detained. As with food generally, administrative detention will provide further assurance that the article of food will not be distributed in domestic commerce.

Articles of food offered for import into the U.S. and subject to an administrative detention order under section 304(h) of the FD&C Act should be held in import status pending the outcome of the administrative detention process.

1. References

5-3-3 Issuing and Terminating Detention Orders

Section 304(h) of the Act gives FDA the authority to administratively detain an article of food when it has reason to believe that the food is adulterated or misbranded. An administrative detention order temporarily prevents the potentially adulterated or misbranded food from being distributed in commerce while FDA determines the appropriate legal or other administrative enforcement action (e.g., Emergency Permit Control, food facility registration suspension, mandatory recall order) against the food or persons. Consistent with FDA’s mission to protect the public health, FDA will implement a risk-based approach in its use of administrative detention of food. The Division Director should consider the viability of legal action under sections 304(a) or 302 of the FD&C Act or other administrative enforcement action while considering whether to order administrative detention.

Divisions should focus on, but are not limited to, food that poses either of the following food safety risks in establishing priorities for administrative detention:

- Reasonable probability that the use of, or exposure to, an adulterated or misbranded food will cause serious adverse health consequences or death (i.e., Class I recall and reportable food situations)
- Use of, or exposure to, an adulterated or misbranded food product that may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote (i.e., Class II recall situations).

The timing of the detention should be taken into consideration as much as possible without impacting public health to ensure it doesn’t impact on the available resources within the agency and other supporting agencies. Communicating the intent to order a detention to parties impacted by the order should be occurring as soon as possible for planning resources necessary to support the detention and subsequent seizure action.

1. Basis for Detention

An FDA employee, or state or local officer or employee commissioned by FDA as an officer of the Department, may order a detention, with appropriate FDA Division Director approval as described in this subsection (5-3-3, item #2, below), as part of his/her function of inspecting, examining, or investigating an article of food when FDA has reason to believe that the
article of food is adulterated or misbranded. See section 304(h) of the FD&C Act and 21 CFR 1.378.

2. **Approval of Detention Order by the Division Director**

The FDA Division Director in whose Division the article of food is located must approve the detention order. If prior written approval is not feasible, prior oral approval must be obtained and confirmed in writing as soon as possible. See 21 CFR 1.391.

Prior to approving the detention order, the Division Director should verify that there is reason to believe that the article of food is adulterated or misbranded. When FDA has reason to believe an article of food is adulterated or misbranded the Division will need to act quickly to protect the public health. However, in situations where the food is adulterated within the meaning of section 402(a)(4) of the FD&C Act (e.g., failure to have and implement a seafood or juice HACCP plan when required, or other critical violations of risk-based preventive control standards), the Division should immediately initiate a PA call to consult with and obtain the concurrence of the appropriate Center compliance office, OCC, and OSPOP/DE prior to issuing an administrative detention order. Appropriate supporting documentation should be provided before the PA call. A PA call initiates a collaborative process between the Divisions, Programs, OSPOP/DE, appropriate Centers (CFSAN or CVM) and OCC regarding possible Agency enforcement actions. PA calls are identified in Chapter 6 of the RPM for instructions on seizures and injunctions.

3. **Notification**

If the article of food presents a threat of serious adverse health consequences or death to humans or animals, the Division should also notify FDA’s Emergency Operations Center (EOC) at 1-866-300-4347. EOC will coordinate any emergency response activities associated with the food and will notify the appropriate office(s) (OFVM, CFSAN, CVM and ORA offices), either orally or in writing.

4. **Issuing the Detention Order**

The detention order must be issued in writing, in the form of a Detention Order. See Form FDA 2289. The ADO form must be issued in its entirety with no pages missing to ensure the firm has adequate notice. The detention order must be signed and dated by the FDA employee (usually an investigator) or commissioned officer who has reason to believe that the article of food is adulterated or misbranded. FDA must issue the detention order to the custodian (i.e., the owner, operator, or agent in charge of the place where the article of food is located). If this individual is not the owner of the article of food, FDA must provide a copy of the detention order to the owner of the article, if the
owner’s identity can be readily determined. See 21 CFR 1.392(a). Copies that cannot be hand delivered by an investigator must be sent as soon as possible via overnight delivery, with documentation of receipt of delivery.

If the article of food is detained in a vehicle or other carrier used to transport the detained article, FDA must provide a copy of the detention order to the shipper of record, importer of record (if applicable), the owner and operator of the vehicle or carrier, and the owner of the food, if their identities can be readily determined. Copies that cannot be hand delivered by an investigator must be sent as soon as possible via overnight delivery, with documentation of receipt of delivery.

5. **Detention Order and Detention Tags – Forms**

Section 2.7.2.3 of the IOM provides instructions for completing the Detention Order (Form FDA 2289). Section 2.7.2.4 provides instructions for completing the Detention Tag (Form FDA 2290), which should be affixed to the article of food subject to the detention order. If necessary, a label other than the Detention Tag may be used to identify the detained article of food, provided the label includes the information required in 21 CFR 1.382.

The detention order frames the issues for any appeal, including any informal hearing that may result from the detention. Therefore, the information on the order concerning the reason for detention is important. Provide clear direction to the plaintiff regarding the mechanism (courier, mail, email, fax) and to whom (DD) should they respond to the ADO.

The detention order must provide a brief, general statement of the reason(s) for the detention. There is no requirement that the order include all of the reasons for believing that the article of food is adulterated or misbranded. As such, the reasons outlined in the detention order do not limit the charges that may be included in a subsequent legal action. If the detention is based on classified information, this information must not be provided in the detention order.

6. **Length of Detention**

The article of food initially should be detained for twenty (20) calendar days, unless the Division believes that additional time will be required to institute a seizure or injunction. In such cases, the detention should be made for thirty (30) calendar days at the time the order is issued.

If the article of food is detained for twenty (20) days and a seizure, injunction or other administrative action cannot be instituted against the article of food within that time frame, the detention can be extended to a total of thirty (30) days. If a detention is extended from twenty (20) to thirty (30) days, FDA will issue
another detention order and place new tags or labels on the product. The entire detention period may not exceed thirty (30) days.

7. **Movement of a Detained Article of Food**

An article of food offered for import into the U.S. and also subject to a detention order may not be delivered under the conditions of a bond held with U.S. Customs and Border Protection. Notwithstanding section 801(b) of the FD&C Act, any article of food subject to a detention order under section 304(h) of the FD&C Act may not be further delivered to any of its importers, owners, or consignees. However, this does not preclude the movement of the detained articles of food, at FDA's direction, to a secure facility under an appropriate Customs' bond when that bond is required by Customs' law and regulation as described below.

The detained article of food must be held in the location and under the conditions specified by FDA in the detention order. The movement of an article of food in violation of a detention order is a prohibited act under section 301(bb) of the FD&C Act.

Except as noted below, no person may transfer a detained article of food within or from the place where it has been ordered detained, or from the place to which it was removed, until the detention order is terminated by the Division Director or the detention period expires, whichever occurs first.

The Division Director may approve, in writing, a request to modify a detention order to permit movement of a detained article of food for any of the following purposes under 21 CFR 1.381(c):

i. To destroy the article of food;

ii. To move the detained article of food to a secure facility under the terms of a detention order (see below);

iii. To maintain or preserve the integrity or quality of the article of food; or

iv. For any other purpose that the Division Director believes is appropriate in the case.

The required tags or labels must accompany the detained article of food during and after movement and must remain with the article of food until FDA terminates the detention order or the detention period expires, whichever occurs first, unless otherwise permitted by the Division Director who approves the modification of a detention order. 21 CFR 1.381(f).
The Division Director's letter approving a request to modify a detention order to allow the article of food to be moved should state (21 CFR 1.381(e)):

i. That the detained article of food remains under detention before, during, and after the transfer; and  

ii. That FDA must supervise the transfer OR  

iii. That FDA has declined to supervise the transfer and that the person who received the detention order, or his representative, must immediately notify the Division Director of the specific location to which the article of food was moved. Such notification must be sent to the Division Director who approved the order by fax, e-mail, or other written form as agreed to by the Division Director.

8. **Movement to a Secure Facility at FDA's Request**

If, after a food is detained, FDA determines that removal to a secure facility is necessary, the article of food must be removed to a secure facility at the expense of the owner or claimant. Prior to moving the food to a secure facility, the owner or claimant must receive a modification of the detention order (21 CFR 1.380(c)). The investigator who issued the initial detention order or other qualified official will issue a modified detention order, indicating:

i. The location to where the article of food must be moved;  

ii. That the detained article of food remains under administrative detention before, during, and after movement to a secure facility; and  

iii. The conditions of transportation applicable to the detained article of food.

As noted above in this subsection, item #7, the detained article of food must not be moved to the secure facility until FDA modifies the detention order.

9. **Legal Actions against Detained Food, Including Perishable Food**

- **Legal action** - The Division should expedite the preparation of a legal action against the detained food or its owner, to obtain control over the temporarily (i.e., twenty (20) to thirty (30) calendar days) detained food, particularly perishable food. This will most often be through a seizure action.

**NOTE:** The timelines for perishable foods are significantly shorter than the general timelines provided in **RPM Chapter 6 - Judicial Actions**.

If FDA initiates a seizure action against a detained perishable food as defined in 21 CFR 1.377, **we are required under 21 CFR 1.383 to send the seizure recommendation to the Department of Justice (DOJ) within four (4) calendar days of issuing the detention order against perishable food,**
unless there are extenuating circumstances. Extenuating circumstances include, but are not limited to, instances where the results of confirmatory testing or other evidentiary development requires more than four (4) calendar days to complete. If the fourth (4th) calendar day is not a working day, OCC should advise DOJ on the last working day before the deadline of its plans to recommend a seizure and will send the seizure as soon as practicable on the first working day after the non-work day.

All recommendations for legal action against a detained article of food must be flagged to indicate the action involves product that is under administrative detention, must include the date the detention expires (and, for perishable food, the deadline for sending the recommendation to DOJ). For procedures on the approval process for seizures and injunctions, refer to the approval process in RPM Chapter 6 section 6-1-5. The Center, Division of Enforcement (DE), and OCC will concurrently review the case initiation memorandum (CIM) and supporting evidence. The Center compliance office, DE, and OCC should expedite their reviews to ensure that the legal action is to be instituted prior to expiration of the detention. A final, signed inspection report is preferred for seizure actions; however, a final narrative inspection report may not be necessary in all situations. For instance, seizure actions have been implemented on the basis of the FDA Form 483 accompanied by supporting evidence (e.g., photographs, official samples, copies of records, affidavits) documenting the violations. Divisions should be mindful that perishable food seize actions must go to DOJ within four (4) calendar days after issuing the detention order. Decisions on suitability of the available evidence will be made on a case-by-case basis among the reviewing coordinators with final determination by OCC. Logistics should be discussed during the PA calls for both the administrative detention and the seizure action.

When the action is a seizure, the Division is responsible for coordination with the U.S. Attorney’s office and the U.S. Marshals Service, to facilitate the prompt filing of the complaint and seizure of the food. The Division also is responsible for immediately providing oral or e-mail notice of the accomplishment of the seizure to the appropriate Center compliance office, DE, OCC, and the presiding officer of any in-process appeal of a detention order. CMS should be promptly updated with legal documentation including dates actions take place.

When a seizure or injunction action is filed regarding the article of food involved in the detention order, the process for the appeal of a detention order terminates 21 CFR 1.402(c).

- **Administrative Action** – Divisions should initiate other administrative actions (i.e., emergency permit control, mandatory recall order, or food facility registration suspension), if appropriate and possible, during the period of detention. An administrative detention is in effect for at least twenty (20)
calendar days and will terminate if the detention period is not extended. If more time is necessary to enable FDA to institute an administrative action, the administrative detention can be extended, if necessary, for up to ten (10) calendar days, for a total of thirty (30) calendar days.

Administrative detention may be used in conjunction with other administrative actions, as necessary to control movement of the food while instituting that enforcement action. Please note that, administrative detention is distinct from, and not a prerequisite for, other administrative actions. Administrative detention does not alter the processes or timeframes established for other administrative actions. However, when multiple regulatory actions relating to the detained food or the implicated firm are initiated, the respective actions should be coordinated to the extent necessary and appropriate to control the movement and disposition of the detained food.

10. **Termination or Expiration of Detention Orders**

If FDA terminates a detention order, the Division Director will issue a detention termination notice releasing the article of food to any person who received the detention order or that person’s representative and will remove, or authorize in writing the removal of, the required tags or labels. See 21 CFR 1.384. While the regulation does not give a time frame for FDA to issue the termination notice, we expect that we will normally issue the termination notice to the person who received the detention order within one (1) calendar day of the decision to terminate the detention order.

FDA will terminate a detention order when one of the following occurs:

i. FDA determines that the food is not adulterated or misbranded;

ii. FDA approves voluntary destruction and the destruction is accomplished;

iii. The detention order is appealed with or without an informal hearing and the presiding officer revokes the detention order; or

iv. A seizure action under section 304(a) of the FD&C Act has been instituted in court and the goods have been seized by the U.S. Marshals pursuant to a court-issued warrant, or an injunction action under section 302 of the FD&C Act has been instituted in court.

The Division Director issues a Detention Termination Notice (Form FDA 2291) to the person(s) who received the Detention Order, or his representative(s) and, if movement of the article of food occurred pursuant to a modification of the detention order prior to the termination, to the person possessing the article of food. The notice may be issued in person or by mail. If the termination notice is issued by mail, request that the Detention Tags (Form FDA 2290) be returned. If
the termination notice is issued in person, see Section 2.7.2.5 of the IOM for instructions.

Once the detention period expires, the detention automatically terminates. In general, the Division Director will acknowledge the expiration and the release of the article of food, using the Form FDA 2291 Detention Termination Notice and the procedures described in this subsection.

11. Responsibilities For Issuing And Terminating Detention Orders

FDA responsibilities for issuing and terminating a detention order are as follows. Note, all components should identify alternate personnel to include in case activities should the assigned individual become unavailable or unable to remain on the case.

a. Division Responsibilities - The Division is responsible for:
   i. Notifying the appropriate Center, OSPO/DE, and OCC as soon as it becomes aware of a situation where administrative detention may be appropriate. The Division is to make a determination that it has a reason to believe an article of food is adulterated or misbranded and then respond accordingly to protect the public health. In situations where the food is adulterated within the meaning of section 402(a)(4) of the FD&C Act (e.g., failure to have and implement a seafood or juice HACCP plan when required, or other critical violations of risk-based preventive control standards), the Division should immediately initiate a PA call to consult with and obtain the concurrence of the appropriate Center compliance office, OCC, and OSPOP/DE prior to issuing an administrative detention order. Appropriate supporting documentation should be provided before the PA call.
   ii. Ensuring scientific and policy support from the appropriate Center, policy support of OSPOP/DE, and legal support of OCC before issuing a detention order based on 402(a)(4) adulteration.
   iii. Acquiring the approval of the Division Director in accordance with 21 CFR 1.391.
   iv. Issuing the detention order.
   v. Notifying the Director of DE, the senior compliance official or designee of the appropriate Center, and OCC by phone or e-mail that the order has been issued and supplying them with a copy of the detention order by the most expeditious means available (loading scanned copy into CMS, fax, express mail, e-mail, etc.) immediately after issuance. Notify the ACRA by Hot Item.
   vi. Providing a copy of the supporting information, e.g., FDA Form 483, to DE compliance officer, the senior compliance official or designee of the appropriate Center, and OCC.
vii. Notifying the Director of OSPOP/DE that the Division issued a detention order so that a presiding officer may be designated. At this time, the Division should provide a copy of the detention order and supporting information to the Director of OSPOP/DE so that he may provide a copy to the presiding officer, once one is designated.

viii. Once the food is detained, approving and monitoring the movement of detained food.

ix. Regularly monitoring the relevant phone, e-mail, and other incoming communications in the issuing Division’s office, even over weekends, for receipt of an appeal with or without a hearing from the firm whose food is subject to the detention.

x. If the Division receives any communications from the firm whose food is subject to the detention, the Division must immediately notify the relevant parties in OCC and the presiding officer. If a presiding officer has not yet been named, this information should be provided to the Director of OSPOP/DE who will give this information to the presiding officer once one is designated.

xi. Pursuing, with appropriate speed, the follow-up legal or administrative enforcement action.

xii. When warranted, issuing a Detention Termination Notice (Form FDA 2291) in a timely manner (usually within one (1) calendar day).

b. Center Responsibilities - The Center is responsible for:

i. Providing a prompt review and a determination on whether there is reason to believe the article of food is adulterated or misbranded in conjunction with the PA call. The response should be provided concurrently to the Division, OSPOP/DE, and OCC by phone, fax, or e-mail and to EOC and CORE, if involved.

ii. Providing written documentation from a senior compliance official of the appropriate Center (i.e., Director, Division of Enforcement, Office of Compliance, CFSAN; or Director, Division of Compliance, Office of Surveillance and Compliance, CVM) of the confirmation on whether there is reason to believe that the article of food is adulterated or misbranded, including documentation necessary to support the subsequent legal or administrative action.

iii. Working with the Division Compliance Office to identify evidence needed to support the legal case.

iv. Promptly notifying the Division, OSPOP/DE, and OCC of any issues or Center concerns that need to be resolved, prior to providing support for the legal and/or administrative action.
v. Expeditiously reviewing the subsequent legal or administrative action recommendation and providing expert witnesses and other support, as appropriate, for the legal and/or administrative action.

vi. Coordinating the legal and/or administrative action with DE and OCC.

vii. Selecting a center expert to serve on the PO’s team should a hearing be granted. The enter expert should avoid participating in the investigation and action that is the subject of the hearing to remain free of bias or prejudice.

viii. If more than one program/center is involved. The centers will decide a lead center. Depending on which center takes the lead, the corresponding ORA program office will take the lead.

c. OSPOP/DE responsibilities – OSPOP, DE is responsible for:

i. Providing a prompt review in conjunction with the PA call. The response should be provided concurrently to the Division, appropriate Center and OCC by phone, fax, or e-mail and to EOC and CORE, if involved.

ii. Coordinating the legal and/or administrative action with the Division, the appropriate Center and OCC.

iii. Arranging the designation of the presiding officer. This should be accomplished as soon as possible in the process once FDA makes a final determination to order a detention of food in consideration for the presiding officer’s responsibilities in the potential appeal and informal hearing process and to provide the presiding officer notice of his/her role as soon as possible.

iv. Providing a copy of the detention order and supporting information to the designated presiding officer and confirming that copies of any communications between the firm whose food is detained, and the Division are provided to the presiding officer.

v. Confirm that copies of all materials provided to the presiding officer are provided to the team of OCC attorneys assigned to provide legal support to the presiding officer.

d. OCC responsibilities – OCC is responsible for:

i. Providing legal support and assessment during the PA call.

ii. Providing legal support to the personnel in the Division, appropriate Center, and OSPOP/DE involved in the administrative detention order and subsequent legal or administrative action.

iii. Assigning OCC attorney(s) to review information on the detention order.
iv. Appointing a separate team of attorneys to provide legal support to the presiding officer for his/her role in making determinations on the informing hearing process and procedures.

5-3-4 Appeal of a Detention Order

1. Appeal, With or Without an Informal Hearing

Any person, who would be entitled to be a claimant for the article of food, if seized under section 304(a) of the Act, may appeal a detention order. The appeal must be submitted in writing, to the Division Director in whose Division the detained article of food is located, at the mailing address, e-mail address, or fax number identified in the detention order. The appeal must include a verified statement identifying the appellant’s ownership or proprietary interest in the detained article of food, in accordance with Supplemental Admiralty Rule G of the Federal Rules of Civil Procedure. The appeal must include materials on which the appellant bases its request for an appeal.

If the detention order is appealed, the Agency must provide the appellant with an opportunity to request an informal hearing. The request for a hearing must be in writing, must be included in the request for an appeal, and must conform to the time frames specified below. The presiding officer has the authority to deny a hearing when the appeal raises no genuine and substantial issue of fact and FDA is entitled to judgment as a matter of law. If the presiding officer, in consultation with OCC, determines that a hearing is not justified, the presiding officer will issue written notice of that determination and provide it to all parties explaining the reason for denial. See Exhibit 5-12 for Model letter denying hearing.

If the presiding officer grants the appellant’s request for a hearing, then an informal hearing will be held within two (2) calendar days after the date the appeal is filed. The informal hearing will be conducted in accordance with 21 CFR Part 16 except where modified by 21 CFR 1.403.

2. Time Frames

The following time frames apply to filing an appeal of a detention order:

a. Perishable food - The appeal must be filed within two (2) calendar days of receipt of the detention order.

b. Non-perishable food - The appeal must be filed within ten (10) calendar days of receipt of the detention order. However, if the appeal includes a request for a hearing, the notice of intent to request a hearing must be filed within four (4) calendar days of receipt of the detention order, or the hearing
will not be granted. The notice of intent only relates to a hearing, which is part of an appeal.

The date of filing the appeal will be the date the submission is received by the Division office.

If a hearing is requested, and FDA grants the request as outlined in this chapter, the hearing must be held within two (2) calendar days after the date the appeal is filed. The decision to affirm or revoke the detention must be made within five (5) calendar days after the appeal is filed.

For additional operational guidance regarding administrative detention of food offered for import into the U.S., Divisions should refer to the Administrative Detention of Imported Foods sub-chapter of Chapter 9 of the RPM.

A summary of these timeframes is presented in Exhibits 5-8 and 5-9 "Deadlines for Administrative Detention of Food."

3. **Presiding Officer**

The Director, OSPOP/DE, ORA will designate the presiding officer upon the Division Director issuing a detention order. The presiding officer for an appeal must be a Division Director or another FDA official senior to the Division Director (21 CFR 1.404). Generally, a Director outside the Division where the detained article of food is located will serve as the presiding officer. The Director, OSPOP/DE, ORA should contact the potential presiding officer upon the Division Director issuing a detention order. If that individual is not able to serve as the presiding officer, the OSPOP/DE Director is responsible for arranging to have another Director or Agency official designated to serve as the presiding officer. All presiding officers must be designated consistent with current Agency regulations and delegations. OSPOP/DE will create a memorandum reflecting such designation and share it with the relevant parties.

**Presiding Officer Responsibilities** – The presiding officer is responsible for:

a. Making a determination on whether to grant or deny an appeal with or without an informal hearing request from the owner of the detained article. Any person who would be entitled to be a claimant for the article of food, if seized under section 304(a) of the FD&C Act, may appeal a detention order and request an informal hearing as specified in 1.402. Procedures for establishing entitlement to be a claimant for purposes of section 304(a) of the FD&C Act are governed by Supplemental Rule C to the "Federal Rules of Civil Procedure."

b. If an appeal with a hearing is requested, making a determination on whether the owner has raised a genuine and substantial issue of fact justifying a hearing (21 CFR 16.26(a)), and if not, the presiding officer will
issue correspondence to deny the request for an informal hearing on the administrative detention order. If the hearing is denied, the presiding officer must still decide a timely appeal (i.e. whether the administrative detention was proper under FDA’s laws and regulations), as discussed below. All correspondence between the firm and the PO must be uploaded to CMS.

c. If there is an appeal, but no hearing is requested, making a determination, as discussed below, on whether the administrative detention was proper under FDA’s laws and regulations.

d. Making determinations on whether to waive, modify, or suspend any provision under 21 CFR part 16 as authorized by 21 CFR 10.19 and 21 CFR 16.60(h).

e. Presiding over the informal hearing. A Division Director or an individual senior to the Division Director will be designated for this role. Although the designated official should be informed about an impending administrative detention, the individual should refrain from becoming involved in decisions relating to issuing or monitoring the detention order. After the detention order has been issued, the designee, if serving as presiding officer, must insulate himself/herself from all aspects of the detention except those relating to his/her responsibilities as a presiding officer for the hearing, if requested as part of an appeal.

f. Issuing appeal decisions in accordance with 21 CFR 1.405 as follows:

i. If there is an appeal with or without a request for a hearing, the presiding officer must issue a written report that includes a proposed decision confirming or revoking the detention by noon on the fifth (5th) calendar day after the appeal is filed; after providing four (4) hours in which the hearing participants could submit comments on the presiding officer’s report under 21 CFR 1.403(h), the presiding officer must issue a final decision. The final decision must be issued by the end of the fifth (5th) calendar day after the appeal was filed. If FDA either fails to provide the appellant with an opportunity to request an informal hearing or fails to confirm or terminate the detention order within the five (5)-calendar day period, the detention order is deemed terminated.

ii. Even if the presiding officer denies the hearing request, the presiding officer must issue a decision on the appeal confirming or revoking the detention within five (5) calendar days after the date the appeal is filed. If the presiding officer fails to confirm or terminate the detention order during such five (5)-calendar day period, the detention order is deemed terminated. The PO’s hearing report must be uploaded to CMS.

iii. If the owner of the detained article appeals the detention order and provides notice that he intends to request an informal hearing but does not file a timely request for an informal hearing, the presiding officer must issue a decision on the appeal confirming or revoking the
 detention within five (5) calendar days after the date the appeal is filed. If the presiding officer fails to confirm or terminate the detention order during such five (5)-calendar day period, the detention order is deemed terminated.

In addition, 21 CFR 1.405 provides the following:

a. If the presiding officer confirms a detention order, the article of food remains detained until we terminate the detention under 21 CFR 1.384 or the detention period expires under 21 CFR 1.379, whichever occurs first.

b. If the presiding officer terminates a detention order, or the detention period expires, FDA must terminate the detention order as specified under 21 CFR 1.384.

c. Confirmation of a detention order by the presiding officer is considered a final Agency action for purposes of 5 U.S.C. 702.

d. See subsection 5-3-4 item #5(b) below for further responsibilities of the presiding officer.

4. Communications between Parties to the Hearing and the Presiding Officer

Parties to the hearing should avoid any off-the-record communication with the presiding officer. If any communication of this type occurs, it must be reduced to writing and made part of the administrative record of the hearing. The other party must be provided with a copy of the letter or memorandum of the communication and must be provided an opportunity to respond. See 21 CFR 16.44(b). Presiding Officers should consider placing delivery and read receipts on the email communications between the PO and the plaintiff.

The person who writes a letter or memorandum of the meeting between a participant in the hearing and the presiding officer must send a copy to all of the participants. See 21 CFR 16.44(c).

5. Appeal Processing Responsibilities

Division Responsibilities

a. Preparation for an appeal should begin when the Division decides to detain an article of food. When the Division receives an appeal, the Division Director:

i. Dates and time stamp the appeal and notifies the appellant of receipt of the appeal in writing.

ii. Notifies, orally or by email, the Center, DE, OCC, and the Presiding Officer of the appeal immediately and forwards a copy of the appeal to them as soon as possible by fax or electronically.
Requests assistance of the Center, OSPOP/DE and OCC as needed. OCC will designate attorneys to advise the Division/Center and attorneys to advise the Presiding Officer.

b. When the appeal includes a request for a hearing, the Division Director:

i. Prepares a general summary of the information that will be presented by FDA at the hearing in support of the detention order (“general summary”) and a comprehensive statement of the basis for the detention order (“comprehensive statement”), in accordance with 21 CFR 16.24(f).

ii. EXCEPTION: When a detention order is based on classified information, 21 CFR 16.24(f) does not apply, and the Division should consult with OCC to determine whether the presiding officer can give the appellant notice of the general nature of the information consistently with safeguarding the information and its source (21 CFR 1.403(e) and 1.406).

iii. The detention order (Form FDA 2289) may serve as the comprehensive statement only if the reason for detention is described in sufficient detail. See Exhibit 5-10 for an example of a model letter for reasonable notice of matters to be considered at hearing. The model letter includes a general summary and a comprehensive statement.

c. If the presiding officer grants the appellant’s request for a hearing, the Division Director forwards the general summary and the comprehensive statement to the appellant (excluding classified information), the presiding officer, and to the Center, OSPOP/DE and OCC representatives to the hearing. The Division office sends the documents immediately to all parties so that they arrive as soon as possible, but at least one (1) day prior to the hearing. However, if the detention order is based on classified information, the Division Director must not provide such information to the appellant. The Division Director must consult with OCC before issuing a detention order based on classified information.

d. At least one (1) day before the hearing, provides the appellant, presiding officer, Center, OSPOP/DE, and OCC representatives to the hearing, written notice of, or copies of, if they could not reasonably be expected to obtain copies, any published articles or written information to be presented at or relied on at the hearing. See 21 CFR 16.24(g).

e. When the appeal does not include a request for a hearing, the Division Director:

i. Forwards all the information that supports the detention to the presiding officer and the OCC attorneys representing the presiding officer. This includes FDA’s referenced general summary and...
comprehensive statement and the information provided by the appellant on which the appellant bases its request for an appeal.

ii. The information should arrive no later than the third (3rd) calendar day after the appeal is filed, so that the information can be reviewed, and a decision rendered within five (5) calendar days after the date the appeal is filed.

Presiding Officer Responsibilities

a. When notified of an appeal, with or without a request for a hearing, the presiding officer:

i. Determines whether the appeal is not valid because the appeal has not been submitted within the established time frame or if the appeal does not demonstrate ownership or proprietary interest as required in 21 CFR 1.402(b). The presiding officer will notify the appellant if he/she determines that the appeal is not valid.

ii. At the discretion of the presiding officer, if sufficient time is available, the presiding officer may notify the appellant of the requirement to provide written demonstration of ownership or proprietary interest and allow the appellant to re-submit the appeal with the required information. The submission of the appeal must be accomplished within the applicable timeframe. The OCC attorneys representing the presiding officer should be consulted on this issue.

b. When notified of an appeal, and a hearing is requested, the presiding officer:

i. Determines whether a hearing should be granted. A hearing will only be granted if the material submitted by the appellant raises a genuine and substantial issue of fact. See 21 CFR 16.26(a). A hearing will not be granted on matters of law or policy.

ii. If the appeal does not clearly specify that a hearing is requested, a hearing will not be granted.

iii. If the presiding officer denies a hearing, the presiding officer notifies the appellant of the denial of a hearing in writing. See Exhibit 12 for an example of a model letter denying the appellant’s request for a hearing.

iv. If the presiding officer grants a hearing, the presiding officer orally contacts the parties as soon as possible and sets a date for a hearing to be held within two (2) calendar days after the date the appeal is filed. The hearing normally takes place at the Division office where the goods are located. If practical, a hearing may be conducted via teleconference or video conference.
v. Provides all parties with written notification of the time, date, and location of the hearing, and secures technology (e.g., phone conference lines) for the hearing.

vi. Provides the appellant with oral and written notification. See form letter as Exhibit 5-11:

1. of those portions of 21 CFR part 16 that are excluded or modified under 21 CFR 1.403 and waived or modified for hearings on appeal of administrative detentions (see "Informal Hearing on Appeal of a Detention Order." See subsection 5-3-5 item # 2);

2. that the informal hearing is not a public hearing per 21 CFR 16.60(a), in order to protect investigatory records compiled for law enforcement purposes that are not available for public disclosure under 21 CFR 20.64, or trade secrets and confidential commercial information that is not available for public disclosure under 21 CFR 20.61;

3. that the appellant should provide, at the hearing, a brief summary of any lengthy documents for presentation at the hearing (e.g., volumes of computer printouts);

4. that the appellant should provide the Division Director written notice of, or a copy of (if the Division Director could not reasonably be expected to obtain a copy), any published articles or written information for presentation at or relied on at the hearing, at least one (1) day before the hearing, if feasible, as required by 21 CFR 16.24(g); and

5. Of the requirements under 21 CFR 16.44(c). See Section 5-3-4, item # 4 "Communications between Parties to the Hearing and the Presiding Officer."

vii. When notified of an appeal, and no hearing is requested, the presiding officer orally notifies the:

1. parties that they should submit information supporting their positions as soon as possible, and no later than the third (3rd) calendar day after the appeal is filed, so that the information can be reviewed, and a decision issued within five (5) calendar days after the date the appeal is filed.

2. Appellant of the requirement under 21 CFR 16.44(c). See Section 5-3-4, item # 4 "Communications between Parties to the Hearing and the Presiding Officer," above.

OCC Responsibilities; OCC is responsible for:

a. Assigning OCC attorneys to represent the Division and Center during any appeal and hearing;
b. Assigning different OCC attorneys to represent the Presiding Officer during any appeal and hearing;

c. Expediting review of information provided by the Division; and,

d. Working with the division to prepare for any hearing and appeal.

Center Responsibilities; The Center is responsible for providing:

a. scientific, technical, and policy support to the Division; and,

b. representatives to the hearing, if necessary.

DE Responsibilities; DE is responsible for confirming that all:

a. Agency and OCC components are notified of and prepared for a hearing; and,

b. documentation from the Division relating to the detention and hearing is provided to the Center compliance office and OCC.

6. Termination of an Appeal

The appeal process terminates if FDA institutes a seizure or injunction action regarding the article of food involved in the detention order. 21 CFR 1.402(c). A seizure or injunction action is instituted when such action is filed in court.

If a seizure or injunction action is filed in court, the Division Director will notify the presiding officer. The presiding officer will issue a letter to the appellant that the appeal has been terminated because a seizure or injunction action has been filed in court. See Exhibit 5-24 for an example of a model letter notifying the appellant that the appeal has been terminated.

5-3-5 Informal Hearing on Appeal of a Detention Order

1. Background

Section 304(h)(4) of the FD&C Act requires FDA to provide the appellant with an opportunity for an appeal including an "informal hearing." Section 201(x) of the FD&C Act defines this term. 21 CFR 1.403 requires that FDA conduct the hearing in accordance with 21 CFR part 16, Regulatory Hearing before the Food and Drug Administration, with the waivers and modifications noted below in 5-3-5 item #2. 21 CFR 16.5(b) advises that Part 16 procedures apply to the extent that they are supplementary to, and not in conflict with, the other procedures specified in a regulation that provides a person with an opportunity for a hearing. 21 CFR 10.19 and 21 CFR 16.60(h) give the presiding officer the authority to suspend, modify, or waive provisions under part 16. A request for a hearing may be denied, in whole or in part, if the presiding officer determines that no genuine and
substantial issue of fact has been raised by the material submitted. The regulations at 21 CFR 16.26(a)). 21 CFR 10.19 and 21 CFR 16.60(h) give the presiding officer the authority to suspend, modify, or waive provisions under Part 16.

2. **Waivers and Modifications to 21 CFR Part 16**

If FDA grants a request for an informal hearing on an appeal of a detention order, FDA must conduct the hearing in accordance with 21 CFR Part 16, except that:

a. The detention order under 21 CFR 1.393, rather than the notice under 21 CFR 16.22(a), provides notice of opportunity for the hearing and is part of the administrative record of the regulatory hearing under 21 CFR 16.80(a);

b. A request for a hearing must be addressed to the FDA Division Director in whose Division the article of food involved is located;

c. The provision in 21 CFR 16.22(b), providing that a person not be given less than three (3) working days after receipt of notice to request a hearing, does not apply;

d. The provision in 21 CFR 16.24(e), stating that a hearing may not be required to be held at a time less than two (2) working days after receipt of the request for a hearing, does not apply;

e. 21 CFR 1.406, rather than 21 CFR 16.24(f), describes the statement that will be provided to an appellant where a detention order is based on classified information;

f. 21 CFR 1.404, rather than 21 CFR 16.42(a), describes the FDA employees, e.g., Division Directors or other official’s senior to a Division Director, who preside at hearings;

g. The presiding officer may require that the hearing be completed within one (1) calendar day, as appropriate;

h. 21 CFR 16.60(e) and (f) do not apply to the hearing. The presiding officer must prepare a written report of the hearing. All written material presented at the hearing will be attached to the report. The presiding officer must include as part of the report of the hearing a finding on the credibility of witnesses (other than expert witnesses) whenever credibility is a material issue, and must include a proposed decision, with a statement of reasons. The hearing participant may review and comment on the presiding officer’s report within 4 hours of issuance of the report. The presiding officer will then issue the final Agency decision;
i. 21 CFR 16.80(a)(4) does not apply to the hearing. The presiding officer's report of the hearing and any comments on the report by the hearing participant under 21 CFR 1.403(h) are part of the administrative record;

j. No party shall have the right under 21 CFR 16.119 to petition the Commissioner of Food and Drugs for reconsideration or a stay of the presiding officer's final Agency decision; and,

k. If FDA grants a request for an informal hearing on an appeal of a detention order, the hearing must be conducted as a regulatory hearing pursuant to regulation in accordance with 21 CFR Part 16, except that 21 CFR 16.95(b) does not apply to the hearing. With respect to the regulatory hearing on an appeal of a detention order, the administrative record of the hearing specified in 21 CFR 16.80(a)(1), (a)(2), (a)(3), and (a)(5), and 1.403(i) constitutes the exclusive record for the presiding officer's final decision on an administrative detention. For purposes of judicial review under 21 CFR 10.45, the record of the administrative proceeding consists of the record of the hearing and the presiding officer's final decision.

In addition, 21 CFR 16.60(b), which provides that all parties may confront and conduct reasonable cross-examination of any person (except for the presiding officer and counsel for the parties) who makes any statement on the matter at the hearing, is modified. Reasonable questions will be allowed instead. Reference Congressional intent: House of Representatives Report no. 94-853. Also, see 21 CFR 16.5 and 16.60(h).

3. Conducting the Hearing

The presiding officer should inform the parties of the applicable modifications to 21 CFR Part 16 “Regulatory Hearing Before the Food and Drug Administration,” as provided for in the administrative detention regulation (21 CFR 1.403). The presiding officer will explain that the purpose of the hearing is to determine whether FDA, at the time of the detention and as charged in the detention order, had reason to believe that the article of food is adulterated or misbranded. The FDA representative(s) must explain the basis for the detention and answer reasonable questions from the appellant.

The appellant may present relevant information to support his/her position that the article should not be subject to detention. Both parties may conduct reasonable questioning of the other (section 201(x) (4) of the FD&C Act; 21 CFR 16.60(b), as modified in Section 5-3-5, item #2).
The presiding officer will ensure that the material presented, and the questions asked are relevant to the issue of the hearing.

The presiding officer may, once the hearing commences, issue a summary decision on any issue in the hearing if the presiding officer determines from the material submitted in connection with the hearing, or from matters officially noticed, that there is no genuine and substantial issue of fact respecting that issue. 21 CFR 16.26(b).

The appellant may request that a transcript of the hearing be taken. However, the appellant must pay the cost of the transcript and furnish the presiding officer a copy for the record. FDA also may request a transcript of the hearing, in which case the costs are borne by the government.

The appellant may obtain a copy of the government transcript by submitting a request under the Freedom of Information Act (FOIA) (5 U.S.C. 552 et seq.). 21 CFR Part 20 applies to the release of the transcript.

The presiding officer should notify the parties that his/her decision will not await transcription or correction of the transcripts so ordered.

4. Responsibilities For The Hearing:
   a. Center Responsibilities -
      The Center will provide documents, witnesses, or office representatives for the hearing if requested by the Division or the OCC attorney counseling the Division.
   b. OCC Responsibilities -
      OCC will provide counsel for the Division, the Center and/or the presiding officer, as appropriate, for the hearing.
   c. Division and Presiding Officer Responsibilities -
      Section 5-3-5, item #3 “Conducting the Hearing” includes responsibilities of the Division and the presiding officer.

5-3-6 Issuing the Decision on an Appeal

1. Decision on an Appeal after a Hearing

   The presiding officer must issue a written report of the hearing that includes a proposed decision confirming or revoking the detention by noon on the fifth (5th) calendar day after the appeal is filed. The hearing participants then have four (4) hours to review and comment on the report (21 CFR 1.405(a) and 1.403(h)). If classified information was used to support the detention, then any
confirmation of the detention must state whether it is based in whole or in part on that classified information but will not reveal the classified information.

The presiding officer must issue a final decision within five (5) calendar days after the appeal is filed. If the presiding officer fails to confirm or terminate the detention order within this five (5) calendar day period, the detention order is deemed terminated. 21 CFR 1.405(a). The appellant should be orally notified of the termination immediately. A copy of the termination notice should then promptly be mailed to the appellant via overnight delivery with delivery confirmation. See Exhibit 13A for Model Letter Final Decision on Appeal Detention Order Confirmation and Exhibit 13B for Model Letter Final Decision on Appeal Detention Order Revocation.

2. Decision on an Appeal When Appellant Does Not Request a Hearing

If there is an appeal of the detention order, but the appellant does not request a hearing, the presiding officer must issue a decision on the appeal confirming or revoking the detention within five (5) calendar days after the date the appeal was filed. If classified information was used to support the detention, then any confirmation of the detention must state whether it is based in whole or in part on that classified information but will not reveal the classified information.

If the presiding officer fails to confirm or terminate the detention order during this five (5) calendar day period, the detention order is deemed terminated. 21 CFR 1.405(b). The appellant should be orally notified of the termination immediately. A copy of the termination notice should then promptly be mailed to the appellant via overnight delivery with delivery confirmation. See Exhibit 13A for Model Letter Final Decision on Appeal Detention Order Confirmation and Exhibit 13B for Model Letter Final Decision on Appeal Detention Order Revocation.

3. Decision on an Appeal When Appellant’s Request for a Hearing is Denied

If the presiding officer denies the appellant's request for a hearing, the presiding officer must issue a decision on the appeal confirming or revoking the detention within five (5) calendar days after the date the appeal was filed. If classified information was used to support the detention, then any confirmation of the detention must state whether it is based in whole or in part on that classified information but will not reveal the classified information.

If the presiding officer fails to confirm or terminate the detention order during the five (5) calendar day period, the detention order is deemed terminated. 21 CFR 1.405(c). The appellant should be orally notified of the termination immediately. A copy of the termination notice should then promptly be mailed to the appellant to via overnight delivery with delivery confirmation. See Exhibit 13A for Model Letter Final Decision on Appeal Detention Order Confirmation and Exhibit 13B for Model Letter Final Decision on Appeal Detention Order Revocation.
5-3-7 Administrative Record and FOIA Requests

1. Administrative Record of Appeal with Hearing

The presiding officer should prepare the administrative record of the hearing, which consists of the following (21 CFR 1.403(k)):

i. The notice of opportunity for hearing and the response (e.g., the detention order that indicates the opportunity for a hearing and the appeal with a request for hearing or appeal without a request for a hearing);

ii. All written information and views submitted to the presiding officer in conjunction with the appeal with a hearing;

iii. Any transcript of the hearing;

iv. All letters and memoranda of meetings and communications between participants and the presiding officer referred to in 21 CFR 16.44(c);

v. The presiding officer’s written report of the hearing which includes the decision confirming or revoking the detention, with a statement of the reasons. The report must include a finding on credibility of witnesses (other than expert witnesses) whenever credibility is a material issue; and

vi. The hearing participant’s comments on the report, including comments on the proposed decision. 21 CFR 1.403(h) and (i).

The Division should file the original Administrative Record of the Hearing with the firm’s official file at the Division office after completion of the report and send a copy to the appropriate Centers’ compliance office, DE, OCC and to the presiding officer. The Division compliance branch should also upload a copy into CMS.

2. FOIA Requests

21 CFR Part 20 applies to all requests for the administrative record and other documents relating to administrative detentions.

5-4 DETENTION OF FOODS – OTHER STATUTORY AUTHORITY

5-4-1 Purpose

This section contains the procedures for exercising FDA’s authority to detain meat, poultry and egg products as delegated to FDA under the provisions of the Federal Meat Inspection Act (FMIA), the Poultry Products Inspection Act (PPIA), or the Egg Products Inspection Act (EPIA).
For the purpose of this section only, the following definitions apply:

1. **Meat And Meat Products**
   The carcasses of cattle, sheep, swine, goats, horses, other equines, parts of such carcasses, and products made wholly or in part from such carcasses.

2. **Poultry And Poultry Products** –
   The carcasses of domesticated birds, parts of such carcasses, and products made wholly or in part from such carcasses.

   **EXCEPTION** - In the case of both meat and poultry products, certain products are exempted from the above referenced Acts by USDA because they contain a relatively small portion of meat or poultry or historically have not been considered meat or poultry products.

3. **Eggs**
   The shell eggs of the domesticated chicken, turkey, duck, goose or guinea.

4. **Egg Products**
   Dried, frozen or liquid eggs, with or without added ingredients, except products exempted by USDA because they contain a relatively small proportion of eggs or historically have not been considered egg products.

5-4-2 Authority

The Federal Meat Inspection Act, (MIA) as amended by Public Law (P.L.) 90-201; and Sections 19 and 20(b) of the Poultry Products Inspection Act (PPIA) as amended by P.L. 90-492; and Sections 19 and 23(d) of the EPIA provide certain detention powers.

The detention authority under the MIA and the PPIA provide that FDA representatives may detain articles subject to these acts if they are outside a USDA inspected plant and there is reason to believe that the products are adulterated or misbranded under the Act.

The detention authority under the EPIA provides that FDA representatives may detain products subject to that act if the products are found outside a USDA inspected plant and there is reason to believe that the products are in violation of the EPIA.

**NOTE:** Interstate Commerce is not a requirement for FDA jurisdiction over eggs and egg products because authority is based on violation of the Egg Products Inspection Act rather than the FFDCA.

The detention process is another regulatory tool to achieve compliance with the Act. It should be considered when such products are encountered during regular division operations, on assignment, or as a follow-up to complaints. This procedure becomes
most appropriate when no immediate arrangements can be made for local or state authority to take control of the product, and/or it appears that the product will not be held voluntarily.

5-4-3 Criteria For Effecting And Terminating Detentions

Use the following procedures in detention situations:

1. Exercise Of Detention Authority

   a. Meat and Poultry Products

      Detentions may be made when all of the following criteria are met:

      i. The article meets the jurisdictional requirement of interstate commerce in Section 304 of the Act and the article is in commercial channels;

      ii. The article is located in an establishment that does not have USDA meat or poultry inspection service;

      iii. The article is intended for human food or could readily be diverted into use for human food;

      iv. The article is adulterated or significantly misbranded under the Act.

      NOTE: Detentions based solely on misbranding or on adulteration involving Section 402(b) of the Act must be cleared by the Center for Food Safety and Applied Nutrition (CFSAN) before detention; and,

      v. The respective USDA, Food Safety Inspection Service Division Office has been notified and the action is coordinated with that office.

   b. Eggs and Egg Products

      Detentions may be made when all of the following criteria are met:

      i. The article is in commercial channels.

      NOTE: Interstate commerce is not a requirement for jurisdiction under the EPIA;

      ii. The article is located in an establishment that does not have USDA egg products inspection service;

      iii. The article is intended for human food or could readily be diverted into use for human food; and,

      iv. There is reason to believe the article is in violation of the EPIA.
2. **Termination Of A Detention Action**

   Detention should be continued until one of the following criteria is met:

   a. State, county or municipal authorities have exercised jurisdiction and control of the article; or, in the case of meat or poultry, USDA has assumed control;

   b. It has been determined that there is no significant violation of the FFDCA, or the EPIA, and the USDA has been notified that we intend to terminate the detention action;

   c. The detained article has been denatured, destroyed or reconditioned under appropriate supervision;

   d. The detention period of twenty (20) consecutive days, counting the day the detention was executed as the first day, has expired; or,

   e. Seizure has been accomplished.

   **NOTE:** Forward seizure recommendation as soon as possible after detention is accomplished, because the detention cannot be reinstated after the twenty (20) day detention period expires.

3. **Procedures**

   The IOM, Chapter 2, subchapter 2.7- Detention Activities contains specific inspectional instructions including initial reporting requirements, detention initiation, reconditioning, and termination.

5-5 **ADMINISTRATIVE DETENTION OF DRUGS**

5-5-1 **Purpose**

   This section provides procedures and defines responsibilities for the Administrative Detention of drugs.

5-5-2 **Background**

   The Food and Drug Administration Safety and Innovation Act (FDASIA) provided FDA with the authority to administratively detain drugs intended for human or animal use. It did so by amending section 304(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) to add drugs to the list of products subject to administrative detention. As a result, FDA has authority to detain drugs, devices, and tobacco products under section 304(g) of the FD&C Act as amended by FDASIA. Section 301(r) of the FD&C Act was also later amended to make it a prohibited act to move a detained drug in violation of a detention order under section 304(g). This authority is distinct from the authority to administratively detain
foods under section 304(h) of the FD&C Act (see Sec. 5-3 of the RPM for procedures related to the administrative detention of foods).

The intent of administrative detention is to protect the public health by preventing the movement, distribution, and use of products believed to be adulterated or misbranded until FDA has time to consider what regulatory action it should pursue concerning such products, including initiating enforcement action, if appropriate. FDA may conduct a seizure under section 304(a) of the FD&C Act, an injunction under section 302 of the FD&C Act or take other actions. Administrative detention is designed to permit swift and immediate action to ensure that adulterated or misbranded drugs do not enter commerce or, if they are already in commerce, to stop them from reaching consumers. FDA’s administrative detention authority may only be exercised during an inspection of a facility or vehicle conducted under section 704 of the FD&C Act.

Administrative detention of a drug requires prior approval by the Division Director in whose geographic Division the drug is located (21 CFR 1.980(e)).

If the geographic Division Director is not the program Division Director, the geographic Division Director should coordinate with the program Division Director in whose division the drugs are located. In these cases, the program Division Director is generally expected to perform the work associated with the administration detention (in coordination with the geographic Division Director) except those actions which, by regulation, must be performed by the geographic Division Director, such as approval of the detention order.

The detention period should be for 20 calendar days after the detention order is issued, unless the Division Director determines that a greater period is needed in order to seize the product, institute an injunction proceeding, or evaluate the need for legal action. In that case, he or she may extend the period by up to 10 calendar days.

Any person who would be entitled to claim the detained drug, may appeal the administrative detention and may also request an informal hearing on the appeal. The presiding officer’s decision to affirm or revoke the detention order must occur within five (5) working days after receipt of the appeal if there is no request for an informal hearing or if appellant requests that the informal hearing be held within 5 working days from the appeal’s filing date. If the appellant requests that a regulatory hearing be held at a date later than 5 working days after the appeal is filed, but not later than 20 calendar days after receipt of a detention order, the presiding officer must hold the hearing at a date agreed upon by FDA and the appellant. The presiding officer must decide whether to affirm or revoke the detention within 5 working days after the conclusion of the hearing.

1. References
The regulatory authority for administrative detention of drugs, relevant prohibited acts, and associated operations appears in sections 304(g), 301(r), and 201(x) of the FD&C Act, and in 21 CFR 1.980, 21 CFR part 16, 21 CFR 10.19, and 21 CFR 10.45. Investigations Operations Manual (IOM) Subchapter 2.7 Detention Activities also contains instructions for implementing the administrative detention authority. See IOM 2.7.2.2 for high-level instructions for administrative detention of drugs.

5-5-3 Issuing and Terminating Detention Orders

Section 304(g) of the FD&C Act gives FDA the authority to administratively detain a drug when an investigator has reason to believe that the drug is adulterated or misbranded. An administrative detention order temporarily prevents the drug from being distributed in commerce while FDA determines whether to institute a seizure, injunction action, or other actions.

This enforcement tool should be considered when there is likelihood that the drug will be moved or distributed before a seizure can be accomplished. The Division Director should determine the applicability of their counterpart state’s authorities when reasonable. The Division Director should contact the appropriate state officials to inquire if the state is willing to conduct a state embargo. Even if the state has embargo authority and is willing to use such authority, the Division Director should still consult with the Center Compliance Official, OSPOP/DE and OCC to determine whether the state embargo or FDA administrative detention is the appropriate enforcement action. The Division Director should contemplate leveraging public health resources including requesting state assistance in making the decision on whether an ADO should be placed on an adulterated or misbranded drug product.

If the Division Director concludes that the person in possession of the drug will voluntarily hold the drug and will provide assurances that integrity and security will be maintained over the drug on hand and/or provides adequate assurance they are willing and able to correct all violations prior to shipment, there is no need to detain the drug.

1. Basis for Detention

An investigator or other authorized FDA representative who is performing an inspection may order a drug detention (with appropriate Division Director approval) during an inspection of a facility or vehicle when he or she has reason to believe that the drug is adulterated or misbranded (section 304(g) of the FD&C Act and 21 CFR 1.980).

2. Approval of Detention Order by the Division Director

The Division Director in the geographic Division where the drug is located,
must approve the detention order in writing. If prior written approval is not feasible, prior oral approval must be obtained and confirmed in writing as soon as possible (21 CFR 1.980(e)).

The Division Director should verify that there is reason to believe that the drug is adulterated or misbranded. When there is reason to believe a drug is adulterated or misbranded, the Division Director may need to act quickly to protect the public health.

Prior to approving the detention order, the Division Director is expected to contact the Director of Compliance or their designee in the appropriate Center to ensure that the Center supports administrative detention. There should be sufficient reason to believe based on the observations made during the inspection that a product is adulterated or misbranded. Additionally, the Division Director should verify that the authorized FDA representative with reason to believe the drug is adulterated or misbranded has initiated a valid inspection under FDCA 704 (i.e. displayed credentials and issued a written notice of inspection to the most responsible person). (21 CFR 1.980(b)). Administrative detentions may not be ordered outside of an inspection (FDCA § 3014(g)(1)).

If the Division Director attempts, but is unable to make immediate contact with the senior compliance official and the Division Director has reason to believe a delay in issuance of an ADO covering finished product might result in serious injury or illness, the Division Director may immediately approve a detention order if one of the following exigent circumstances exist:

i. There is evidence of product tampering or intentional adulteration;

ii. A state or federal official has declared an emergency and the product appears to be adulterated or misbranded in response to that emergency after an FDA Notice of inspection has been issued and the FDA representative confirms the adulteration or misbranding appearance.

iii. The firm is actively distributing finished product which is already subject to a center-approved Class I recall;

iv. There is visible, gross microbiological contamination in a sterile product;

v. The firm is distributing a finished sterile product with positive sterility test results or contains endotoxins that exceed specifications, and the firm does not claim the results are invalid;

vi. The firm is distributing a finished non-sterile product with positive test
results for a known pathogen, and the firm does not claim the results are invalid;

If the Division Director approves a Detention Order under these circumstances, the Director must immediately notify the Center and attempt to gain center concurrence. If the Division Director is unable to obtain center concurrence within 24 hours of establishing contact with the Center, the Division Director must immediately terminate the order unless the center requests more time to evaluate.

**Detention Order and Detention Tags – Forms**

Section 2.7.2.3 of the IOM provides instructions for completing the Detention Order (Form FDA 2289). Section 2.7.2.4 provides instructions for completing the Detention Tag (Form FDA 2290), which should be affixed to the drug that is subject to the detention order.

Because the detention order frames the issues for an appeal and informal hearing, if any, the violation must be identified as below. Although the agency may initiate judicial action based on any appropriate violation (whether or not listed as a basis for detention), FDA may not introduce additional basis for detention during an appeal or informal hearing if they were not included in the written order. The detention order must include the information required by 21 CFR 1.980(d)(3):

1. a statement that the drugs identified in the order are detained for the period shown
2. a brief, general statement of the reason(s) for the detention;
3. the location of the drugs;
4. a statement that these drugs are not to be used, moved, altered, or tampered with in any manner during that period, except as otherwise permitted in this document, without the written permission of the Division Director or designee;
5. identification of the detained drugs;
6. the detention order number;
7. the date and hour of the detention order;
8. the period of the detention;
9. the text of section 304(g) and information about the appeal process.
located in 21 CFR 1.980(g)(1) and (2);

(10) a statement that any informal hearing on an appeal of a detention order must be conducted as a regulatory hearing under 21 CFR part 16, with certain exceptions as described in 21 CFR 1.980(g)(3).

(11) the location and telephone number of the FDA Division Office and Division Director. A continuation sheet may be used when all the information will not fit on the form.

3. **Length of Detention**

Initially, the drug should be detained for no more than 20 calendar days, unless the Division Director determines that additional time will be required to institute a seizure or to evaluate the need for other action. In such cases, the Division Director should authorize a detention period not to exceed 30 calendar days at the time the order is issued.

If the drug is detained for 20 calendar days and a seizure or other enforcement action cannot be instituted against the drug within that time frame, the detention can be extended to a total of 30 calendar days. If a detention is extended from 20 to 30 calendar days, amend the original detention order and place new tags or labels on the drug.

4. **Movement of Detained Drug**

No person may move a detained drug within or from the place where it has been detained until the Division Director terminates the detention order or the detention period expires, whichever comes first. This restriction prohibits any movement, use, alteration, or tampering with a detained drug (21 CFR 1.980(h)(1)), except to complete manufacturing or with written permission as explained below.

**Movement to Complete Manufacturing** (21 CFR 1.980(h)(2))

When a detained drug is not in final form for shipment (e.g. bulk tablets, unpackaged blister packs) and the manufacturer wants to complete work on the drug, then the manufacturer may move the drug within the establishment where it is detained in order to complete the work needed to put the drug in final form for shipment. In this instance, the manufacturer must orally notify the FDA official that issued the detention order or another responsible Division official of the movement as soon as it occurs. As soon as the drug is put into final form for shipment, it must be segregated from other drugs and the individual responsible for its movement must notify the FDA official that issued the detention order or another responsible Division official of its new location. Once in final form for shipment, the detained
drug must not be moved further without prior written approval from the appropriate FDA official.

**Other Movement with Written Permission** (21 CFR 1.980(h)(3))

The Division Director that issued the detention order or another responsible Division official may authorize, in writing, the movement of the detained drug for any of the following purposes:

i. To prevent interference with an establishment’s operations or harm to the drug.

ii. To destroy the drug.

iii. To bring the drug into compliance with the FD&C Act and its implementing regulations.

iv. For any other purposes that the FDA representative who issued the detention order, or other responsible FDA Division official, believes is appropriate in the case.

If the relevant FDA official grants permission to move the detained drug for any of the reasons listed above, the detained drug must remain segregated from other drugs and the person responsible for its movement must immediately notify the official orally or in writing who approved the movement, or another responsible FDA Division official, of the detained drug’s new location. 21 CFR 1.980(h)(4). Unless otherwise permitted by the FDA representative who is notified of, or who approves, the movement of the drugs, the required tags must accompany the drugs during and after movement and must remain with the drugs until FDA terminates the detention or the detention period expires, whichever comes first. 21 CFR 1.980(h)(5). To effectuate this requirement, the authorizing official may specify in the written authorization how the tags should “accompany” the drugs in situations where it is unclear how the firm can comply with this requirement (e.g. firm needs to transfer drug from one large, tagged container into multiple containers for shipment/reprocessing.)

5. **Termination or Expiration of a Detention Order**

If FDA terminates a detention order, the FDA representative authorized to terminate the detention will issue a Detention Termination Notice releasing the drug to any person who received the detention order or that person’s representative and will remove, or authorize in writing the removal of, the required tags or labels (21 CFR 1.980(j)). The Division Director has the authority to terminate a detention. Generally, the Program Division Director or program division employees will serve as the “FDA representative.
authorized to terminate” the detention and the Division Director, or other FDA representative authorized to terminate the detention, shall endeavor to issue the termination notice as soon as possible after one of the following occurs:

i. FDA determines that the drug is not adulterated or misbranded.

ii. FDA approves the voluntary destruction of the drug and the destruction is accomplished.

iii. FDA approves voluntary compliance by reconditioning or other means (e.g., relabeling, voluntary recall, etc.).

iv. A seizure action under section 304(a) of the FD&C Act has been instituted in court and the goods have been seized by the U.S. Marshals pursuant to a court-issued warrant. The filing of a complaint does not automatically terminate a detention order.

v. The detention period expires.

vi. The detention order is appealed, with or without an informal hearing, and the presiding officer revokes the detention order.

If any of the above conditions occurs, the Division Director must approve the termination of detention order and may do so by giving oral or written approval. The Division Director, or the investigator or compliance officer at the direction of the Division Director, issues a Detention Termination Notice (Form FDA 2291) to the person(s) who received the detention order. This termination notice should be provided to the person identified in the order or modified order who currently possesses the detained drug. Per 21 CFR 1.980(k), the termination notice must include or be accompanied by a statement advising the owner, operator, or agent in charge to keep records concerning the detention for the remainder of the two-year period from the date of detention, or such shorter period as FDA directs.

The Detention Termination Notice may be issued in person or by mail. If the Division issues the termination notice by mail, then the Division must also request that the Detention Tags (Form FDA 2290) be returned. The Division should, as matter of practice when a Detention Termination Notice is sent by mail, concurrently verbally notify the person who received the original detention order, or that person’s representative, that the detention has been terminated. Any delivery receipt should be documented.

If the termination notice is issued in person, see Section 2.7.2.5 of the
IOM for instructions. If the Division Director gives oral approval, then the Division Director should issue a written confirmation as well.

6. **Responsibilities for Issuing and Terminating Detention Orders**

The responsibilities of the relevant FDA components involved in issuing and terminating a detention order are set forth below.

a. Program Division Responsibilities - The Division is responsible for:

i. Verifying that the investigator has reason to believe a drug is adulterated or misbranded and then responding accordingly to protect the public health.

ii. Notifying the appropriate Center, OSPOP/DE, OCC, and other applicable program divisions as soon as it becomes aware of a situation where administrative detention may be appropriate.

iii. Determining whether the person in possession of the drug will voluntarily hold the drug and provide assurance that integrity and security will be maintained over the drug on hand, in which case, there is no need to detain the goods.

iv. Exploring the applicability of state regulatory oversight to include embargo authorities and license suspensions instead of administrative detention to conserve FDA resources (See 5-3-3 Issuing and Terminating Detention Orders).

v. Ensuring support from the senior compliance official of the appropriate Center and OCC before issuing a detention order, unless exigent circumstances exist, and the Division attempts to make contact, but Center or OCC are not immediately available.

vi. Obtaining the approval of the Division Director in accordance with 21 CFR 1.980(e).

vii. Obtaining OCC approval of draft detention order (unless exigent circumstances exist, and the Division attempts to make contact, but OCC is not immediately available).

viii. Issuing the detention order on Form FDA 2289, providing a brief, general statement of the reason(s) for the detention and stating the charge in the order in plain language. Ensuring all pages of the Form FDA 2289 are issued.

ix. Informing the owner, operator, or agent in charge of the place...
where the drug is located that the drug is being administratively detained and that he or she has an opportunity to appeal and have a hearing on the detention.

x. Informing the owner, operator, or agent in charge of the establishment where the drug is detained of his or her responsibility to establish and maintain records as required by 21 CFR 1.980(k) at the time the FDA official issues the detention order, or as soon as possible thereafter.

xi. Notifying the senior compliance official, or designee, of the appropriate Center, Director of OSPOP/DE, and OCC by phone or e-mail that the order has been issued and supplying them with a copy of the detention order and a copy of any supporting information, e.g., FDA Form 483, by the most expeditious means available (loading scanned copies into CMS, fax, express mail, e-mail, etc.) immediately after issuance. Coordinate with OSPOP/DE to ensure that an appropriate presiding officer is identified.

xii. Notifying the ORA Office of Pharmaceutical Quality Operations Program Director that the Division Director issued a detention order. However, the Program Director should not become involved in decisions relating to issuing or monitoring the detention order. The Program Director may be the presiding officer who decides any appeal of the detention order, and consequently, this individual must avoid participating in the investigation or action that is the subject of the detention order and to remain free from bias or prejudice (21 CFR 16.42(b)).

xiii. If CMS is not used for initial notification, loading copies of all related documents into CMS within a reasonable time.

xiv. Expediting the preparation and processing of a seizure recommendation involving the detained drug. The Division should flag the recommendation to indicate that it involves a detained drug and show the date the detention expires and should forward the recommendation to the responsible Center and notify the OCC Regional Litigation Senior Enforcement Advisor by the most expeditious means available (loading scanned copy into CMS, fax, express mail, e-mail, etc.) immediately after completion.

xv. Approving and monitoring any permitted movement of the drug once FDA issues the detention order.

xvi. Monitoring regularly the relevant phone, e-mail, and fax machine in the issuing Division’s office, over weekends and
holidays, for an appeal from any person that would be entitled to claim the drug had it been seized, unless the Program Division has no employees located in the Division office, in which case Division Office Personnel will monitor the fax machine.

xvii. If the Division Director or Program Division receives any communications regarding the ADO from any person that would be entitled to claim the detained drug had it been seized, the Division must immediately notify the relevant parties in ORA OPQO, the Division, OCC, OSPOP/DE, Center Compliance, and the presiding officer. All communications should be uploaded into CMS.

xviii. Monitoring the length of the detention and the progress of the seizure recommendation, as well as extending the detention order from 20 to 30 calendar days if the order will expire prior to the agency or State initiating any appropriate legal action.

xix. Coordinating with OCC, the U.S. Attorney’s Office and the Marshal's Service if a complaint for seizure is to be filed.

xx. Issuing a Detention Termination Notice (Form FDA 2291) in a timely manner.

b. Center Responsibilities - The Center is responsible for:

i. Deciding whether to support the reasonable belief that the product is adulterated or misbranded at the time of the proposed detention. If the Center with jurisdiction over the product does not support the proposed detention, then the Division Director may not issue the order. Generally, a formal submission of documents supporting the detention is not necessary; rather, the Center the senior compliance official communicates his or her decision to the Division Director by phone, email, or other expedited communication.

ii. Coordinating Center case review with other Centers as necessary.

iii. Reviewing quickly any information provided by the Program Division, through OSPOP/DE, alerting the Program Division and OCC of any problems, and forwarding to the Program Division all requested documents.

iv. Providing expert testimony and other support, as appropriate.

v. Working with the Program Division Compliance Branch and OCC
to identify evidence needed to support the legal case and appeal.

vi. Promptly notifying the Program Division, OSPOP/DE, and OCC of any issues or Center concerns that need to be resolved, prior to providing support for the administrative detention and subsequent enforcement action.

vii. Coordinating the administrative detention and subsequent enforcement action with the Program Division, OSPOP/DE and OCC.

c. OSPOP/DE responsibilities – OSPOP, Division of Enforcement is responsible for:

i. Ensuring that the Center and OCC have received copies of the detention order, any appeal (with or without a request for hearing), and other supporting documents. OSPOP/DE will coordinate the detention to ensure that all appropriate FDA components have received notification and are preparing for a hearing in a timely manner.

ii. Designating the appropriate Presiding Officer should a hearing be necessary and ensure the Presiding Officer is in contact with designated attorneys from OCC to assist with the hearing process.

iii. Coordinating location for the conduct of a hearing as necessary.

iv. Obtaining transcription services to document the hearing as necessary.

v. Coordinate the administrative detention and subsequent enforcement action with the Program Division, the appropriate Center, and OCC. For example, OSPOP/DE enlists the support of the presiding officer, alerts ACRA, and assures that legal representation is available to the Division/Center and the presiding officer.

d. OCC Responsibilities – The Office of Chief Counsel is responsible for:

i. Reviewing quickly any information provided by the Program Division, including the proposed detention order, and, through OSPOP/DE, alerting the Program Division, Division Director, and the Center’s senior compliance officials and OSPOP of any problems prior to the detention being put in place.

ii. Beginning preliminary preparations for any appeal. The
appropriate Deputy Chief Counsel for Litigation shall make staff assignments in OCC and notify the Program Division of the attorneys assigned to the case. The Principal Deputy Chief Counsel shall make staff assignments in OCC for the presiding officer.

iii. Providing litigation support for any subsequent Agency enforcement action.

e. ORA Office of Pharmaceutical Quality Operations Program Director Responsibilities –

i. Acting as a presiding officer, unless he or she removes himself or herself or is unavailable (21 CFR 1.980(g)(4), 21 CFR 16.40 and 16.42).

ii. Insulating himself or herself from all aspects of a detention except those relating to his/her responsibilities as a presiding officer.

5-5-4 Appeal of a Detention Order

1. Appeal, With or Without an Informal Hearing

Under section 304(g) of the FD&C Act, any person who would be entitled to claim the drug if it had been seized under section 304(a) of the FD&C Act, may appeal a detention order. The appeal must be submitted in writing, to the Division Director in whose Division the detained drug is located, at the mailing address, e-mail address, or fax number identified in the detention order. The appeal must include a statement by the appellant asserting an ownership or proprietary interest in the detained drug. If the detained drug is located at a place other than an establishment owned and operated by the appellant, the appellant must include documents showing that the appellant would have legitimate authority to claim the drug if it had been seized.

If the detention order is appealed, the appellant has the right to request an informal hearing. The request for a hearing must be in writing and must conform to time frames. The presiding officer has the authority to deny a hearing, in whole or in part, when the appeal raises no genuine and substantial issue of fact and FDA is entitled to judgment as a matter of law. If the presiding officer, in consultation with OCC, determines that a hearing is not justified, the presiding officer will issue written notice of that determination and provide it to all parties explaining the reason for denial. 21 CFR 16.26(a). See Exhibit 5-25 for Model letter denying a hearing.
If granted, the informal hearing will be conducted in accordance with 21 CFR Part 16, except where modified by 21 CFR 1.980(g)(3) or as waived by the presiding officer under 21 CFR 16.60(h), as appropriate. See Exhibit 5-24 for Model letter granting a hearing.

2. Time Frames

The regulation allows an appellant 5 working days from receipt of the detention order (which also serves as notice of opportunity for a hearing) to appeal the detention, with or without a request for an informal hearing. The appeal must be in writing, must be addressed to the Division Director in whose Division the detained goods are located, and must contain a statement asserting an ownership or proprietary interest in the detainted drug that would qualify the appellant to claim the drug if it had been seized. FDA will file the appeal on the day the appeal is received.

If the appellant does not request an informal hearing, the decision to affirm or revoke the detention must be rendered within 5 working days after the Division receives the appeal.

If the appellant does request a hearing, then the appellant must indicate whether the hearing is requested to be held within 5 working days after the appeal is received (an immediate hearing) or at a later date, but not later than 20 calendar days after the detention order was received (a delayed hearing).

When the appellant requests an immediate hearing, then the presiding officer holds the hearing and renders his/her decision within 5 working days after the date the appeal was filed. When the appellant requests a delayed hearing, the presiding officer schedules the hearing for no later than 20 calendar days after the detention order was received and issues his/her decision within 5 working days after the hearing concludes. If the appellant requests a delayed hearing, the presiding officer still must endeavor to conduct the hearing and issue his or her decision within 30 calendar days of the detention order being issued.

Presiding Officer Responsibilities – The presiding officer is responsible for:

1) Determining whether to grant or deny an appeal with or without an informal hearing request from the appellant in accordance with 21 CFR 1.980 and, as applicable, 21 CFR part 16. Any person who would be entitled to claim the drug if seized under section 304(a) of the FD&C Act, may appeal a detention order and may request an informal hearing as specified in 21 CFR 1.980.

2) If an appeal with a hearing is requested, determining whether the appellant has raised a genuine and substantial issue of fact justifying a hearing on the administrative detention order (21 CFR 16.26(a)), and if
not, denying the request for an informal hearing, in whole or in part. If the hearing is denied, the presiding officer must still issue a decision to revoke or affirm the detention order (i.e., whether the investigator had reason to believe the drugs were adulterated or misbranded at the time of the detention).

3) If there is an appeal, but no hearing is requested, determining whether the investigator had reason to believe the drugs were adulterated or misbranded at the time of the detention, i.e. affirming or revoking the detention order. 21 CFR 1.980(g)(7).

4) Determining whether to waive, modify, or suspend any provision under 21 CFR part 16 as authorized by 21 CFR 10.19 and 21 CFR 16.60(h).

5) See section 5-3-4 item # 5(b) below for further responsibilities of the presiding officer.

4. **Communications Between Parties to the Hearing and the Presiding Officer**

Parties to the hearing should avoid any off-the-record communication with the presiding officer. If any communication of this type occurs, it must be documented in writing and made part of the administrative record of the hearing. The other party must be provided with a copy of the letter or memorandum of the communication and must be provided an opportunity to respond (21 CFR 16.44(b)).

The person who writes a letter or memorandum of the meeting between a participant in the hearing and the presiding officer must send a copy to all the participants (21 CFR 16.44(c)).

5. **Appeal Processing Responsibilities**

a. **Program Division Responsibilities**

The Program Division should begin preparing for an appeal at the time it decides to detain a drug, because a potential claimant to the detained drugs may request an immediate hearing.

i. When the Division Director receives an appeal, the Division Director, or the Program Division acting at the direction of the Division Director:

   Date and time stamp the appeal and notifies the appellant in writing that it has received the appeal. If the appeal does not demonstrate an ownership or proprietary interest as required in 21 CFR 1.980(g)(1) and (2), contact the appellant and clarify this
information. The appellant must submit any missing information to the Division Director in writing.

Immediately notifies, orally or by email, the Center, OSPOP/DE, OCC, and the presiding officer of the appeal, and forwards a copy of the appeal to them as soon as possible by fax or electronically. Requests assistance of the Center, OSPOP/DE, and OCC as needed. OCC will designate attorneys to advise the Program Division, Center, and presiding officer.

ii. When the appeal includes a request for a hearing, the Division Director, or the Program Division acting at the direction of the Division Director:

Prepares a general summary of the information that will be presented by FDA at the hearing in support of the detention order ("general summary") and a comprehensive statement of the basis for the detention order ("comprehensive statement"), in accordance with 21 CFR 16.24(f). The detention order may serve as the comprehensive statement only if the reason for detention is described in sufficient detail.

Forwards the general summary and the comprehensive statement to the appellant (21 CFR 16.24(f)), the presiding officer, and the Center, OSPOP/DE, and OCC representatives. The Program Division sends the documents immediately to all parties so that they arrive as soon as possible, but at least one day prior to the hearing.

At least one day before the hearing, provides the appellant, presiding officer, and the Center, OSPOP/DE, and OCC representatives to the hearing, written notice of any published articles or written information to be presented at or relied upon at the hearing. A copy will also be provided in advance if the other participants could not reasonably be expected to have or be able to obtain a copy. If written notice or a copy is not provided, the presiding officer may, if time permits, allow the party who did not receive the notice or copy additional time after the close of the hearing to make a submission concerning the article or information. (21 CFR 16.24(g)).

iii. When the appeal does not include a request for a hearing, the Division Director, or the Program Division acting at the direction of the Division Director:

Forwards all the information that supports the detention to the
presiding officer and all OCC attorneys participating in the appeal. This includes the general summary and comprehensive statement and any additional information provided by the appellant. The information is expected to arrive within sufficient time for the presiding officer to render a decision on the appeal, affirming or revoking the detention, within 5 working days after the filing of the appeal.

b. Presiding Officer Responsibilities

i. When notified of an appeal, with or without a request for hearing, the presiding officer:

Determines whether the appeal is valid because the appeal has been submitted within the established time frame or if the appeal demonstrates ownership or proprietary interest as required in 21 CFR 1.980(g)(1), (2).

ii. When notified of an appeal, and a hearing is requested, the presiding officer:

Determines whether a hearing should be granted in whole or in part. A hearing will only be granted if the material submitted by the appellant raises a genuine and substantial issue of fact (21 CFR 16.26(a)). A hearing will not be granted on matters of law or policy. See Exhibit 5-24 Model Letter Granting a Hearing.

If the presiding officer denies a hearing, the presiding officer notifies the appellant of the hearing denial in writing. See Exhibit 5-25 for an example of a model letter denying an appellant’s request for a hearing.

If the presiding officer grants a hearing, the presiding officer orally contacts the parties as soon as possible to set a hearing date. Depending on whether the appellant selected an immediate or delayed hearing, the presiding officer will set a hearing date and time to allow for a decision with the time frames. If practicable, a hearing may be conducted via teleconference or video conference.

Provides all parties with written notification of the time, date, and location of the hearing. The hearing normally takes place at the Division Office in the geographic Division where the detained drugs are located.

Provides the appellant with oral and written notification of the following:
Notification of those portions of 21 CFR Part 16 that are excluded or modified under 21 CFR 1.980(g)(3) and waived or modified for hearings on appeal of administrative detentions (see "5-X-5").

Notification whether the informal hearing is to be public or not per 21 CFR 16.60(a). The Commissioner, or other official with delegated authority, determines whether all or part of a hearing should be closed to prevent a clearly unwarranted invasion of personal privacy; to prevent the disclosure of a trade secret or confidential commercial or financial information that is not available for public disclosure under 20.61; or to protect investigatory records compiled compiled for law enforcement purposes that are not available for public disclosure under 20.64.

Notification that the appellant should briefly summarize at the hearing any lengthy documents that they are presenting (e.g., voluminous computer printouts).

Notification that, if feasible, the appellant should provide the Division Director, at least 1 day before the hearing, written notice of, or a copy of (if the Division Director could not reasonably be expected to have or be able to obtain a copy), any published articles or written information that appellant intends to present or rely upon at the hearing, as required by 21 CFR 16.24(g).

Notification of the requirements under 21 CFR 16.44(c) (see "Communications Between Parties to the Hearing and the Presiding Officer").

iii. When there is an appeal, and no hearing is requested, the presiding officer is responsible for:

Immediately notifying the parties orally to submit information supporting their positions as soon as possible so that the information can be reviewed, and a decision reached within 5 working days after the appeal was received.

Orally notifying the appellant orally or in writing of the requirement under 21 CFR 16.44(c) (see “Communication Between Parties to the Hearing and the Presiding Officer”).

c. OCC Responsibilities – The Office of Chief Counsel is responsible
for all of the following:

i. Assigning OCC attorney(s) to represent advise the Division during any appeal and hearing.

ii. Assigning different OCC attorney(s) to represent the presiding officer during any appeal and hearing.

iii. Expediting review of information provided by the Division (or presiding officer, depending on whom OCC is supporting).

iv. Working with the Division (or presiding officer, depending on whom OCC is supporting) to prepare for any hearing and appeal.

d. Center Responsibilities - The Center is responsible for providing:

i. Scientific, technical, and policy support to the Division.

ii. Subject Matter Expert Witnesses at the hearing, if necessary.

e. Division of Enforcement (DE) Responsibilities - Division of Enforcement is responsible for ensuring that all:

i. All relevant FDA components are notified of and prepared for a hearing; and

ii. Documentation from the Division Director and/or the Program Division relating to the detention and hearing is provided to the Center's senior compliance official and OCC.

5-5-5 Informal Hearing on Appeal of a Detention Order

1. Background

Section 304(g) of the FD&C Act requires FDA to provide the appellant with an opportunity for an appeal including an "informal hearing," as defined in 201(x) of the FD&C Act. 21 CFR 1.980(g)(3) requires that FDA conduct the hearing in accordance with 21 CFR part 16, Regulatory Hearing before the Food and Drug Administration, with certain limited exceptions noted below. 21 CFR 16.5(b) advises that part 16 procedures apply to the extent that they are supplementary to, and not in conflict with, the other procedures specified in a regulation, in this case 21 CFR 1.980, that provides a person with an opportunity for a hearing and specifies some procedures for the hearing, but not a comprehensive set of procedures. Further, 21 CFR 10.19 and 21 CFR 16.60(h) give the presiding
officer the general authority to suspend, modify, or waive provisions under part 16.

According to 21 CFR 1.980(g), the presiding officer must be the ORA Program Director or another senior official above Division Director. DE is responsible to ensuring a presiding officer is assigned.

**Modifications to procedural requirements in 21 CFR Part 16**

The presiding officer must conduct the hearing in accordance with 21 CFR part 16, except the following sections of 21 CFR 16, as detailed in 21 CFR 1.980(g)(3):

a. §16.22(a). Under 21 CFR 1.980(d), the detention order provides notice of the opportunity for the hearing, rather than the notice under 21 CFR 16.22(a), and the detention order is part of the administrative record of the regulatory hearing under 21 CFR 16.80(a).

b. §16.22(b). Under 21 CFR 1.980(g)(3)(ii), a request for a hearing must be addressed to the FDA Division Director in whose Division the detained drug is located.

c. §16.24(e). The hearing may be held within 2 working days after the request for hearing is received. The last sentence in 21 CFR 16.24(e), stating that a hearing may not be required to be held at a time less than 2 working days after the request for hearing is received does not apply to a hearing under this section. §16.42(a).

d. §16.42(a). 21 CFR 1.980(g)(4), rather than §16.42(a), notes that ORA Program Directors or other FDA officials senior to an FDA Division Director may preside at hearings under this section.

After making the requisite findings under 21 CFR 10.19, the presiding officer has the authority to waive, suspend, or modify any of the other provisions in 21 CFR part 16. 21 CFR 16.60(h). In conducting a hearing under this section, the presiding officer should also waive the following other provisions, if appropriate:

a. §16.60(f), which requires the presiding officer to include as part of the report of the hearing: a finding on the credibility of witnesses (other than expert witnesses) whenever credibility is a material issue; and a proposed decision, with a statement of reasons.

b. §16.95(b)(1) & (2) states that the Administrative Record of a Regulatory Hearing (21 CFR 16.80(a)(1)-(5)) is the exclusive record and basis for the decision. These provisions may be modified as follows: the presiding officer bases the decision, in most cases, on all information presented to him or her prior to or during the hearing. The decision is not to be based on the following information or documents, if they are not received or completed by the presiding officer prior to the end of the hearing as required by the FD&C Act and its implementing regulations:
i. Information and views submitted to the presiding officer after the hearing are not part of the official record unless the presiding officer permits post-hearing submissions and the information is submitted within the period specified by the presiding officer (21 CFR 16.80(a)(2)).

ii. Any transcript of the hearing (21 CFR 16.80(a)(3)).

iii. The presiding officer's report of the hearing and comments on the report under 21 CFR 16.60(e) and 16.80(a)(4).

In addition, the presiding officer may, if appropriate, waive the part of 21 CFR 16.60(b) providing that all parties may confront and conduct reasonable cross-examination of any person (except for the presiding officer and counsel for the parties) who makes any statement on the matter at the hearing. See 21 CFR 16.5 and 16.60(h).

2. Conducting the Hearing

At the start, the presiding officer reminds the parties of the applicable modifications under 1.980(g)(3), to 21 CFR part 16 “Regulatory Hearing Before the Food and Drug Administration.” The presiding officer explains that the purpose of the hearing is to determine whether the FDA investigator, at the time of the detention and as set forth in the detention order, had reason to believe that the drug was adulterated or misbranded. The issue is not whether the drugs are actually adulterated or misbranded. That question is properly left to the Division Court in any subsequent enforcement action.

The FDA representative(s) is/are present to explain the basis for the detention and answer reasonable questions from the appellant.

The appellant then presents relevant information to support his/her position that the drug should not be subject to detention.

The presiding officer will ensure that the material presented, and the questions asked are relevant to the issue of the hearing and reasonable.

The presiding officer may, once the hearing commences, issue a summary decision on any issue in the hearing, if the presiding officer determines from the material submitted in connection with the hearing, or from matters officially noticed, that there is no genuine and substantial issue of fact respecting that issue (21 CFR 16.26(b)).

The appellant may request that the hearing be transcribed. However, the appellant must pay the cost of having the hearing transcribed and furnish FDA a copy for the record. FDA also may request a transcript of the hearing, in which case the costs are borne by the agency.
The presiding officer should notify the parties that his/her decision will not await transcription or any correction of the transcripts that is ordered.

3. **Responsibilities For The Hearing:**

   a. Center Responsibilities -
      The Center will provide documents, Subject Matter Expert witnesses, and office representatives for the hearing if requested by the Program Division and/or the OCC attorney representing the Program Division.

   b. OCC Responsibilities -
      OCC will provide counsel for the Program Division and the presiding officer, as appropriate, for the hearing.

   c. Program Division and Presiding Officer Responsibilities -
      Section 5-5-5, item # 2 “Conducting the Hearing” includes responsibilities of the Program Division and the presiding officer. The Program Division is responsible for assigning a Compliance Officer who has not previously been involved in the case to provide regulatory background and administrative assistance to the Presiding Officer.

5-5-6 Issuing the Decision on an Appeal

1. **Decision on an Appeal When Appellant Does Not Request a Hearing**

   If there is an appeal of the detention order, but the appellant does not request a hearing, the presiding officer must render a decision on the appeal, affirming or revoking the detention, within 5 working days after the appeal has been filed. The rationale behind the decision made should be documented in the record under 21 CFR 1.980(g)(7).

2. **Decision on an Appeal after a Hearing**

   The appellant has the option of selecting an immediate or delayed hearing. If the appellant requests an immediate hearing (within 5 working days after the appeal is received), then the presiding officer must hold the hearing and render a decision affirming or revoking the detention within 5 working days after the appeal was received (21 CFR 1.980(g)(5)). In contrast, if the appellant requests a hearing be held later than 5 working days after the appeal was filed, but not more than 20 calendar days after the detention order issued, then the presiding officer must hold the hearing on an agreed-upon date and decide whether to affirm or revoke the detention order within 5 working days after the hearing closes (21 CFR 1.980(g)(6)). The detention may not be extended past the otherwise applicable 30-day period.
3. **Basis for Rendering a Decision**

If the presiding officer determines that the investigator had reason to believe that the drug was adulterated or misbranded at the time of the detention under one or more of the bases set forth in the detention order, the presiding officer will affirm the detention order. If there was no reason to believe the drugs were adulterated or misbranded, the presiding officer will revoke the detention order.

4. **Issuance of the Order**

The presiding officer issues the decision in the form of an order. (See Exhibit 5-26 for model order confirming detention and Exhibit 5-27 for a model order revoking the detention.) The parties to the appeal should be orally notified of the order immediately. Copies of the order should then be mailed to the parties via overnight delivery with documented return receipt.

The presiding officer must render his/her decision on the detention within the time frames listed previously. The presiding officer cannot delay his/her order pending completion of a written decision and any report of the hearing (discussed subsequently). When possible, the presiding officer’s order should be issued at the same time as the written decision and any report of the hearing. However, in cases where the presiding officer needs additional time to complete the written decision and any report of the hearing, the written order may issue first, and the written decision may issue separately from and shortly thereafter the order. All parties involved should receive a copy of both the written order and the written decision.

5. **Written Decision and Report of Hearing**

The presiding officer must prepare a written decision report that includes the reasons and bases for his or her order (§ 16.95(b)(2)). The written decision must include any report of the hearing required under 21 CFR 16.60(e), if applicable. All written material submitted during the hearing and any report of the hearing must be attached to the written decision (21 CFR 16.60(e)). Any transcripts of the hearing should be included, if available.

Whenever time permits, the participants will be given the opportunity to review and comment on the written decision and report of the hearing. However, the presiding officer should set a time limit for the participants to comment. (As previously noted, whenever possible, the written decision and report of the hearing should be issued with the order as a single document).

5-5-7 **Administrative Record and FOIA Requests**

1. **Administrative Record of Appeal without a Hearing**
The presiding officer must prepare the administrative record of the appeal, which consists of the following:

a. The detention order and the appeal.
b. All written information submitted to the presiding officer in conjunction with the appeal.
c. All letters and memoranda of meetings and communications between participants and the presiding officer referred to in 21 CFR 16.44(c).
d. The presiding officer’s order and written decision.

2. Administrative Record of Appeal with Hearing

The presiding officer must prepare the administrative record of the hearing, which consists of the following:

a. The detention order and the appeal.
b. All written information submitted to the presiding officer in conjunction with the appeal and hearing.
c. Any transcript of the hearing, if available.
d. All letters and memoranda of meetings and communications between participants and the presiding officer referred to in 21 CFR 16.44(c).
e. The presiding officer’s written decision, report of the hearing, order, and any comments or written decision or report of the hearing permitted under Section 201(x) of the FD&C Act and 21 CFR 16.60(e).

The presiding officer will forward the completed original administrative record to the Program Division Director. The Program Division will ensure storage of the original Administrative Record, with the firm’s official file at the Division office after completion of the report. The Program Division will ensure that an electronic copy is uploaded into the CMS Case and is distributed to the Division Director, OCC, OSPOP/DE, the Center, and the ORA Office of Pharmaceutical Quality Operations.

3. FOIA Requests

21 CFR part 20 applies to all requests for the administrative record and other documents relating to administrative detentions.

5-6 ADMINISTRATIVE DETENTION OF DEVICES

5-6-1 Purpose

This section provides the procedures and defines responsibilities for the Administrative Detention of Devices.
5-6-2 Detention of Devices

1. Background

Section 304(g) of the Act authorizes the FDA to detain devices intended for human use for a period of up to thirty (30) calendar days if, during an inspection, the FDA has reason to believe the devices are adulterated or misbranded. The intent of administrative detention is to protect the public by preventing distribution or use of violative devices until FDA has had time to consider the appropriate action to take and, where appropriate, to initiate a regulatory action. The action of choice, in most cases, is a seizure. Detention of devices requires prior approval from the division director in which the devices are located and the concurrence of the appropriate center's director for compliance.

Any person entitled to claim the devices, if seizure occurred, may appeal the detention and may request a hearing on the appeal. The decision to affirm or revoke the detention must occur within five (5) working days of receipt of the appeal if there is no request for a hearing or if the request for a hearing is within five (5) working days after filing the appeal. If requesting the hearing for a date more than 5 working days after receiving the appeal, the decision must occur within five (5) working days after the conclusion of the hearing.

The Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH) are responsible for administering the medical device amendments. See 21 CFR Part 3.

2. References

The regulatory authority for administrative detention and associated operations appears in Sections 304(g) and 201(x) of the Act, and in 21 CFR 800.55, 21 CFR Part 16, 21 CFR 5.47, and 21 CFR 10.19. The IOM Chapter 2, Subchapter 2.7, Detention Activities contains the instructions for implementing the detention authority.

3. Detention Procedure

This enforcement tool should be considered when there is likelihood that the device(s) will be moved or distributed before seizure can be accomplished. Whenever possible, state embargoes should be used instead of administrative detention because the latter can be resource intensive.

If the division director concludes that the person in possession of the device(s) will voluntarily hold the product, will provide assurance that integrity and security will be maintained over the devices on hand, and agrees to correct the violation(s) prior to shipment, there is no need to detain the goods.
At a minimum, prior to approving the detention order, the division director contacts the senior compliance official in the appropriate center to ensure that the Agency supports an administrative detention based on the violations observed. This ensures that the Agency considers recent developments or changes not yet communicated to the division. In addition, the division director notifies headquarters of the impending seizure recommendation. Contacts are:

For a conventional medical device:
Director, Office of Compliance (HFZ-300), CDRH
(301) 796-5500

or, for a biological device:
Director, Office of Compliance and Biologics Quality (HFM-600), CBER
240-402-9153.

Concurrence is by telephone. The division or headquarters does not require written concurrence except for cause, for example, for issues of science, policy, or law involving precedent or questionable facts.

a. Approval of Detention Order By The Division Director
The division director approves a detention order, before issuance, either orally or in writing. If the approval is oral, it should be placed in writing as soon as possible.

b. Detention Order Issuance
An investigator or other authorized agent signs the order. Issue the order in writing to the owner, operator, agent, or other responsible person in charge of the place where the device is located.

When issuing the order, the FDA investigator informs the owner, agent or other responsible person that they have the opportunity to appeal and have a hearing on the detention as noted on the order. If the order is not issued to the owner or agent of the owner of the device, then the division sends, as soon as possible, copies of the detention order and 21 CFR 800.55(g)(1) & (2) to the owner, via certified mail return receipt requested.

c. Form of Order
Issue the detention order on [Form FDA 2289 Detention Notice](#). Section 2.7.2.3 of the [IOM](#) contains instructions for completion of the form.

The detention order frames the issues for appeal or informal hearing, which may result from the detention. Therefore, the information on the order concerning the reason for detention is very important.
There is no requirement that the order include all of the reasons for believing that the product is adulterated or misbranded. Only list the more significant violations. However, if a violation is not identified in the order, it may not be relied on to support the detention. State the charge in the order in factual, non-statutory language. For example, if the investigator finds a sterile, individually packaged syringe with holes along the seams of the packaging, black greasy spots on the needle, and the label lacks the Zip Code of the manufacturer, describe the apparent violation in the reason for detention as "there is reason to believe the device is:

Adulterated per Section 501(a)(2)(A) of the Act because there are holes in the package and black spots on the needles. The firm prepared, packed, or held the product under insanitary conditions whereby it may have been rendered injurious to health.

Misbranded per Section 502(a) because the label states that it is sterile and the integrity of the package is compromised by holes. The labeling is false or misleading."

**Note:** Use a "continuation sheet" if all of the charges will not fit on the form.

**Note:** Charges used in the detention order do not necessarily limit the charges that may be identified in a subsequent complaint filed in court.

d. Length of Detention

According to statute, a detention is for twenty (20) calendar days unless the division believes that additional time is required to accomplish a legal action. In such cases, the detention is for thirty (30) calendar days at the time of issuing the order. When extending a detention from twenty (20) to thirty (30) days, issue another detention order and place new tags on the devices.

By statute, the detention cannot last for longer than thirty (30) calendar days.

e. Movement, Use, etc. of Detained Devices

Except as noted below, without the written permission of the Agency, detained devices cannot be moved, used, altered, or tampered with in any manner. Therefore, if possible, the investigator should segregate the detained devices from other devices or products at the time of the detention, so they remain undisturbed.

With the approval of the division director, the investigator who detained the devices or any other responsible division official may authorize, in writing,
the movement of detained material. Whoever moves the devices must immediately notify (orally) the authorizing official of the new location.

The only exception to the prohibition on movement without written permission is when the goods are not in final form for shipment and the manufacturer wants to complete work on them. The manufacturer may move them within the facility where detained to complete manufacture but must orally notify FDA of the movement as it occurs. When completing manufacturing, the manufacturer must immediately segregate the detained devices from other products and orally notify FDA of their new location.

However, the manufacturer may not move the devices from the establishment without prior written approval of the division director as referenced above.

Note: 21 CFR 800.55(h)(2) prohibits further movement even within the establishment without FDA approval.

f. Legal Actions Against Detained Devices

The division should expedite the preparation and processing of a seizure recommendation involving the detained devices. The recommendation should be flagged to indicate that it involves detained devices and show the date the detention expires and should be forwarded to the responsible center by overnight delivery service.

The center compliance office, ORA, and OCC should likewise expedite their reviews to accomplish the legal action prior to expiration of the detention. If the move the goods and the violative product may find its way into commercial distribution.

The division is responsible for monitoring the length of the detention and the progress of the recommendation. If a twenty (20)-day detention expires prior to accomplishing the legal action, the division should extend the detention for an additional ten (10) days.

The division is responsible for coordination with the U.S. Attorney's office and the Marshal's Service, ensuring prompt filing of the complaint, and seizure of the goods.

The division is also responsible for immediately providing oral notice to the appropriate center compliance office, OCC, and the presiding officer of the accomplishment of the seizure or of any appeal of a detention order.
g. Recordkeeping Requirements

At the time of issuance of a detention order, or as soon as possible thereafter, the division informs the owner, operator, or agent in charge of the establishment where the devices are detained of their responsibility to establish and maintain records as required by 21 CFR 800.55(k).

h. Termination of Detention Orders

i. The reasons for termination of Detention orders:

- FDA determines that the device(s) is (are) not violative.
- FDA approves voluntary destruction or compliance by reconditioning or other means (e.g., relabeling).
- FDA revokes the detention on appeal.
- FDA accomplishes a regulatory action against the product. Actual seizure or entry of TRO or an order by consent or otherwise of preliminary injunction is necessary. The filing of a complaint does not necessarily terminate a detention order.
- The detention period expires.

The division director, within whose division the devices are detained, must approve termination of detention orders. Approval is oral or written, and if oral, confirmation is in writing. The division issues the Detention Termination Notice (Form FDA 2291) to the person(s) who received the Detention Notice, or his representative and, if movement of the devices occurred prior to the termination, to the person possessing the devices. Issuance of the notice is in person or by mail. If the termination notice is issued by mail, request that the Detention Tags (Form FDA 2290) be returned. If the termination notice is issued in person, see IOM 2.7.2.5 for advising the owners, operators, or agents in charge to keep the records concerning the detention for the remainder of the two year period from the date of detention or such shorter period as FDA directs.

4. Responsibilities for Issuing and Terminating Detention Orders

a. Division Responsibilities As referenced above, the division is responsible for:

i. Ensuring support from the senior compliance official of the appropriate center before issuing a detention order.

ii. Issuing the detention order.

iii. Notifying the Director of the Division of Enforcement (DE) by phone of the detention and supplying that person with a copy of the detention order by the most expeditious means available (fax, express mail, etc.) immediately after issuance.
iv. Approving and monitoring the movement of detained devices.

v. Notifying OSPOP/DE and the program director that the division issued a detention order.
   
   **NOTE:** Keep the Division Director insulated from detention proceedings after the detention is in place in order to avoid even the appearance of bias or prejudice.

vi. Pursuing the follow-up legal action as discussed under the heading, "Legal Actions Against Detained Devices."

b. Center Compliance Office Responsibilities

Division contact with the center, for concurrence, is a routine procedure. If the director of compliance for the center will not support a proposed detention, do not issue the order. Communication of the director's decision to the division is by phone, e-mail, or other expedited communication. Generally, a formal submission of documents supporting detention is not necessary.

The compliance office will quickly review any information provided by the division, through DE, alert the division, and OCC of any problems, and forward to the division all requested documents. The compliance office will provide expert witnesses and other support, as appropriate.

c. Office of Chief Counsel Responsibilities

OCC will quickly review any information provided by the division, and through DE, alert the division, the center office, of any problems, prior to the detention being put in place.

The Deputy CC for Litigation or the Deputy CC for Regulations and Hearings shall make staff assignments in OCC and notify the center and DE of the attorney assigned to the case. OCC will begin preliminary preparations for any appeal. OCC will determine whether the division and the program(s) require legal counsel.

d. DE Responsibilities

Upon notification that a detention has been affected or a subsequent appeal received by the division:

DE will immediately notify the center compliance office and OCC, and deliver to them copies of the detention order, request for hearing, and other supporting documents. DE will coordinate the detention to ensure that all Agency and OCC components receive notification and prepare for a hearing in a timely manner.
e. Division Responsibilities

The Division must insulate himself/herself, after the detention is in place, from all aspects of a detention except those relating to his/her responsibilities as a presiding officer. Responsibilities at that time are in the next section, "Appeal of a Detention Order."

5-6-3 Appeal Of A Detention Order

1. General Information
   a. Background

   Section 304(g) of the Act permits anyone who is entitled to claim the goods, if seized, to appeal a detention order.

   If appealing the detention, Section 304(g) requires that the Agency afford the appellant with an opportunity for an informal hearing. If the appellant does not request an informal hearing, the decision to affirm or revoke the detention must be rendered within five (5) working days after the filing of the appeal. The appellant may request the holding of an informal hearing either within five (5) working days after filing the appeal or at a later date, but not later than twenty (20) calendar days after receipt of the detention order. 21 CFR 800.55(g)(1). If the appellant requests a hearing within five (5) working days after filing the appeal, the presiding officer holds the hearing and renders a decision within five (5) working days of the filing of the appeal. In the event of a request for a delayed hearing, the scheduling of the hearing must occur after the fifth working day following the appeal, and a decision must be issued within five (5) working days of the hearing's conclusion.

   Regardless of the scheduling of the hearing, there is no extension past the thirty (30)-calendar day detention period without the consent of the appellant. (The provision for extension of the detention found in 21 CFR 800.55(g)(6) is incorrect and should not be followed.)

   b. Time to Appeal

   The regulations allow an appellant five (5) working days from the receipt of the detention order (which also serves as a notice of opportunity for a hearing) to appeal the detention, with or without a request for an informal hearing. The appeal must be in writing, must be addressed to the division director of the division office within whose area the goods are detained, and must contain a statement asserting that interest (e.g., ownership) in the detained goods would qualify the appellant to claim the goods if they were to be seized. The postmark on the appeal letter will determine the date of the appeal.
The division director will allow one (1) day of additional time for the receipt of an appeal request. Allow additional time if the appellant shows that it was impossible to appeal earlier.

c. Presiding and Deciding Official

The director for the division where the division is located and in which the goods were detained must be the presiding and deciding official unless he/she disqualifies him/herself (21 CFR 800.55(g)(4), 21 CFR 16.40 and 16.42, and 21 CFR 5.47). In the event of disqualification, the Division will immediately arrange for another Division to preside and provide immediate notification of any such change to the division director and the appellant.

Communications Between Parties to the Hearing And the Presiding Officer

Avoid any off-the-record communication between parties to the hearing and the presiding officer. If any such communication occurs, reduce it to writing and make it a part of the record. The presiding officer must supply a copy of any memoranda of such communication, which would affect his or her decision, to the other party, giving them an opportunity to respond. 21 CFR 16.44(b).

The person who originates any written communication between a participant in the hearing and the presiding officer must send a copy of any such communication to all of the participants. 21 CFR 16.44(c).

2. Appeal Processing Responsibilities

a. Division Responsibilities

Preparation for an appeal should begin when the division decides to detain a device(s), in case a hearing is requested within five (5) working days of the filing of the appeal.

i. When the division receives an appeal, the director:

- Dates and time-stamps the appeal, and notifies the appellant of receipt of the appeal. If the appeal does not specify that a hearing is or is not requested, does not demonstrate ownership or proprietary interest as required in 21 CFR 800.55(g)(1) and (2), or does not specify the time period within which to hold a hearing (see “Appeal of a Detention Order- Background”), contact the appellant and clarify this information. Make any declaration of ownership or proprietary interest in writing.
• Orally notifies the Division and the Director, DE of the appeal immediately and forwards a copy of the appeal to them as soon as possible. Requests assistance of OCC and the appropriate center for completing the next item.

ii. When the appeal includes a request for a hearing:

• Prepare (1) a general summary of the information that the detention and (2) a comprehensive statement of the basis for the action. The Detention Order (notice) may serve as the comprehensive statement only if the reason for detention is described in sufficient detail. See Exhibits 5-14 and 5-15 for an example of a general summary and a comprehensive statement respectively. See Exhibit 5-16 for examples of reasons detailed enough for the FDA 2289 to serve as a comprehensive statement.

• Forward the general summary and comprehensive statement to appellant (21 CFR 16.24 (f) and Section 201 (x)(3) of the Act, the Division, and any office and OCC representatives to the hearing. Send the documents immediately so that they arrive as soon as possible, but at least one (1) day prior to the hearing.

• At least one (1) day before the hearing, provide the appellant, the Division, and any office and OCC representatives to the hearing, written notice of, or copies or, if they could not reasonably be expected to obtain copies, and published articles or written information to be presented at or relied on at the hearing (21 CFR 16.24 (g)).

iii. When the appeal does not include a request for a hearing, the division forwards all the information that supports the detention to the Division acting as the deciding official. The division includes the referenced general summary and comprehensive statement and any additional information provided by the appellant. It must arrive within sufficient time to be reviewed and for a decision to be rendered within five (5) working days after receipt of the appeal.

b. Presiding Division Responsibility

When notified of an appeal, the Division

i. If a hearing is requested,

• Orally contact the parties as soon as possible. Depending on the time period within which the appellant requests a hearing, either set a hearing date and time to allow for a decision within five (5) working days after the date of receipt of the appeal by the division, or set a hearing date and time later than five (5) working days after
receipt of the appeal by the division, but not later than twenty (20) calendar days after issuance of the detention order. The hearing normally takes place at the division office where the goods are located.

- Provide all parties with written notification of the time, date, and location of the hearing.

- Provide the appellant with oral and written notification (see form letter as Exhibit 5-17) of the following:

  ii. Notification of those portions of 21 CFR Part 16 that are excluded or modified under 21 CFR 800.55(g)(3) and waived or modified for hearings on appeal of administrative detentions. See subsection 5-5-4 "Informal Hearing on Appeal of a Detention Order."

  iii. Notification that the informal hearing is not a public hearing per 21 CFR 16.60(a), in order to protect investigatory records compiled for law enforcement purposes that are not available for public disclosure under 21 CFR 20.64, or trade secret material under 21 CFR 20.61.

  iv. Notification that the appellant should provide, at the hearing, a brief summary of any lengthy documents for presentation at the hearing (e.g., volumes of computer printouts).

  v. Notification that if feasible, at least one (1) day before the hearing, the appellant should provide the division director written notice of, or a copy of (if the division director could not reasonably be expected to obtain a copy), any published articles or written information for presentation at or relied on at the hearing as required by 21 CFR 16.24(g).

  vi. Notification of the requirements under 21 CFR 16.44(c) (see "Communications Between Parties to the Hearing and the Presiding Officer.")

  vii. If an appeal is made but no hearing is requested, the presiding officer must immediately orally notify the parties to submit information supporting their positions as soon as possible so that the information can be reviewed, and a decision reached within five (5) working days of the receipt of the appeal. We will accept additional information submitted prior to the decision. The presiding officer orally notifies the appellant of the requirement under 21 CFR 16.44(c) (see "Communications Between Parties to the Hearing and the Presiding Officer.")

When advice of the CC is needed, contact the Deputy CC for Litigation.
5-6-4  Informal Hearing On Appeal Of A Detention Order

Section 304(g) of the Act states that upon appeal of a detention order, the Agency will afford the appellant with an opportunity for an "informal hearing." Section 201(x) of the Act defines an informal hearing and lists specific provisions. 21 CFR 800.55(g)(3) provides that 21 CFR Part 16, Regulatory Hearing, establishes the procedures for conducting the informal hearing. 21 CFR 16.5 of the regulations advises that Part 16 procedures apply to the extent that they are supplementary to, and not in conflict with, other procedures specified for the hearing. 21 CFR 16.60(h) gives the presiding officer the power to suspend, modify, or waive provisions under Part 16.

1. Waivers, Modifications, Etc. To 21 CFR Part 16

21 CFR 800.55(g)(3) waives the following sections of 21 CFR Part 16:

a. §16.22(a) concerning the issuance of a separate notice of opportunity for hearing because the detention notice FDA 2289 serves that function under 21 CFR 800.55(g)(3)(i).

b. §16.22(b) concerning the forwarding of the appeal to the presiding officer because 21 CFR 800.55 (g)(1) requires sending the appeal to the division director.

c. §16.24(e) concerning not permitting the hearing to be held within two (2) days of the receipt of the appeal because time constraints cannot allow for such a restriction.

d. §16.42(a) regarding those persons who may act as the presiding officer because 21 CFR 800.55(g)(4) only allows Divisions to be presiding officers.

The presiding officer has the authority to waive, suspend, or modify any of the provisions under Part 16 (21 CFR 10.19 and 21 CFR 16.60(h)). The presiding officer must waive the following other provisions:

a. §16.60(f) which requires the hearing officer to make a recommended decision with statement of reasons to the deciding official because the Division performs both functions.

b. §16.95(b)(1) & (2) which state that the Administrative Record of a Regulatory Hearing (21 CFR 16.80(a)(1)-(5)) is the exclusive record and basis for the decision, are modified as follows: FDA bases the decision, in most cases, on all information presented to the presiding officer prior to or during the hearing. The decision is not to be based on the following information or documents, if they are not received or completed by the presiding officer within the time necessary for the presiding officer to review or complete them prior to making the decision as required by the Act or regulation:
i. Information and views submitted to the presiding officer after the hearing are not part of the official record unless the presiding officer permits post-hearing submissions and submittal of information occurs within the period specified by the presiding officer (21 CFR 16.80(a)(2)).

ii. Any transcript of the hearing (21 CFR 16.80(a)(3)).

iii. The presiding officer's report of the hearing and comments on the report under 21 CFR 16.60(e) and 16.80(a)(4).

FDA waives that part of 21 CFR 16.60(b) which provides that all parties may confront and conduct reasonable cross-examination of any person (except for the presiding officer and counsel for the parties) who makes any statement on the matter at the hearing. There is an allowance for reasonable questions instead. Reference Congressional intent: House of Representatives Report no. 94-853. Also, see 21 CFR 16.5 and 16.60(h).

2. **Responsibilities for the Hearing**

   a. **Center Responsibilities**

      The center will provide documents, witnesses, or office representatives for the hearing if requested by the division or the OCC attorney counseling the division.

   b. **Office Of Chief Counsel Responsibilities**

      OCC will provide for the division and/or the presiding officer, as appropriate, for the hearing.

   c. **Division And Presiding Division Responsibilities**

      The section “Conducting the Hearing” includes individual responsibilities of the division and the presiding Division.

3. **Conducting The Hearing – General Procedures/Responsibilities**

   At the onset, the presiding officer reminds the parties of the modifications to Part 16 that apply and explain the purpose or issue of the hearing. The issue at the hearing is whether FDA had reason to believe the devices were adulterated or misbranded at the time of the detention and as charged in the detention order. The issue is not whether the law has been violated. That question is properly left to the court trial, if one is held.

   The FDA representative(s) is present to explain the bases for the detention and answer reasonable questions from the appellant.
The appellant then presents relevant information and reasons why he believes the Agency did not have reason to detain the product.

The FDA representatives may then ask reasonable questions (see Section 201(x)(4) of the Act).

The presiding officer ensures that the material presented, and the questions asked are relevant to the issue of the hearing.

The appellant may request a transcript of the hearing. However, the appellant must pay the cost of it and furnish the presiding officer a copy for the record. The Agency can also request a transcript of the hearing and the costs are borne by the government.

If the appellant wishes a copy of the government transcript, he/she may obtain it via a Freedom of Information (FOI) Act request. 21 CFR Part 20 applies to the release of the transcript.

The presiding officer notifies the parties that his decision will not await transcription or correction of the transcripts so ordered.

5-6-5 Requirements After A Hearing On Appeal Of A Detention Order

1. Presiding Division Responsibility
   a. Confirming or Revoking the Detention Order
      i. Time Period for Rendering Decision
         As referenced in subsection 5-5-3 "Appeal of a Detention Order - Background," the presiding officer must by order, confirm or revoke the detention order within five (5) working days of the receipt of the appeal by the division director, if there is no hearing requested or if the appellant requests a hearing within five (5) working days. However, if the appellant requests a hearing later than the referenced five (5) working day time frame, but not later than twenty (20) calendar days after issuance of the detention order, then the presiding officer must, by order, confirm or revoke the detention order within five (5) working days after the close of the hearing. 21 CFR 800.55(g)(5) and (6). The detention may not be extended past the otherwise applicable thirty (30)-day period (see "Appeal of a Detention Order - Background") without the consent of the appellant.
ii. Basis for Rendering Decision

If the Agency can show that it had a reason to believe that the devices were adulterated or misbranded at the time of the detention under one or more of the charges in the detention order, the presiding officer will affirm the detention order. If not, the presiding officer will revoke the detention order.

iii. Issuance of the Order

The decision is issued in the form of an order. (See Exhibit 5-18 for model order.) The parties to the appeal should be orally notified of the order immediately. Copies of the order should then be mailed to them via certified mail return receipt requested.

FDA must order the decision rendered on the detention within the above time frames; however, the completion of the written decision and report of the hearing (discussed below) cannot delay the order. Normally, the order is consolidated with the written decision and report of the hearing. However, there are cases when the Agency needs additional time to complete the written decision and report of the hearing. In that case, it is separate from and will shortly follow the order.

b. Written Decision and Report of Hearing

The presiding officer must prepare a written decision to include the reasons and basis for his decision. 21 CFR § 16.95(b)(2). The written decision must include the report of the hearing required by Section 201(x)(5) of the Act and 21 CFR 16.60(e). All written material submitted during the hearing must be attached to the written decision and report of the hearing (Section 201(x)(5) of the Act and 21 CFR 16.60(e)). Any transcripts of the hearing must be included.

Whenever time permits, the participants will be given the opportunity to review and comment on the written decision and report of the hearing. However, the presiding officer should set a time limit for the participants to comment. (As previously noted, whenever possible, the written decision and report of the hearing should be issued with the order as a single document).

c. Administrative Record of the Hearing

The presiding officer must prepare the Administrative Record of the Hearing, which consists of the following items:

i. The detention order and the appeal.
ii. All written information and views submitted to the presiding officer in conjunction with the hearing.

iii. Any transcript of the hearing.

iv. The presiding officer's written decision, report of the hearing, order, and any comments on the written decision or report of the hearing permitted under Section 201(y) of the Act and 21 CFR 16.60(e).

v. All letters and memoranda of meetings and communications between participants and the presiding officer referred to in 21 CFR 16.44(c).

File the original Administrative Record of the Hearing with the firm's official file at the division office after completion of the report. A copy should be forwarded to the center involved for its information. A copy should be maintained in the office of the Division that held the hearing.

2. **FOI Requests**

21 CFR Part 20 applies to all requests for documents involved in administrative detentions.

---

### 5-7 LICENSE REVOCATION OR SUSPENSION

#### 5-7-1 Purpose

This section contains procedures for revoking and suspending biologic licenses issued under the Public Health Service Act (PHS Act) [42 U.S.C. 264]. These procedures are applicable to actions recommended by the division or by CBER.

"Revocation" is the cancellation of a license and the withdrawal of the authorization to introduce or deliver for introduction into interstate commerce, biological products, at either the request of the manufacturer or when grounds exist for the Agency to initiate such an action.

"Suspension" is a summary action taken by the Agency and may be an initial or intermediate step in the revocation process. Suspension provides for the immediate withdrawal of the authorization to introduce or deliver for introduction, biological products into interstate commerce when the Commissioner has reasonable grounds to believe that any of the grounds for revocation exist and that by reason thereof there is a danger to health.

#### 5-7-2 General

Licenses issued for the manufacture of specific biologic products under the provisions of Section 351(a) of the PHS Act, may be: 1) revoked upon request of the licensee or by
initiative of the Commissioner when sufficient grounds exist; or 2) suspended if one or more of the grounds for revocation exists and presents a danger to health (see 21 CFR 601.5 and 601.6).

CBER’s Office of Compliance and Biologics Quality (OCBQ), Division of Case Management (DCM) reviews recommendations for license revocation and suspension proposed by the division offices or the appropriate unit within CBER. If DCM concurs with the recommendation, it is forwarded to OCC for review. If OCC concurs, the recommendation and action letter are sent to the Director, CBER for concurrence and signature. Pursuant to SMG 1410.203, the Commissioner has delegated the authority to issue notices of revocation and suspension to the Director and Deputy Director, CBER.

OCBQ ensures that recommendations for license revocation or suspension are supported with evidence of violations of the applicable statutes and regulations. License suspensions and revocations are significant enforcement actions with possible far-reaching consequences. As such, it is important to consider the impact that the action may have on product supply as part of the Agency’s review of a proposed license suspension or revocation action.

When the license relates to multiple locations, revocation may be limited to one or more of the locations, if inspectional findings support that approach.

In the absence of willful noncompliance or a history of violations of a significant nature, the division or CBER inspection review unit considers issuing a Warning Letter or conducting a meeting with the firm, rather than recommending revocation as a first-choice remedy.

Part V of the Compliance Program Guides for inspections of CBER-regulated products contains information on deviations that may warrant regulatory or administrative action. These inspection programs are located on CBER’s Compliance Programs page.

5-7-3 General Considerations for Revocation

The Agency may consider revocation of a biologic license when any of the conditions specified in 21 CFR 601.5 exist. In establishing that the grounds for revocation in 21 CFR 601.5 are met, the recommending unit considers the two courses of action provided in the regulations: 1) notice of intent to revoke with the possibility of demonstrating or achieving compliance, or 2) in cases involving willfulness, notice of FDA’s intention to move directly to revocation without providing an opportunity to demonstrate or achieve compliance.

1. Notice of Intent to Revoke

Inspectional findings must demonstrate a current history of repeated or continuous significant deviations that represent a breakdown of process controls, rather than isolated incidents. Ordinarily, a demonstration of prior warning to the
firm is via Warning Letter and/or a meeting or other contact with the firm before consideration of license revocation. If a past Warning Letter issued and one or more non-violative inspection(s) follows it, a recommendation for license revocation based on current significant deficiencies must document whether the deficiencies are of a continuing nature and how the current inspection relates to any previous inspection which resulted in the Warning Letter or other communication with the firm that provided the firm notice of such deficiencies. Issuance of a Warning Letter in the past may not preclude issuance of an additional Warning Letter, especially if the nature and cause of the violation have changed. For example, a firm issued a Warning Letter three years ago for viral marker testing violations may warrant issuance of another Warning Letter or other action, rather than proceeding to license revocation, if the current inspection shows violations in different areas of the operation or manufacturing practices, e.g., computer validation.

In addition, FDA may proceed to revocation upon suspension of a license, as provided by 21 CFR 601.6(b).

Upon issuance of a "Notice of Intent to Revoke" letter (except in cases involving willfulness), we provide the licensee an opportunity to demonstrate or achieve compliance before instituting proceedings for revocation of the license.

2. Direct Revocation

FDA may proceed directly to revocation in cases involving willful conduct. Willful conduct is established by showing that an individual: 1) knowingly committed a prohibited act, such as records falsification or concealment; or 2) acted with careless disregard of the regulatory requirements, as exemplified by repeatedly failing to correct violations. In cases involving willfulness, FDA ordinarily does not provide the licensee with the opportunity to demonstrate or achieve compliance, in accordance with 21 CFR 601.5(b). In all cases, FDA notifies the licensee of the opportunity to request a hearing pursuant to 21 CFR 12.21(b).

5-7-4 Issues Not Supporting License Revocation

CBER ordinarily will not support license revocation when the following issues are the basis for the recommendation to revoke:

1. Biological Product Deviation Reports

Biological product deviation reports, in and of themselves, ordinarily may not form the basis for a license revocation unless the firm failed to recognize the error, failed to investigate and properly document the investigation, failed to implement corrective action to prevent its recurrence, or failed to notify FDA if so required under 21 CFR 600.14. In addition, in order to meet the grounds for license revocation, the deviation must be of such a nature or extent as to
represent a firm’s failure to establish or maintain control over one or more of the systems employed for the manufacture of biological products.

2. *Isolated Incidents*

Isolated occurrences do not ordinarily establish grounds for license revocation, unless there is documentation to demonstrate that the occurrences represent a pattern of violative activity.

3. *Past Violations*

Violations that occurred prior to the current FDA inspection, and for which implementation of appropriate corrective action prevents reoccurrence, ordinarily do not form the basis for license revocation. However, FDA must document previous violations even with correction, or no repeats, because they may demonstrate a pattern or history of non-compliance. If violations persist, such a pattern is pertinent to a future decision to proceed to revocation.

5-7-5 Revocation Procedures

If the inspection review unit is considering revocation as an enforcement option, contact CBER, DCM, during the inspection or soon after issuance of the FDA 483. Discussions with CBER prior to submission of a recommendation will facilitate the processing of the recommendation.

If the inspection review unit believes license revocation is appropriate, that office submits a recommendation to DCM for revocation with supporting documentation. Include the division director’s concurrence on recommendations for revocation. In addition to forwarding documentation of the violations, the recommending unit submits a detailed summary of the firm’s inspectional and compliance history over the past five years. The recommending unit also assesses the impact of license revocation on the supply of the biological products involved. The initial CBER contact is DCM, HFM-610, 240-402-9155.

CBER assigns a consumer safety officer from HFM-610 to each revocation recommendation. If using express delivery, send to:

Food and Drug Administration  
Center for Biologics Evaluation & Research  
Attn: Division of Case Management (HFM-610)  
WO Building 75 Room 5004  
10903 New Hampshire Ave.  
Silver Spring, MD 20993

CBER personnel review the information received and determine whether the inspectional findings support revocation of the firm’s license.
If CBER does not concur with the revocation recommendation, it communicates its decision to the recommending unit. CBER sends a memorandum confirming the reasons for the disapproval and provides other enforcement options, if appropriate.

If CBER concurs with the division’s recommendation, it prepares an Action Memorandum with supporting documentation to the Director, CBER, and a letter notifying the licensee of the Agency’s intention to initiate proceedings to revoke the license. This package is forwarded to OCC for review (see RPM Chapter 4, Exhibit 4-1). If OCC concurs, the recommendation and action letter are sent to the Director, CBER for concurrence and signature. Recommendations that CBER has initiated are also routed to the Director of CBER for clearance. Prior to doing so, however, the CBER initiating office contacts the appropriate division office to advise the division of the action proposed by CBER.

After the Director signs the letter, the Director, DCM verbally advises the most responsible person at the firm of the Agency’s intention to revoke the license. DCM then transmits a copy of the letter to the firm electronically (by e-mail or fax) and sends the original with proof of delivery.

CBER’s OCBQ advises the division office and/or recommending unit within CBER of the action concurrently. In addition, OCBQ transmits copies of the Action Memorandum and the revocation letter to the recommending unit via e-mail.

Both CBER and the recommending unit review the establishment's response to the letter of revocation expeditiously. The recommending unit provides CBER with its conclusions and comments regarding the adequacy of the firm's response.

The Agency usually gives an establishment the opportunity to demonstrate or achieve compliance. If the establishment has not waived its opportunity for a hearing by voluntarily requesting revocation, CBER's OCBQ and the firm continue to correspond until all corrective actions appear satisfactory. CBER will distribute copies of all correspondence between CBER and the firm to the recommending unit for review. When the recommending unit and CBER's OCBQ agree that all corrective actions appear satisfactory, CBER will ask the division office to conduct a follow up inspection expeditiously.

The division will advise CBER of the approximate date of reinspection and notify CBER by telephone or electronically of its findings and recommendation. Afterwards, the division sends a written recommendation either to move toward revocation or to discontinue proceedings for license revocation.

In some instances, the firm may have made significant progress in demonstrating or achieving compliance, but after review of the FDA 483 and the firm's response(s), the
division and/or CBER may view a limited follow-up inspection as necessary prior to making a final determination on the matter of revocation.

Following reinspection, if CBER and the division determine that the firm demonstrated or achieved compliance, CBER will notify the firm of this determination.

In cases involving willfulness, ordinarily the establishment has ten (10) days from the date of the revocation letter to waive the opportunity for hearing by requesting voluntary revocation in writing. If the establishment does not waive the opportunity for a hearing by surrendering the license within the ten (10)-day time frame, DCM forwards a request to CBER’s Regulations and Policy Staff, to prepare the Federal Register Notice of Opportunity for Hearing.

FDA publishes the Notice of Opportunity for Hearing on a proposal to revoke a license in the Federal Register together with an explanation of the grounds for the proposed action. A person subject to the notice has thirty (30) days after its issuance to request a hearing. There is no extension of the thirty (30)-day period. A request for hearing must set forth specific facts showing that there is a genuine and substantial issue of fact that justifies a hearing, and may not rely upon mere allegations or denials.

5-7-6 General Considerations For Suspension

Pursuant to 21 CFR 601.6, the Commissioner may suspend a license if the Commissioner has reasonable grounds to believe that any of the grounds for revocation exist and that by reason thereof there is a danger to health. Investigators obtain documentary evidence to support revocation and danger to health, and CBER conducts an evaluation of the danger to health.

Once CBER determines that a danger to health exists, the recommending unit immediately contacts the appropriate state health authorities. In addition, the division considers legal actions such as injunction or seizure, particularly if a given state health department lacks regulatory authority over intrastate operations or if the license suspension does not result in immediate corrective action. The recommending unit provides CBER with any information obtained regarding the state health department authority and the likelihood it may take regulatory action based on FDA's findings.

If a blood establishment is involved, the recommending unit determines the approximate number of annual collections and the percentage of blood products distributed in interstate commerce. The recommending unit, together with CBER, examines supply issues and considers contacting the large national blood organizations to ensure that a license suspension will not adversely affect the public health.

As in the case of revocation, when there are multiple locations encompassed by one license, suspension may be limited to one or more of the locations, if inspectional findings warrant that approach.
5-7-7 Suspension Procedures

If the inspecting unit believes a danger to health exists, it should contact CBER’s DCM, HFM-610, 240-402-9155 immediately, during the inspection, and provide specific, substantive information relating to the grounds for suspension. It must not wait until the conclusion of the inspection to make contact. At that time, DCM assigns a consumer safety officer from HFM-610 to the suspension recommendation who will work with the investigators in case development.

The inspecting unit should transmit a copy of the FDA 483 (draft or final copy) as quickly as possible to DCM by facsimile, e-mail, or express delivery, along with any additional requested preliminary information and/or documentation. To avoid delay, do not send supporting documentation through the regular mail system if other means of transmission are available. If using overnight express delivery, send to:

Food and Drug Administration
Center for Biologics Evaluation & Research
Attn: Division of Case Management (HFM-610)
Building 75, Room 5004
19093 New Hampshire Avenue
Silver Spring, MD 20993

DCM will consult, as necessary, with the appropriate scientific/medical staff to determine if a danger to health exists. If a danger to health exists, the inspecting office will be advised and should submit a recommendation in a brief memorandum that includes the basis of the recommendation. Transmit the recommendation by e-mail. Recommendations for suspension are given a high priority and supervisors are to act promptly. Recommendations for suspension should have the concurrence of the division director. The division will make every effort to expedite the submission of a recommendation to CBER to suspend operations under license at an establishment whose practices present an imminent danger to health.

Frequently DCM may concur with a suspension recommendation after receiving the FDA 483 but before receiving the EIR. In cases involving complex issues, DCM may need to review the completed EIR before reaching a decision. In either event, write the EIR promptly and forward by express mail service to DCM.

Depending upon the products involved, CBER may ask the recommending unit to obtain a complete inventory of the products on the firm’s premises.

If DCM concurs with the suspension recommendation, it will prepare an Action Memorandum and a letter of suspension within three (3) working days of receipt of the recommendation. Documents will be sent to OCC for review as soon as available. See RPM Chapter 4, Exhibit 4-1. Upon OCC concurrence, the Director, CBER, who notes the date and time of signature, signs the Action Memorandum and letter of suspension.
The Director, OCBQ or DCM will immediately telephone the firm and advise it of the suspension of its biologics license. DCM will then send the letter to the firm electronically and by certified mail.

CBER may concurrently advise the recommending unit of FDA's action. In some situations, CBER may arrange to transmit a copy of the suspension letter to the division for hand delivery to the firm.

If CBER does not concur with a suspension recommendation, it communicates its decision to the recommending unit. DCM will prepare a memorandum explaining the reasons for the disapproval. If CBER disagrees with the suspension recommendation based on the absence of a danger to health, and any of the conditions specified in 21 CFR 601.5(b) exist, DCM considers whether it is appropriate to revoke the license or send a Warning Letter and will discuss these options with the recommending unit.

DCM and the recommending unit concurrently review the reply to a letter of suspension and continue to correspond with the firm until both agree that all corrective actions appear satisfactory. At this point, DCM notifies the firm, ordinarily by telephone (later confirmed by letter), that limited operations may resume for the purpose of a reinspection to determine that the corrective actions implemented are effective. CBER requests that the division office conduct a follow up inspection expeditiously, generally within thirty (30) days of resumption of limited operations.

The division office advises CBER of the approximate date of reinspection. As soon as possible upon its conclusion, the division notifies CBER by telephone of its findings and recommendation (CBER contact is DCM, HFM-610, 240-402-9155). The division follows-up by sending a written recommendation on the last day of the inspection or shortly thereafter. If issuing a FDA 483, the division forwards a copy of the firm’s response, if any, to CBER. In addition, the division sends a written copy of the establishment inspection report to CBER as quickly as possible to support continued suspension, revocation or reinstatement.

In some instances, the firm may have made significant progress in achieving compliance, but after review of the FDA 483 and the firm’s response(s), the division and/or CBER may view a limited follow-up inspection as necessary prior to making a final determination as to whether to recommend reinstatement of the license.

If the follow-up inspection indicates inadequate corrective actions and continued deviations, the division obtains additional documentation and notifies CBER as soon as possible. CBER decides whether to allow the firm to continue in limited operations or to cease all operations. In addition, CBER considers the possibility of proceeding toward license revocation.

If the firm is achieving compliance, CBER prepares an Action Memorandum and letter of reinstatement for the signature of the Director, CBER. After the letter is signed, the
Director OCBQ or DCM telephones the firm and advises it that the Agency has lifted the suspension of the firm's activities and they may now ship products collected or manufactured since the date they resumed limited operations. Also, DCM advises the division by telephone and sends a copy of the reinstatement letter, which, if appropriate, may contain instructions to the firm for filing a request to use products in inventory at the time of suspension.

On a case-by-case basis, CBER evaluates written requests for release of products in inventory at the time of suspension. Communicate in writing all decisions regarding the disposition of products to the firm (copy to the division). CBER may request that the division monitor the disposition of the inventory.

Send copies of all correspondence, verbal and written communications, and EIRs relating to suspensions of operations under license, to the attention of:

Food and Drug Administration  
Center for Biologics Evaluation & Research  
Bldg 75, Room 5004  
10903 New Hampshire Avenue  
Silver Spring, MD 20903  
ATTN: Division of Case Management, HFM-610

5-8 ORDERS OF RETENTION, RECALL, DESTRUCTION AND CESSATION OF MANUFACTURING RELATED TO HUMAN CELL, TISSUE AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps)

5-8-1 Purpose

This section contains procedures for issuing an Order of Retention, Recall, Destruction and Cessation of Manufacturing (Order) related to human cell, tissue, and cellular and tissue-based products (HCT/Ps) pursuant to 21 CFR 1271.440 - promulgated under section 361 of the PHS Act.

5-8-2 Background

In February 1997, FDA proposed a new, comprehensive approach to the regulation of human cells, tissues, and cellular and tissue-based products (HCT/Ps). FDA proposed a tiered, risk based approach under which some HCT/Ps would be regulated only under Section 361 of the PHS Act and the newly proposed regulations in order to prevent the introduction, transmission, and spread of communicable diseases. Other HCT/Ps would also be regulated as drugs, devices, and/or biological products.
Since that time, the agency has published multiple regulations to fully implement this approach. In January 2001, we issued regulations to create a new, unified system for registering HCT/P establishments and for listing their HCT/Ps (66 FR 5447). In May 2004, FDA issued regulations requiring most cell and tissue donors to be tested and screened for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (69 FR 29786). In November 2004, FDA issued regulations requiring HCT/P establishments to follow current good tissue practice (CGTP), which governs the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps; recordkeeping; and the establishment of a quality program. The CGTP regulations also contain certain labeling and reporting requirements, as well as inspection and enforcement provisions (69 FR 68612). These regulations apply to HCT/Ps recovered on or after May 25, 2005. HCT/Ps that were recovered before this effective date are subject to 21 CFR Part 1270, and subparts A and B of Part 1271, as appropriate.

HCT/Ps that meet all of the criteria set forth in 21 CFR 1271.10(a) are subject to regulation solely under 21 CFR Part 1271 and section 361 of the PHS Act, so no premarket approval is required. HCT/Ps that do not meet all of the criteria in 21 CFR 1271.10(a) are regulated also as drugs, devices, and/or biological products.

Part 1271 contains six subparts:
- Subpart A of Part 1271 – scope, purpose, and definitions
- Subpart B of Part 1271 - registration
- Subpart C of Part 1271 - screening and testing of donors to determine eligibility
- Subpart D of Part 1271 - provisions on CGTP
- Subpart E of Part 1271 - certain labeling and reporting requirements
- Subpart F of Part 1271 - inspection and enforcement provisions.

The subparts apply as follows:
- Subparts A through D apply to all HCT/Ps, i.e., to HCT/Ps regulated solely under section 361 of the PHS Act and Part 1271, as well as to those regulated as drugs, devices, and/or biological products.
- Subparts E and F, which pertain to labeling, reporting, inspection, and enforcement, apply only to those HCT/Ps regulated solely under section 361 of the PHS Act and Part 1271. However, with the exception of two provisions (Sec. Sec. 1271.150(c) and 1271.155), subparts D and E are not being implemented for reproductive HCT/Ps.

21 CFR 1271.440 authorizes FDA to issue Orders of Retention, Recall, Destruction, and Cessation of Manufacturing in certain circumstances. Such an order is intended for use in situations when needed to prevent the introduction, transmission, or spread of communicable diseases, and applies only to those HCT/Ps regulated solely under section 361 of the PHS Act and Part 1271.
5-8-3 General Considerations

The agency may consider an Order of Retention, Recall, Destruction, or Cessation of Manufacturing when any of the conditions specified in 21 CFR 1271.440(a) exist. Under this provision, an Order may be justified when the agency finds that there are reasonable grounds to believe that an HCT/P is a violative HCT/P because:

1. The HCT/P was manufactured in violation of the regulations in Part 1271 and, therefore, the conditions of manufacture of the HCT/P do not provide adequate protections against the risk of communicable disease transmission; or
2. The HCT/P is infected or contaminated so as to be a source of dangerous infection to humans; or
3. An establishment is in violation of the regulations in Part 1271 and, therefore does not provide adequate protections against the risks of communicable disease transmission.

Based upon one or more of the above findings, the agency may order the retention, recall, and/or destruction of the violative HCT/P; take possession of and/or destroy the violative HCT/Ps; or order the establishment to cease manufacture until compliance with Part 1271 has been achieved.

NOTE: FDA will not issue an order for the destruction of reproductive HCT/Ps, nor will FDA carry out such destruction itself. 21 CFR 1271.440(f).

5-8-4 Procedures for Orders of Retention, Recall, or Destruction of HCT/Ps

An Order of Retention, Recall, or Destruction of HCT/Ps may be appropriate in situations where there are significant concerns regarding the source or violative nature of the HCT/P, the adequacy of the screening and/or testing, or a failure of the establishment to fulfill stated commitments to gain control over violative HCT/Ps.

As soon as practicable after the possibility of issuing an Order of Retention, Recall, or Destruction is first identified, the division should contact the Chief, Blood and Tissue Compliance Branch (BTCB)/DCM, in CBER’s OCBQ. It is important to make this initial contact during the inspection if possible; do not wait until the conclusion of the inspection to contact CBER. Discussions with CBER prior to submission of a recommendation will facilitate the processing of the recommendation.

The division should upload a copy of the FDA 483 (draft or final) into CMS along with any additional, preliminary information and/or documentation as quickly as possible and should notify BTCB/DCM, for example by e-mail. BTCB/DCM, will notify CBER’s Office of Cellular, Tissue, and Gene Therapies (OCTGT) and OCC of the potential for an Order as appropriate.
If the division believes an Order of Retention, Recall, or Destruction is appropriate, complete documentation of the violative conditions should be collected, including an inventory of products on the premises as well as those products distributed (including names and addresses of consignees and HCT/Ps shipped to consignees) as of the last day of the inspection.

The division prepares and submits a written recommendation for an Order of Retention, Recall, or Destruction to CBER. Include the division director’s concurrence with recommendations for Orders. Transmit the Order recommendation, FDA 483, and all supporting documentation via MARCS-CMS or, where needed, by e-mail.

All divisions should identify Order recommendations as high priorities and make every effort to expedite submissions of the documents described above. BTCB/DCM reviews the information received, also as a high priority, and determines whether the inspectional findings support the issuance of an Order of Retention, Recall, or Destruction.

CBER may concur with issuance of an Order after reviewing the FDA 483 and supporting documentation, but before receiving the EIR, if the violations are serious and if there are not adequate protections against risks of communicable disease transmission. It is essential that the division completes the EIR expeditiously and forwards it, along with the exhibits and additional supporting documentation, by uploading it into MARCS-CMS. In cases involving complex issues, CBER may need to review the completed EIR before deciding whether to concur with the recommendation to issue an Order.

BTCB/DCM transmits the FDA 483 and other available supporting documentation as needed to the Division of Human Tissues (DHT), OCTGT. If one or more of the conditions in 21 CFR 1271.440(a) (as described above in subsection 5-7-2) are present, DHT will confirm this in writing, signed by the Director, DHT or designee.

If CBER concurs with the Order recommendation, and OCTGT has confirmed that one or more of the conditions in 21 CFR 1271.440(a) are present, BTCB/DCM drafts the Order of Retention, Recall, or Destruction.

The draft Order, FDA 483, and supporting documentation are uploaded into MARCS-CMS for OCC review. If OCC concurs with the issuance of the Order, BTCB/DCM prepares the Order for signature by the CBER Center Director and delivers it to the Office of the Center Director for signature.

On the date that the Order is signed, the Director, OCBQ attempts to contact the HCT/P establishment by phone to notify the establishment that the Order is in effect. A copy of the order will be sent to the establishment by fax if possible, as soon as possible, after this call has taken place.
Also on the date the Order is signed, BTCB/DCM forwards the Order via overnight delivery to the division office for delivery to the HCT/P establishment. It is preferable to have the original, signed Order hand-delivered to the HCT/P establishment by an FDA investigator. If this is not practicable, the original signed order can be sent to the HCT/P establishment via overnight delivery.

If CBER does not concur with the Order recommendation, BTCB/DCM will notify the division regarding this decision by telephone or electronic mail, and forward a memorandum to the responsible division official explaining the reasons for non-concurrence and describing other potential regulatory actions, if appropriate.

If OCC does not concur with the Order recommendation, OCC will provide a written statement of its rationale to CBER, with a copy to the division office.

**5-8-5 Follow-Up to Orders of Retention, Recall, or Destruction**

The Order of Retention, Recall, or Destruction will ordinarily provide that the HCT/P be recalled and/or destroyed within five (5) working days from the date of receipt of the Order. The division should promptly verify that the recall and/or destruction is carried out expeditiously, and the HCT/P establishment’s action should be monitored or witnessed, as appropriate, by an FDA investigator. The division should manage recalls as provided for in Chapter 7. The Order will require the HCT/P establishment to notify its consignees to return or retain affected HCT/Ps in their inventories.

As an alternative to proceeding with recall and/or destruction, other arrangements for ensuring the proper disposition of the HCT/P may be agreed upon by the person receiving the written Order and FDA. Such arrangements may include, among other things, providing FDA with records or other written information that adequately ensures that the HCT/P has been recovered, processed, stored and distributed in compliance with the regulations and that, except as provided under 21 CFR 1271.60, 1271.65, and 1271.90, the donor of the cells or tissue for the HCT/P has been determined to be eligible. If the violative HCT/Ps can be reconditioned to become suitable for implantation, transplantation, infusion, or transfer into a human recipient as a result of these corrective actions, the establishment may be authorized to release the HCT/P for distribution.

If alternative arrangements are proposed by the HCT/P establishment, the division and CBER should review the proposal concurrently. The HCT/P establishment must retain the violative HCT/Ps in quarantine status until FDA agrees that the appropriate corrective actions have been implemented and adequate documentation has been provided to FDA to address the issues identified in the Order of Retention, Recall, or Destruction.

If FDA orders the destruction of HCT/Ps, it is the firm’s responsibility to destroy all violative HCT/Ps and provide to FDA records documenting destruction. The division monitors the destruction of violative HCT/Ps and obtains destruction records.
The regulations provide the agency with the authority to take possession of and/or destroy the violative HCT/Ps. The division must notify BTCB/DCM if it believes that taking possession of HCT/Ps may be appropriate. If CBER agrees that taking possession of HCT/Ps is appropriate in a particular situation, CBER will provide guidance on procedures for handling and destroying the HCT/Ps safely.

The division will schedule a follow-up inspection as appropriate. If the division observes continued deviations, it should contact BTCB/DCM during the inspection. The division and CBER will jointly consider what action to take.

**5-8-6 Procedures for Orders of Cessation of Manufacturing**

An Order of Cessation of Manufacturing may be appropriate in situations where there are significant concerns regarding one or more steps in the manufacture of HCT/Ps, or a failure of the establishment to fulfill stated commitments to gain control over or to bring the areas of manufacturing into compliance with the applicable regulations.

As soon as practicable after the possibility of issuing an Order of Cessation of Manufacturing is first identified, the division should contact the Chief, BTCB/DCM, in CBER’s OCBQ. It is important to make this initial contact during the inspection if possible; do not wait until the conclusion of the inspection to contact CBER. Discussions with CBER prior to submission of a recommendation will facilitate the processing of the recommendation.

The division should transmit a copy of the FDA 483 (draft or final) as quickly as possible to BTCB/DCM by e-mail, along with any additional, preliminary information and/or documentation. BTCB/DCM will notify CBER's OCTGT and OCC of the potential for an Order as appropriate.

If the division believes an Order of Cessation of Manufacturing is appropriate, complete documentation of the violative conditions should be collected, including an inventory of products on the premises as of the last day of the inspection.

An Order of Cessation of Manufacturing will be effective immediately if FDA determines there are reasonable grounds to believe there is a danger to health. BTCB/DCM will consult, as necessary, with the appropriate scientific/medical staff to determine whether there are reasonable grounds to believe that there is a danger to health. This evaluation will be documented by BTCB/DCM, working with appropriate scientific/medical staff. If a determination is made that a danger to health exists, the division will be advised immediately.

The division prepares and submits a written recommendation for issuance of an Order of Cessation of Manufacturing to CBER. Include the division director’s concurrence with
recommendations for Orders. Transmit the Order recommendation, FDA 483, and all supporting documentation via MARCS-CMS or, where needed, by electronic mail.

All divisions should identify Order recommendations as high priorities and make every effort to expedite submissions of the documents described above. BTCB/DCM reviews the information received, also as a high priority, and determines whether the inspectional findings support the issuance of an Order of Cessation of Manufacturing.

CBER may concur with issuance of an Order after reviewing the FDA 483 and supporting documentation, but before receiving the EIR if the violations are serious and if there are not adequate protections against the risks of communicable disease transmission. It is essential that the division completes the EIR expeditiously and forwards it to BTCB/DCM, along with the exhibits and additional supporting documentation, by uploading it into MARCS-CMS. In cases involving complex issues, CBER may need to review the completed EIR before deciding whether to concur with the recommendation to issue an Order.

BTCB/DCM transmits the FDA 483 and other available supporting documentation as needed to the Division of Human Tissues (DHT), OCTGT. If one or more of the conditions in 21 CFR 1271.440(a) (as described above in subsection 5-7-2) are present, DHT will confirm this in writing, signed by the Director, DHT (or designee). If there are reasonable grounds to believe there is a danger to health, this must also be documented and signed by the Director, DHT (or designee).

If CBER concurs with the Order recommendation, and OCTGT has confirmed that one or more of the conditions in 21 CFR 1271.440(a) are present, BTCB/DCM drafts the Order of Cessation of Manufacturing.

The draft Order, FDA 483, and supporting documentation are uploaded into MARCS-CMS for OCC review. If OCC concurs with the issuance of the Order, BTCB/DCM prepares the Order for signature by the CBER Center Director and delivers it to the Office of the Center Director for signature.

On the date that the Order is signed, the Director, OCBQ attempts to contact the HCT/P establishment by phone to notify the establishment that the Order is in effect. A copy of the Order will be sent to the establishment expeditiously, by fax or e-mail if possible, as soon as possible after this call has taken place.

Also on the date the Order is signed, BTCB/DCM forwards the Order via overnight delivery to the division office for delivery to the HCT/P establishment. It is preferable to have the original, signed Order hand-delivered to the HCT/P establishment by an FDA investigator. If this is not practicable, the original signed order can be sent to the HCT/P establishment via overnight delivery.
If CBER does not concur with the Order recommendation, BTCB/DCM will notify the division regarding this decision by telephone or electronic mail, and forward a memorandum to the responsible division official explaining the reasons for non-concurrence and describing other potential regulatory actions, if appropriate.

If OCC does not concur with the Order recommendation, OCC will provide a written statement of its rationale to CBER, with a copy to the division office.

5-8-7 Follow Up to Orders of Cessation of Manufacturing

When FDA determines there are reasonable grounds to believe there is a danger to health, an Order of Cessation of Manufacturing is effective immediately. In other situations, the Order of Cessation of Manufacturing is effective after one of the following events, whichever is later: 1) passage of five (5) working days from the establishment’s receipt of the Order; or, 2) if the establishment requests a Part 16 hearing, a decision in the proceedings. The Order will specify the regulations with which the HCT/P establishment must achieve compliance and will ordinarily specify the particular operations covered by the Order. The establishment is permitted to implement corrective actions in order to resume operations. However, the firm may not resume any operations subject to the Order without written authorization from FDA.

The division and CBER should concurrently review all correspondence received subsequent to issuance of an Order of Cessation concurrently. All meetings between the FDA and the Order recipient should include the appropriate division and CBER personnel.

5-8-8 Part 16 Hearing

The recipient of an Order may request a hearing by submitting a written request in accordance with 21 CFR Part 16 as described in the Order and in 21 CFR 1271.440(e). The recipient must make the request within five (5) working days of receipt of a written Order of Retention, Recall, Destruction, and/or Cessation of Manufacturing, or within five (5) working days of the agency’s possession of an HCT/P. The HCT/P establishment may request additional time (beyond five (5) working days) to consider whether to request a hearing. Reasonable requests for additional time will usually be granted. OCC, the ORA Ombuds, and FDA Office of the Ombudsman, and the division office should be notified promptly upon receipt of a Part 16 hearing request, and for a request for additional time to request a hearing.

For an Order requiring destruction of HCT/Ps, a request for a Part 16 hearing places the portion of the Order requiring destruction of the violative tissue in abeyance, pending the outcome of the hearing. The portion of the Order requiring recall and retention of violative HCT/Ps, however, is not placed in abeyance or affected by the hearing request.
As described above, if an Order of Cessation of Manufacturing is not immediately in effect, it is effective after one of the following events, whichever is later: 1) passage of five (5) working days from the establishment’s receipt of the Order; or, 2) if the establishment requests a Part 16 hearing, a decision in the proceeding. If a Part 16 hearing is requested but denied, or if the Presiding Officer concludes after a Part 16 hearing that the Order was properly issued, the procedures in section 5-7-6 will be followed to notify the HCT/P establishment of the requirement to cease manufacturing.

5-9 CIVIL MONEY PENALTIES AND NO-TOBACCO-SALE ORDERS

5-9-1 Civil Money Penalty Authorities

The Civil Money Penalties (CMPs) included in this section are monetary penalties that are assessed by FDA for violations of the FFDCA (the Act) or the PHS Act. Information on electronic products civil penalties under section 539(b) of the Act can be found in RPM Chapter 6, section 6-6.

CMPs are authorized under the following sections of the Act and the Public Health Service Act. See 21 CFR 17.2 for the current maximum CMP amounts allowed.

1. Food
   a. Section 303(f)(2)(A) of the Act, 21 U.S.C. 333(f)(2)(A) – Authorizes CMPs against any person who introduces, or delivers for introduction, into interstate commerce an article of food that bears or contains a pesticide chemical residue that is unsafe within the meaning of section 408(a).

   Section 303(f)(2)(B) of the Act, 21 U.S.C. 333(f)(2)(B), states that a CMP cannot be assessed against any person who grew the article of food. That section also prohibits use of the seizure, injunction, or criminal authorities if a CMP is assessed.

2. Drugs
   a. Section 303(b)(2) of the Act, 21 U.S.C. 333(b)(2) – Authorizes CMPs against a manufacturer or distributor:
      i. if one of their representatives, during the course of their employment or association with the manufacturer or distributor, is convicted of selling, purchasing, or trading or offering to sell, purchase, or trade a prescription drug sample in violation of section 503(c)(1) and 301(t); or is convicted of violating any State law that prohibits the sale, purchase, or trade of a prescription drug sample subject to section 503(b), or the offer to sell, purchase, or trade such a prescription drug sample.
b. Section 303(b)(3) of the Act, 21 U.S.C. 333(b)(3) – Authorizes CMPs against a manufacturer or distributor:
   i. if they fail to report to the Secretary any convictions of their representatives for violations of section 503(c)(1) or a State law because of the sale, purchase, or trade of a prescription drug sample, or the offer to sell, purchase, or trade a prescription drug sample.

   i. failing to submit the certification required by section 402(j)(5)(B) of the Public Health Service Act, 42 U.S.C. 282(j)(5)(B), when submitting certain human drug applications and submissions to FDA, or knowingly submitting a false certification;
   ii. failing to submit clinical trial information required by section 402(j) of the Public Health Service Act, 42 U.S.C. 282(j); or
   iii. submitting clinical trial information under section 402(j), 42 U.S.C. 282(j), that is false or misleading in any particular under section 402(j)(5)(D), 42 U.S.C. 282(j)(5)(D).

d. Section 303(f)(3)(B) of the Act, 21 U.S.C. 333(f)(3)(B) – Authorizes CMPs (in addition to those under section 303(f)(3)(A) above) if a violation of section 301(jj), 21 U.S.C. 331(jj), is not corrected within the thirty (30)-day period following notification under section 402(j)(5)(C)(ii), 42 U.S.C. 282(j)(5)(C)(ii), for each day of the violation after such period until the violation is corrected.

e. Section 303(f)(4)(A) of the Act, 21 U.S.C. 333(f)(4)(A) – Authorizes CMPs against any responsible person (defined in section 505-1, 21 U.S.C. 355-1) that violates a requirement of:
   i. Section 505(o), 21 U.S.C. 355(o) – Postmarket studies and clinical trials; labeling;
   ii. Section 505(p), 21 U.S.C. 355(p) – Risk evaluation and mitigation strategy; or

f. Section 303(g)(1) of the Act, 21 U.S.C. 333(g)(1) – Authorizes CMPs against a person who is a holder of an approved new drug application for a prescription drug, or the holder of an approved biologics license application, if such person disseminates or causes another party to
disseminate a direct-to-consumer advertisement that is false or misleading.

g. Section 307(a) of the Act, 21 U.S.C. 335b (a) – Authorizes CMPs against any person that:
   i. knowingly made or caused to be made, to any officer, employee, or agent of the Department of Health and Human Services (“DHHS personnel”), a false statement or misrepresentation of a material fact in connection with an abbreviated new drug application (ANDA);
   ii. bribed or attempted to bribe or paid or attempted to pay an illegal gratuity to “DHHS personnel” in connection with an ANDA;
   iii. destroyed, altered, removed, or secreted, or procured the destruction, alteration, removal, or secretion of any material document or other material evidence which was the property of or in the possession of DHHS for the purpose of interfering with DHHS’s discharge of its responsibilities in connection with an ANDA;
   iv. knowingly failed to disclose to an officer or employee of DHHS, a material fact relating to any drug subject to an ANDA, which such person had an obligation to disclose;
   v. knowingly obstructed a DHHS investigation into any drug subject to an ANDA;
   vi. has an approved or pending drug product application and has knowingly used in any capacity the services of a person who was debarred under section 306; or
   vii. is debarred and, during the period of debarment, provided services in any capacity to a person that had an approved or pending drug product application.

3. Biologics
      i. failing to submit the certification required by section 402(j)(5)(B) of the Public Health Service Act, 42 U.S.C. 282(j)(5)(B), when submitting certain biological product applications and submissions to FDA, or knowingly submitting a false certification;
      ii. failing to submit clinical trial information required by section 402(j) of the Public Health Service Act, 42 U.S.C. 282(j); or
      iii. submitting clinical trial information under section 402(j), 42 U.S.C. 282(j), that is false or misleading in any particular under section 402(j)(5)(D), 42 U.S.C. 282(j)(5)(D).
301(jj), 21 U.S.C. 331(jj), is not corrected within the thirty (30)-day period following notification under section 402(j)(5)(C)(ii), 21 U.S.C. 282(j)(5)(C)(ii), for each day of the violation after such period until the violation is corrected.

c. Section 303(f)(4)(A) of the Act, 21 U.S.C. 333(f)(4)(A) – Authorizes CMPs against any responsible person (defined in section 505-1, 21 U.S.C. 355-1) that violates a requirement of:

   i. section 505(o), 21 U.S.C. 355(o) – Postmarket studies and clinical trials; labeling;

   ii. section 505(p), 21 U.S.C. 355(p) – Risk evaluation and mitigation strategy; or


d. Section 303(g)(1) of the Act, 21 U.S.C. 333(g)(1) – Authorizes CMPs against a person who is a holder of an approved new drug application for a prescription drug, or the holder of an approved biologics license application, if such person disseminates or causes another party to disseminate a direct-to-consumer advertisement that is false or misleading.

e. Section 351(d)(2) of the Public Health Service Act, 42 U.S.C. 262(d)(2) – Authorizes CMPs for any violation of an order issued by the Secretary to immediately recall a batch, lot, or other quantity of a licensed biological product that presents an imminent or substantial hazard to the public health.

f. Section 2128(b)(1) of the PHS Act, 42 U.S.C. 300aa-28(b)(1) – Authorizes CMPs against any vaccine manufacturer who intentionally destroys, alters, falsifies, or conceals any record or report required by 42 U.S.C. 300aa-28(a)(1) or (2).

The penalty applies to the person who intentionally destroyed, altered, falsified, or concealed such record or report; to the person who directed that such record or report be destroyed, altered, falsified, or concealed; and to the vaccine manufacturer for which such person is an agent, employee, or representative. Each act of destruction, alteration, falsification, or concealment is treated as a separate occurrence.

4. Devices


   i. failing to submit the certification required by section 402(j)(5)(B) of the PHS Act, 42 U.S.C. 282(j)(5)(B), when submitting certain device applications and submissions to FDA, or knowingly submitting a false certification;
ii. failing to submit clinical trial information required by section 402(j) of the PHS Act, 42 U.S.C. 282(j); or

iii. submitting clinical trial information under section 402(j), 42 U.S.C. 282(j), that is false or misleading in any particular under section 402(j)(5)(D), 42 U.S.C. 282(j)(5)(D).

b. Section 303(f)(3)(B) of the Act, 21 U.S.C. 333(f)(3)(B) – Authorizes CMPs (in addition to those under section 303(f)(3)(A) above) if a violation of section 301(jj), 21 U.S.C. 331(jj), is not corrected within the thirty (30)-day period following notification under section 402(j)(5)(C)(ii), 42 U.S.C. 282(j)(5)(C)(ii), for each day of the violation after such period until the violation is corrected.

c. Section 303(f)(1)(A) of the Act, 21 U.S.C. 333(f)(1)(A)2 – Authorizes CMPs against any person who violates a requirement which relates to devices. Except that, in accordance with Section 303(f)(1)(B), CMPs do not apply to:

i. any person who violates the requirements of section 519(a) (e.g., Medical Device Reporting), or section 520(f) (Quality System Regulation), unless the violations constitute a significant or knowing departure from the requirements, or a risk to public health;

ii. any person who commits minor violations of section 519(e) (Device Tracking), or section 519(g) (only with respect to correction reports), if the person demonstrates substantial compliance with such section; or

iii. violations of section 501(a)(2)(A) which involve one or more devices which are not defective.

Note that a person accredited under section 704(g)(2) who is substantially not in compliance with the standards of accreditation under that section, or who poses a threat to public health or fails to act in a manner that is consistent with the purposes of that section, is considered to have violated a requirement of the Act that relates to devices.

5. Mammography Facilities

a. Section 354(h)(3) of the PHS Act, 42 U.S.C. 263b(h)(3) – Authorizes CMPs for:

i. Failure to obtain a certificate as required by 42 U.S.C. 263b(b);

2 This section has been variously referred to as section 303(f) and 303(g) because of confusion at the time of legislative enactment in 1990. The explanatory notes to FDAAA of 2007 clarified that this section is now subsection (f).
ii. Each failure by a facility to substantially comply with, or each day on which a facility fails to substantially comply with, the quality standards established under 42 U.S.C. 263b(f), codified at 21 CFR Part 900, or the requirements of 42 U.S.C. 263b(d)(1)(B)(ii);

iii. Each failure to notify a patient of risk as required pursuant to 42 U.S.C. 263b(h)(2); and

iv. Each violation, or for each aiding and abetting in a violation of, any provision of, or regulation promulgated under, this section by an owner, operator, or any employee of a facility required to have a certificate.

6. Tobacco Products


b. Section 303(f)(9)(A) of the Act, 21 U.S.C. 333(f)(9)(A)– Authorizes CMPs against any person who violates a requirement of the Act which relates to tobacco products. Such person shall be liable to United States for a civil penalty in an amount not to exceed $15,000 for each such violation, and not to exceed $1,000,000 for all such violations adjudicated in a single proceeding.

c. Section 303(f)(9)(B) of the Act, 21 U.S.C. 333(f)(9)(B) – Authorizes enhanced CMPs in an amount not to exceed $250,000 per violation, and not to exceed $1,000,000 for all such violations adjudicated in a single proceeding.

i. if a person intentionally violates a requirement of:

   • Section 902(5) of the Act, 21 U.S.C. 387b(5), which deems a tobacco product to be adulterated if it is, or purports to be or is represented as, a tobacco product which is subject to a tobacco products standard established under section 907 unless such tobacco product is in all respects in conformity with such standard.

   • Section 902(6) of the Act, 21 U.S.C. 387b(6), which deems a tobacco product to be adulterated if (A) it is required by section 910(a) to have premarket review and does not have an order in effect under section 910(c)(1)(A)(i). or (B) it is in violation of an order under section 910(c)(1)(A).

   • Section 904 of the Act, 21 U.S.C. 387d, which requires each tobacco product manufacturer or importer, or agents thereof, to submit health information to the Secretary, as set forth in that section.

   • Section 908(c) of the Act, 21 U.S.C. 387h(c), which requires the appropriate person (including the manufacturers,
importers, distributors, or retailers of the tobacco product) to immediately cease distribution of such tobacco product if the Secretary finds that there is a reasonable probability that the product contains a manufacturing or other defect not ordinarily contained in tobacco products on the market that would cause serious, adverse health consequences or death.

- Section 911(a) of the Act, 21 U.S.C. 387k(a), which prohibits any person from introducing or delivering for introduction into interstate commerce any modified risk tobacco product unless an order issued pursuant to subsection 911(g) is effective with respect to such product.

ii. if a person violates a requirement of:

- Section 911(g)(2)(C)(ii) of the Act, 21 U.S.C. 387k(g)(2)(C)(ii), which requires that an order under section 911(g) be conditioned on the applicant’s agreement to conduct postmarket surveillance and studies and to submit to the Secretary the results of such surveillance and studies to determine the impact of the order on consumer perception, behavior, and health and to enable the Secretary to review the accuracy of the determinations upon which the order was based in accordance with a protocol approved by the Secretary.

- Section 911(i)(1) of the Act, 21 U.S.C. 387k(i)(1), which requires with respect to a tobacco product for which an applicant obtained an order under section 911(g)(1) that the applicant conduct postmarket surveillance and studies for such a tobacco product to determine the impact of the order issuance on consumer perception, behavior, and health, to enable the Secretary to review the accuracy of the determinations upon which the order was based, and to provide information that the Secretary determines is otherwise necessary regarding the use or health risks involving the tobacco product. The results of postmarket surveillance and studies must be submitted to the Secretary on an annual basis.

Tobacco Retailers

a. Section 103(q)(2)(A) of the Family Smoking Prevention and Tobacco Control Act, Public Law 111-31 (“Tobacco Control Act”) 21 U.S.C. 333 – Authorizes CMPs against tobacco retailers for violating restrictions promulgated under section 906(d) of the Act, including the regulations at 21 CFR Part 1140. This section provides reduced penalties for retailers with an approved training program. At this time, and until FDA issues
regulations setting the standards for an approved training program, all applicable CMPs will proceed under the reduced penalty schedule.

b. Section 303(f)(8) of the Act, 21 U.S.C. 333(f)(8) – Authorizes imposition of a no-tobacco-sale order prohibiting the sale of tobacco products against a particular tobacco retail outlet that has committed “repeated violations” of restrictions promulgated under section 906(d) of the Act, including the regulations at 21 CFR Part 1140. (Section 103(q)(1)(A) of the Tobacco Control Act defines “repeated violation” as including at least 5 violations of particular requirements over a 36-month period at a particular retail outlet that constitute a repeated violation). A no-tobacco-sale order may be imposed with a CMP.

5-9-2 Reduction Of Civil Money Penalties For Small Entities

The Small Business Regulatory Enforcement Fairness Act of 1996 (SBREFA) (Public Law 10-121) was enacted on March 29, 1996, and seeks to improve the regulatory climate for small entities by, among other things, requiring agencies to establish small entity penalty reduction policies.

The FDA may reduce CMPs for small entities as mandated by the SBREFA and the Presidential Memorandum of April 21, 1995 (60 FR 20621, April 26, 1995).

5-9-3 Civil Money Penalty Recommendations

When it is determined that CMP is the appropriate course of action, the Division’s Compliance Officer should submit the recommendation package to the appropriate Center, except for tobacco retailers.

1. DIVISION RESPONSIBILITIES

The Division recommends a CMP by transmitting to the Center, at a minimum, a cover memorandum recommending the action, a draft cover letter to respondents and a Complaint accompanied by the supporting evidence.

2. CENTER RESPONSIBILITIES

The Center is responsible for the technical, regulatory, policy and scientific review of the Division’s CMP recommendation. Changes to proposed recommendations should be made only after discussion with the Division’s compliance staff.

Note: The Center for Tobacco Products (CTP) will initiate CMP actions against tobacco retailers.
NOTE: The Center with jurisdiction over the product under study in an applicable clinical trial for which there has been a violation of section 301(jj) of the Act will initiate CMP actions under sections 303(f)(3)(A) and 303(f)(3)(B) of the Act.

Approved referrals transmitted to DE should include intact original case files organized as submitted from the Division, the Center’s proposed changes to respondent letters/Complaint and the Center’s approval memorandum providing Center contact information, justification for imposition of civil money penalties and other information necessary to review and process the action.

3. DE RESPONSIBILITIES

OSPOP, DE will review the appropriateness of the action and the adequacy of the draft cover letter to respondents and Complaint to ensure compliance with existing procedures, policies, regulations or statutes. Changes to proposed recommendations should be made only after discussion with the Center and the Division's compliance staff.

Approved recommendations to OCC should include DE’s transmittal memorandum, DE’s proposed changes to the respondent letters/Complaint and original materials submitted by the Division and Center.

4. OFFICE OF CHIEF COUNSEL RESPONSIBILITIES

OCC Approved recommendations will be processed in accordance with procedures outlined in 21 CFR Part 17; or, in the case of civil penalties authorized under section 307(a) of the Act, in accordance with the procedures in section 307(b) of the Act.

5-10 DISQUALIFICATION OF CLINICAL INVESTIGATORS

5-10-1 Purpose

This procedure describes the process, including timeframes, for initiating disqualification proceedings – from completion of the inspection to issuance of the Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) to the clinical investigator. In addition, it includes the processes and timeframes for follow-up to a response to a NIDPOE, through issuance of a Notice of Opportunity for Hearing (NOOH).³ This procedure is intended for use by center Bioresearch Monitoring (BIMO) Program Units, staff in the Office of the Commissioner (OC), the Office of Regulatory Affairs (ORA), and OCC. Adherence to the procedures described in this chapter will assist the agency in achieving a uniform approach to the disqualification process.

³ Criteria for initiation of disqualification proceedings are included in the Compliance Program Guidance Manual (CPGM) 7348.811 for Bioresearch Monitoring: Clinical Investigators, Part V. B.
5-10-2 Criteria for Initiating Disqualification Proceedings

Criteria for initiating disqualification proceedings are found at 21 CFR 312.70, 511.1(c), and 812.119 and are discussed in the clinical investigator CPGM 7348.811. See footnote 2. As discussed in Part V, B., a decision to initiate disqualification proceedings often starts with a decision to classify the EIR as Official Action Indicated (OAI).

5-10-3 Initiating the Disqualification Process

When a clinical investigator inspection reveals serious noncompliance, communication with the center is essential, as noted in the CPGM 7348.811 Part II, B.3., since collection of appropriate supporting evidence is vital. In addition, this will allow the center to provide advance notice to OCC and other appropriate offices if it appears a recommendation for disqualification may be considered. It is also recommended that the division investigator contact the Bioresearch Monitoring Specialist in DE, OSPOP/DE, ORA who can provide assistance with the process and serve as an additional resource. The resulting EIR, with violations indexed to the supporting evidence and exhibits appropriately tabbed for easy reference, should be forwarded to the center BIMO Program Unit within thirty (30) days of completion of the inspection.

Because center BIMO Program Units need to expeditiously review inspectional findings that warrant initiation of disqualification proceedings, center BIMO Program Units should review and prioritize within fourteen (14) days of receipt all EIRs with a division office recommendation of OAI, with or without a recommendation for clinical investigator disqualification. Center BIMO Program Units should review and prioritize EIRs with Referred to Center (RTC) designations within a similar timeframe to determine if any warrant an OAI designation and therefore possible initiation of disqualification proceedings. EIRs with division office recommendations other than OAI or RTC may also support initiation of disqualification proceedings. When a BIMO reviewer identifies such an EIR, the timeframes discussed below would apply.

Once the potential for initiating disqualification proceedings is identified, the assigned BIMO reviewer analyzes the inspectional findings and determines if the findings are supported by sufficient evidence of regulatory significance. The BIMO reviewer also determines if the division office has received any response to the Form FDA 483 and requests a copy of all responses. After reviewing all materials associated with the most recent inspection, as well as any information available in the center’s inspectional files/databases, the BIMO reviewer drafts his/her rationale for or against initiation of disqualification proceedings. Consultation with office/center regulatory personnel and/or OCC attorneys during this review may be warranted.

If initiation of disqualification proceedings is not deemed warranted, the BIMO reviewer prepares a document explaining that conclusion, for review by his/her supervisor, and initiates other appropriate actions. If initiation of disqualification proceedings is deemed warranted, the BIMO reviewer prepares appropriate documentation for the
administrative record which will support all subsequent steps in the process. The portion of the administrative record supporting issuance of a Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE) will include such documents as:

1. A chart and/or memo summarizing the significant inspectional findings and regulatory violations supporting the disqualification action;
2. A chronology/inspectional history of the clinical investigator;
3. A draft NIDPOE (see Exhibit 5-21 for sample); and
4. A draft Consent Agreement (see Exhibit 5-22 for sample)

The NIDPOE file should be appropriately indexed to facilitate review by center management, OCC, and ORA. For example, violations cited in the NIDPOE should be indexed to the supporting evidence supplied with the EIR. During preparation of the NIDPOE file, the BIMO Program Unit should alert all relevant center and Agency offices that this file is in preparation to ensure timely review. Review of the NIDPOE file should proceed according to center-specific procedures. The NIDPOE file should be ready for OCC review within four (4) months from receipt of the EIR. OCC should concur, with comments/suggested edits as necessary, or arrange for a discussion with appropriate center BIMO personnel if non-concurrence is considered, within four (4) months of receipt of the draft NIDPOE.

Upon receipt of OCC concurrence, the BIMO Program Unit incorporates any changes and/or additions to the NIDPOE letter and routes the entire NIDPOE file to the appropriate center official for signature of the NIDPOE. This signature should be affixed within fourteen (14) days of receipt of OCC concurrence. The NIDPOE file and signed NIDPOE are returned to the BIMO Program Unit. The BIMO Program Unit should issue the signed NIDPOE, with the consent agreement, to the clinical investigator within one (1) working day of receipt and distribute copies to the appropriate Agency units, as described below.

The NIDPOE directs the clinical investigator to write or call the center, within fifteen (15) working days, to arrange for an informal conference or to indicate the intent to respond to the allegations in writing. If the clinical investigator chooses to submit a written response, the NIDPOE directs him/her to respond within thirty (30) working days of receipt of the NIDPOE.

**5-10-4 Notice of Initiation of Disqualification Proceedings and Opportunity to Explain (NIDPOE)**

**Delivery**

A NIDPOE should be sent by certified mail (return receipt requested), or other method that documents transmission and receipt of delivery. If such delivery is unsuccessful, the center should contact the Director, Investigations Branch (DIB) in the appropriate
division office and request that the NIDPOE be hand delivered by Agency personnel. The Center will provide the division with addresses and alternative locations for delivery.

**Distribution**

The issuance of a NIDPOE is a significant regulatory action and appropriate Agency units should be promptly advised of its issuance. These include:

[To blind copy electronically, send to the relevant party at firstname.lastname@fda.hhs.gov; for hardcopy distribution at the White Oak (WO) campus, include the building and room numbers]

- OCC; WO31/WO32
- DFOI; ELEM-1029
- OGCP; WO32-5129
- ORA, Division of Enforcement; WO32 [Originating Center - Center files and distribution]

[Relevant Division Office - Division Personnel, including the Division Director; the Director, Investigations Branch; and the Division investigator(s)]

- CDER, OSI; WO51
- CBER, BIMO Group; HFM-664
- CVM, BIMO Group; HFV-234
- CDRH, BIMO Group; WO66, BIMO@cdrh.fda.gov
- CFSAN, BIMO Group; HFS-205

The Center will forward the NIDPOE to the Center’s FOI program for redaction and posting on FDA’s webpage Clinical Investigators - Disqualification Proceedings.

**5-10-5 Consent Agreements**

After issuance of the NIDPOE, the clinical investigator may choose to enter into a consent agreement with FDA. A finalized consent agreement between FDA and the clinical investigator terminates the administrative proceedings in this matter. The option of entering into a consent agreement with the Agency is available at any time throughout the disqualification proceedings, up to the issuance of the Commissioner's Decision under 21 CFR 16.95 or issuance of a notification of disqualification under 21 CFR 312.70, 511.1(c), or 812.119. The consent agreement may be signed by an FDA official as listed in Staff Manual Guide 1410.21- General Redelegations of Authority, Paragraph 1.P. As noted above, a sample consent agreement is included in Exhibit 5-22.

**5-10-6 Informal Conference with the Clinical Investigator**

In the NIDPOE, the center will offer the investigator the opportunity to submit an explanation in writing, or at the investigator's option, in an informal conference. If the clinical investigator submits a written response, the regulations do not require the center to hold an informal conference, but the center may choose to do so. If an informal
conference is requested, the center should schedule it as soon as possible, usually **within thirty (30) days** of the request.

At the informal conference, the clinical investigator may be accompanied by a representative of his/her choosing and may provide documents for the record. A clinical investigator may submit written materials to FDA within fifteen (15) days after the informal conference.

At a minimum, FDA personnel attending the conference will include staff from the center BIMO Program Unit and counsel from OCC who reviewed the NIDPOE. FDA may also include other personnel with appropriate expertise or relevant experience with the case (e.g., a Medical Officer from the review team for the study involved, the FDA division investigator who conducted the inspection at the clinical investigator’s site). The center should make arrangements for the informal conference, notify all pertinent parties of the specifics, and arrange to have the discussion transcribed for the administrative record. These informal meetings should be scheduled for up to two (2) hours. Because the meeting is informal, there is no prescribed format, but the meeting should address all allegations listed in the NIDPOE.

Following the informal conference, the center will provide a copy of the written transcript to the clinical investigator. The center, in consultation with OCC, should promptly review any new explanation or evidence provided by the clinical investigator. If it no longer appears that disqualification is warranted, alternatives such as a detailed corrective action plan may be considered. The center BIMO Program Unit should notify the clinical investigator in writing **within thirty (30) days** of the informal conference of this decision not to proceed with the disqualification and include the specifics of any such alternative corrective action plan.

If the clinical investigator's explanation is not accepted by the Center, disqualification is still warranted and the center should issue a Notice of Opportunity for Hearing (NOOH) to the clinical investigator.

### 5-10-7 The Notice of Opportunity for Hearing (NOOH)

If a clinical investigator fails to respond to a NIDPOE or the center determines that the clinical investigator’s written or oral explanation is inadequate, the regulations provide that the clinical investigator be given an opportunity for a regulatory hearing under 21 CFR part 16 on the question of whether the investigator is eligible to receive test articles and eligible to conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA. Center BIMO Program Units should prepare an NOOH using the sample document provided in Exhibit 5-23. The NOOH should be prepared **within thirty (30) days** of a center’s decision that a clinical investigator's written or oral explanation is inadequate, or after it is clear the clinical investigator has chosen not to respond to the NIDPOE. The center should consult with OCC during the preparation of the NOOH and clear the NOOH in
accordance with center procedures. The center-approved NOOH and the administrative record (which includes the NIDPOE file and all follow-up information/documents) should be forwarded to OCC for review and clearance. **Within thirty (30) working days** of receipt, OCC should concur or provide comments to the BIMO Program Unit as to what is necessary to achieve concurrence with the NOOH.

**Within five (5) working days** of OCC concurrence, after incorporating any OCC additions/changes, the BIMO Program Unit forwards both the paper and electronic copies of the NOOH and the administrative record to the Division of Enforcement (DE). DE has **five (5) working days** to review and clear the NOOH for signature. If DE, during its review, proposes substantive changes to the NOOH, DE will clear their proposed changes with OCC, who will consult with the BIMO Program Unit when necessary. **Within five (5) working days**, after clearing any substantive DE additions/changes with OCC as necessary (OCC will consult with the Center as necessary and notify the center about any changes); DE forwards the NOOH and the administrative record to the Associate Commissioner for Regulatory Affairs (ACRA) in the ORA for review and signature; and, requests redaction of the NOOH by the Center’s FOI office and posting of the redacted NOOH on FDA’s website. The ACRA should sign the NOOH, or provide comments to DE as to what is necessary to achieve his/her signature, **within five (5) working days** of receipt. Upon receipt of the signed NOOH (within one (1) working day), DE date stamps and issues the NOOH to the clinical investigator and/or his/her counsel by certified mail (return receipt requested) or other documented method of transmission. If delivery of the NOOH cannot be confirmed, the Director, DE, will contact the local division office and request that the NOOH be delivered by FDA personnel. The Center will provide the division with addresses and alternative locations for delivery. Upon issuance of the NOOH, DE provides a copy of the signed NOOH to the center BIMO Program Unit, which is responsible for appropriately distributing copies of the NOOH within FDA (see NIDPOE distribution list above). The Center will forward the NOOH to the Center’s FOI program for redaction and posting on FDA’s webpage, Clinical Investigators - Disqualification Proceedings.

The NOOH provides that the investigator has ten (10) working days from receipt of the NOOH to request a hearing. If the clinical investigator does not respond within this time frame, the clinical investigator will be deemed to have waived the right to a regulatory hearing and the Agency will make a decision on the matter based on the facts available to the Agency.

DE will advise the center BIMO Program Unit of the response (or lack thereof) to the NOOH letter after ten (10) working days. Subsequent actions are discussed and determined by the center BIMO Program Unit, OCC, and DE as outlined in the Sample Notice of Opportunity for Hearing in Exhibit 5-23. The center BIMO Program Unit is responsible for preparing a memo for summary decision regarding the disqualification.

See SMG 7711 for details of the process to be followed after issuance of a NOOH.
The clinical investigator disqualification proceedings described above are summarized in the flowchart found in Exhibit 5-20.
5-11 EXHIBITS

Exhibit 5-1  Model Section 305 Notice
Exhibit 5-2  Model Charge Sheet
Exhibit 5-3  Model Charges
Exhibit 5-4  Legal Status Sheet
Exhibit 5-5  Information Sheet
Exhibit 5-6  Summary Format - Section 305 Meeting
Exhibit 5-7  Notification of Non-Prosecution
Exhibit 5-8  Timeframes for Administrative Detention of Food (AD of Food) – Appellant’s Deadlines
Exhibit 5-9  Timeframes for AD of Food – FDA’s Deadlines
Exhibit 5-10 Model General Summary of Information – AD of Food
Exhibit 5-11 Model Comprehensive Statement – AD of Food
Exhibit 5-12 Model Hearing Confirmation Letter – AD of Food
Exhibit 5-13 5-13A  MODEL LETTER – FINAL DECISION ON APPEAL OF ADMINISTRATIVE DETENTION ORDER – CONFIRMATION
5-13B  MODEL LETTER – FINAL DECISION ON APPEAL OF ADMINISTRATIVE DETENTION ORDER – REVOCATION
5-13C  MODEL LETTER TERMINATING APPEAL – Administrative Detention of Food
Exhibit 5-14 Model General Summary of Information (Administrative Detention of Devices (AD of Devices))
Exhibit 5-15 Model Comprehensive Statement – AD of Devices
Exhibit 5-16 Examples of Detailed Statements – AD of Devices
Exhibit 5-17 Model Hearing Confirmation Letter – AD of Devices
Exhibit 5-18 Model Order – AD of Devices
Exhibit 5-19 Model Order of Retention, Recall, And/Or Destruction
Exhibit 5-20 Disqualification Proceedings Flowchart
Exhibit 5-21 Sample NIDPOE
Exhibit 5-22 Sample Consent Agreement
Exhibit 5-23 Sample Notice of Opportunity for Hearing (NOOH)
Exhibit 5-1    MODEL SECTION 305 NOTICE

In reply refer to: Sample No. Product

Firm Name and Individual    Date
Street Address
City, State, Zip

Investigation by this Administration indicates your responsibility for violations of the Federal Food, Drug, and Cosmetic Act, and other Federal Laws, as described in the attached Charge Sheet, with respect to the following:

Shipment of an article labeled in part "Cream Style White Sweet Corn Net Weight 5 lb 10 oz" by (Firm, Location), to (Firm, Location), on or about (date).

A meeting has been scheduled for (day, date, time) at (location), to give you an opportunity to present your views on this matter. The enclosed INFORMATION SHEET explains the purpose and nature of the meeting, and how you may reply. If no response is received on or before the date set, our decision on whether to refer the matter to the Department of Justice for prosecution will be based on the evidence in hand.

By direction of the Secretary of the Department of Health and Human Services:

/s/

Compliance Officer

(IMPORTANT: NOTE ALL ENCLOSURES CAREFULLY)

Enclosures:
Legal Status Sheet (3) Charge Sheet Information Sheet Regulations
Exhibit 5-2  MODEL CHARGE SHEET

CHARGE SHEET

(In Connection with Enclosed Section 305 Notice)

<table>
<thead>
<tr>
<th>Sample Nos.</th>
<th>Sample Nos.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample #, Product</td>
<td>Sample #, Product</td>
</tr>
<tr>
<td>Sample #, Product</td>
<td>Sample #, Product</td>
</tr>
<tr>
<td>Sample #, Product</td>
<td>Sample #, Product</td>
</tr>
<tr>
<td>Sample #, Product</td>
<td>Sample #, Product</td>
</tr>
</tbody>
</table>

PROHIBITED ACT: Section 301(a) of the Federal Food, Drug, and Cosmetic Act. The introduction or delivery for introduction into interstate commerce of any food that is adulterated.

CHARGES: The articles are adulterated in the following respects: Sample #)

| Sample #) | They contain insect fragments and rodent hair fragments. Sample #) |
| Sample #) | Sample #) Sample #) Sample #) Sample #) |
| Sample #) | It contains insects, insect fragments, and rodent hair fragments. |
| Sample #) | It contains insect fragments. |
| Sample #) | It contains insect larvae, insect fragments, and rodent hair fragments. |

All Samples) The factory in which the articles were prepared was infested with insects and rodents which may have contaminated the articles
Exhibit 5-3  MODEL CHARGES

SPECIMEN CHARGE

(Do not quote the section of the Act listed below on the Charge Sheet)

Adulterated Foods

402(a)(1)
- The soybeans contain an added poisonous or deleterious substance, namely, crotalaria seeds, which may render them injurious to health.
- The frozen eggs contain added salmonella microorganisms, pathogenic bacteria, which may render them injurious to health.
- The article contains selenium, a poisonous or deleterious substance, in a quantity that would ordinarily render it injurious to health.

402(a)(2)(A)
- The articles contain an added deleterious substance, namely, metal fragments, which is unsafe since it is not required in the production of this food and can be avoided by good manufacturing practices.
- The cod fillets contain oxytetracycline that is unsafe, since oxytetracycline is not required in the production of this food and can be avoided by good manufacturing practices.

NOTE: Generally, the use of Section 402(a)(2)(A) as a basis for charges should be limited; other sections, such as 402(a)(1), are usually preferred.

402(a)(2)(B)
- The berries contain heptachlor, which is not generally recognized as safe, and for use of which a tolerance has not been prescribed by regulation.
- The cabbage contains excessive Toxaphene.

402(a)(2)(C)
- The article contains a food additive, namely lead, which is unsafe within the meaning of Section 409(a) since its use and intended use are not in conformity with a regulation or exemption in effect.

402(a)(2)(D)
- The meat intended for human food contains a new animal drug, namely MGA, which is unsafe in that there is no approved new animal drug application in effect for this use.

402(a)(3)
- The article contains insect parts and insect excreta.
• The article contains rodent excreta pellets.
• The nuts are rancid.
• Some of the cans contain decomposed salmon.
• The catsup contains decomposed tomatoes
• The peanut butter contains grit.

402(a)(4)
• The factory (warehouse) in which it was prepared and packed (held) was infested with rodents and insects, which may have contaminated it.

402(a)(5)
• Some of the boxes contain emaciated and diseased birds.
• Some of the boxes contained birds that were not slaughtered but that died from other causes.

402(a)(7)
• The article has been subjected to radiation, not provided for by the Food Additives Regulations.

402(b)(1)
• The article is deficient in Vitamin B.
• The butter contains less than 80% milkfat.

402(b)(2)
• Mineral oil has been used to replace part of the vegetable oil.
• Chicory has been used in part instead of coffee.

402(b)(3)
• Blemished, old potatoes have been colored and waxed to resemble new potatoes and to conceal the blemishes.

402(b)(4)
• The ground pepper contains ground olive seeds.
• The poppy seeds are brown and have been artificially colored to appear to be blue poppy seeds.

402(c)
• The article contains a color additive, namely, "butter yellow," not permitted by regulation for use in food.
• The article contains a color additive, namely, FD&C Purple Number 8, for which no tolerance has been established
402(d)
- Some pieces of the candy contain a metallic toy.
- The candy is filled with alcohol

402(e)
- The article contains vegetable oil that is rancid.
- The milk used to manufacture the butter contained flies and manure

**Misbranded Foods**

403(a)
- The label falsely represents it to contain a significant amount of honey but the amount present, if any, is inconsequential.
- The label bears statements that falsely represent, in the setting in which they are presented, that the article will supply an unusually large amount of protein in a quantity which is low in calories, and that the article is therefore of significant value for weight reducing.
- The labeling falsely represents that the product contains copper, folic acid, cobalt and calcium pantothenate.
- The label falsely represents the article to be canned peas, whereas the article is canned spinach

403(b)
- It was offered as lemon extract by the price list sent to the consignee on or about May 2, XXXX, but it is in fact an extract of lemon grass oil

403(c)
- The word "Imitation" on the label is in type of smaller size and less prominence than the type in which the words "Vanilla Extract" appear.
- The label fails to bear the name "Imitation Strawberry Preserves."

403(d)
- The can has a depressed top and bottom and contains a thick corrugated inner liner, which give the container the appearance of containing more nuts than it does.
- The container is slack-filled

403(e)(1)
- The label fails to bear the name of the manufacturer, packer, or distributor.

403(e)(2)
- The label statement "net weight 4 oz." is inaccurate.
• The article is short weight.

403(f)
• The statement of ingredients on the label is inconspicuous.
• The name and address of the manufacturer is printed on the cellophane bag in white ink and lacks contrast with the white candy mints contained therein

403(g)(1)
• The article is represented as raspberry preserves but contains less fruit than the standard of identity requires.
• The article purports to be French dressing but contains less fat than specified in that standard.
• The egg noodles are deficient in egg solids content

403(g)(2)
• The article is bleached flour but the label does not state that it is bleached.
• The article purports to be enriched macaroni, and its label fails to bear the name of that food.
• The article purports to be Fruit Butter, but its label fails to bear the name of the optional ingredient, lime juice, present in the food.

403(h)(1)
• The article contains excessive blemished fruit but its label does not bear the statement of substandard quality prescribed for canned peaches.
• Its quality falls below the standard for canned tomatoes, since it contains excessive peel.

403(h)(2)
• The cans are underfilled but the label does not bear the statement of substandard fill prescribed for canned peas.

403(i)(1)
• The article is ground cinnamon but its label does not bear the name "ground cinnamon."

403(i)(2)
• Flour is present but is not named in the label listing of ingredients.
• The label fails to bear a statement of ingredients of the article by their common or usual names.
403(j)
- Its label fails to bear a statement of the percentage of the USRDA for the vitamins B(1), B(2), niacinamide and the mineral iron, as required by the special dietary regulations.
- The label fails to state the percent by weight of methylcellulose present; and in juxtaposition with name of such constituent, the word "non-nutritive," as required by the special dietary regulations

403(k)
- The labeling fails to state the fact that a chemical preservative has been added.
- The article is artificially colored, but its labeling fails to state that fact

403(l)
- The oranges contain biphenyl (diphenyl applied post harvest), but its shipping container fails to bear labeling declaring the name and function of the pesticide chemical

403(m)
- The article is a color mixture but its label does not declare the name of the color components contained therein

**Adulterated Drugs**

501(a)(1)
- The aspirin tablets contain rodent hairs.

501(a)(2)(A)
- The plant in which the aspirin tablets were manufactured was infested with rodents which may have contaminated them.

501(a)(2)(B)
- The door of the sterile filling room was left open while filling bottles of an eye solution.
- The methods used in its packing do not conform to current good manufacturing practices in that Isopropyl alcohol is labeled as Citrate of Magnesia.

501(a)(3)
- Its container is composed in part of lead, which may render the contents injurious to health.

501(a)(4)(A)
- The color used is in excess of the limits prescribed in the regulations.
501(a)(4)(B)
- FD&C Red #4 intended for use in a drug for internal administration, and such use is for coloring purposes only.

501(a)(5)
- The article is a new animal drug and there is no approved new animal drug application in effect for this drug.

501(a)(6)
- The cattle feed contains a new animal drug, namely Carbadox, which is unsafe in that there is no approved new animal drug application in effect for this use.

501(b)
- The article purports to be an official NF drug but fails to comply with the compendium’s standard for strength.
  - It contains cresol, a substance not permitted by the U. S. Pharmacopeia Monograph for Water for Injection, which the drug purports to be.
  - Magnesium carbonate, which the NF formula requires in Solution of Magnesium Citrate, has been replaced by sodium carbonate

501(c)
- The article contains Neomycin Sulfate which is below the potency declared on the label.
  - The quality of the article namely, Rubber Prophylactics, falls below that which it is purported to possess

501(d)(1)
- The article has been mixed or packed so as to reduce its quality or strength.

501(d)(2)
- P-aminosalicylic acid has been substituted in part for conjugated para-amino salicylic ascorbate.

Misbranded Drugs

502(a)
- Its labeling represents it as a treatment for influenza and related diseases, but it is not an effective treatment for these diseases.
  - The article falsely claims that it will remove ascarids from hogs
502(b)(1)
- Its label does not bear the name and place of business of the manufacturer.

502(b)(2)
- Its label does not bear an accurate statement of the quantity of contents.

502(c)
- The statement "24 tablets" appears on the back label and is on a pink label in red type

502(e)(1)(A)(i)
- The label does not show that the drug is aspirin.

502(e)(1)(A)(ii)
- The quantity of bromide per tablet is not stated on the label.
- Its label fails to list all of the active ingredients.

502(f)(1)
- The directions do not state the uses of the drug.
- Its (O-T-C drug) labeling does not contain directions adequate for the treatment of diabetes, for which use the drug is recommended in advertising (as distinguished from labeling).
- The prescription drug lacks adequate full disclosure information.

502(f)(2)
- The labeling does not warn against use of the drug in case of nausea, vomiting, abdominal pain, or other symptoms of appendicitis.
- The labeling gives no warning that use of the drug in excess of what the directions call for may result in nervousness and sleeplessness.

502(g)
- It is not packaged in tight containers as required by the United States Pharmacopoeia

502(i)(1)
- The container is slack-filled.

502(i)(2)
- It is an imitation of citrate of magnesia.

502(i)(3)
- The article, namely argel leaves, is offered for sale as senna.
502(j)
• It is dangerous to health when one tablet is taken every three hours as recommended in the labeling.
• It is dangerous to health when taken in the dosage suggested in its labeling.

502(m)
• The label fails to provide directions for use to preclude adding excessive color additive to the drug.

502(n)(1)
• The advertisement for Miltown which appeared in the May 19, 20XX edition of the Pleasant Medical Journal did not show the established name.

502(n)(2)
• The advertisement for "Triple Sulfa" tablets which appeared etc. did not list the active ingredients by their established names.

502(n)(3)
• The advertisement for "Triple Sulfa" tablets which appeared in the May 19, 20XX edition contained or recommended indications for use or a dosage recommendation, but not the brief summary of side effects, contraindications, and effectiveness.

502(o)
• The potassium chloride tablets were manufactured in an unregistered plant.

503(b)(4)(A)
• The label for the article, namely chloralhydrate, does not bear the symbol “Rx only”.

503(b)(4)(B)
• The aspirin tablet label bears the symbol “Rx only,” but the drug is not entitled to such designation.

505(a)
• The article, namely, Meprobamate, is a new drug and was shipped in interstate commerce without an approved new drug application.
Cosmetics

601(a)
- The article contains paraphenylenediamine, a coal tar dye which is a deleterious substance, but its label does not carry adequate warnings or directions to make a preliminary patch test before use.
- It contains formaldehyde, a deleterious substance.

601(b)
- Some of its components contain rodent excreta pellets

601(c)
- The plant in which the article was prepared was infested with rodents

601(d)
- Its container is composed in part of lead

601(e)
- The color used is not authorized by the regulations (or is in excess of the limits prescribed in the regulations.)

602(a)
- The article is represented as containing a substantial amount of lanolin, but lanolin is a minor constituent of the cream

602(b)(1)
- The label for the eye shadow does not bear the name and location of the manufacturer, namely, New York Pencil Co., Inc., New York, N.Y.

602(b)(2)
- The article does not bear a statement of the quantity of contents.

602(c)
- The statement of the quantity of contents appears on the bottom of the container (oval jar)

602(d)
- The nontransparent container is composed of an outer and inner wall with a 1/8 inch space between the walls
602(e)

- The label fails to provide directions for use to preclude adding excessive color additive to the cosmetic

**Title 42**

351(a)

- The Source Plasma (Human) was drawn and shipped from an unlicensed establishment.
- The label fails to bear the expiration date and license number of the establishment

351(b)

- The label states the blood is Hgb negative, but the records show the unit is Hgb positive.
- The donor number on the unit label is false.
- The product is pooled serum, but the label falsely states it was drawn from one donor

351(c)

- Inspection of the establishment by a duly authorized investigator was refused

351(e)

- Officers of your firm interfered with the investigator in the performance of his duties by refusing to provide necessary records for his review

**Title 18, Section 1001**

- The firm was aware that test animals had died, but concealed that fact.
- You advised FDA Investigators that you had no connection with the study, knowing the statement to be false.
- The study that was submitted with NDA 80-125 contains fictitious entries.
- The documents submitted in support of your application contain false statements.
Exhibit 5-4   LEGAL STATUS SHEET

SAMPLE NO: ________________________________

A. STATUS OF FIRM AT TIME OF ALLEGED VIOLATIONS

Date __________

Full name of firm ________________________________________________

Please check and fill in appropriate section below:


Names and Titles of principal officers

______________________________________________________________

(include first name and middle initial)

2. Partnership  □

Name of each partner

______________________________________________________________

(include first name and middle initial)

3. Sole Ownership  □

Name of Owner

______________________________________________________________

(include first name and middle initial)

B. STATUS OF FIRM AT PRESENT TIME

Date: ______

Same as above  □  Different  □

Full name of firm ______________________

Names and titles of principal officers

______________________________________________________________
(include first name and middle initial)

2. Partnership

Name of each partner

______________________________________________________________
(include first name and middle initial)

3. Sole Ownership

Name of Owner

______________________________
(include first name and middle initial)

Signature ___________________________

Title ________________________________
Exhibit 5-5  INFORMATION SHEET

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

INFORMATION SHEET IN CONNECTION WITH ENCLOSED SECTION 305 NOTICE

OBJECT OF THE MEETING

This meeting is scheduled to give the person or persons who appear to be responsible for the violations of the Federal Food, Drug, and Cosmetic Act, and other Federal Laws, as specified in the attached Charge Sheet an opportunity to explain voluntarily any circumstances connected with the preparation, handling, shipment, or sale of the articles involved which would indicate that criminal action should not be taken. You are not compelled, however, to answer. Any civil action which may have been taken against the goods involved, such as seizure, does not preclude prosecution of those responsible for the violation: the meeting concerns the possible criminal action only. A copy of the Federal Food, Drug, and Cosmetic Act and regulations for its enforcement may be had upon request.

NATURE OF THE MEETING

This meeting is informal and confined to questions of fact. For your convenience in submitting required information concerning the status of your firm both on the date of response to this notice and on the date of alleged violation, the attached Legal Status forms may be filled out and returned with your answer, whether written or by personal appearance. Your answer may consist of the disclosure of any pertinent facts, letters, files, guaranties, shipping documents, analyses, arguments, etc., which you feel may present valid reasons why you should not be prosecuted.

GUARANTIES

In the case of articles that are adulterated or misbranded when introduced in interstate commerce the Federal Food, Drug, and Cosmetic Act (the Act) places responsibility on the interstate shipper, even though he may be only the distributor and not the manufacturer. Distributors may relieve themselves of responsibility if they hold a legal guaranty under Section 303(c) of the Act. If the articles were sold to you by a person residing in the United States and guaranteed by such person to comply with the provisions of the Act, you should submit:

- Evidence of that fact, and
- A statement as to whether the product at the time of the apparent violation by you was in the identical condition and bore the same labels as when received by you from the guarantor, and
• The full name of the person who, if called upon, can identify the pertinent records and testify to the facts as you present them.

HOW TO ANSWER

You may appear in person or by attorney or other designated representative, or you many submit your response in the form of a letter in lieu of personal appearance. If written response is made, please submit your letter and all accompanying documents in triplicate. Documents submitted at personal appearance should be in triplicate. All documents should be conspicuously identified by the reference number shown on the upper right corner of the Section 305 Notice.

RESULT OF THE MEETING

After the meeting has been held and all the facts considered, if it is the conclusion of the Secretary of the Department of Health and Human Services that prosecution should be recommended, the facts in the matter will be transmitted to the Department of Justice for appropriate action.

FORM FDA 466a (7/80) PREVIOUS EDITION IS OBSOLETE.
Exhibit 5-6 SUMMARY FORMAT - SECTION 305 MEETING

SUMMARY

FIRM AND INDIVIDUAL CITED: SAMPLE NO. AND PRODUCT:

_____________________________________________________________

DATE OF MEETING:

WHERE HELD:

_____________________________________________________________

PRESENT:
(List attendees - name, title, etc.)

_____________________________________________________________

WRITTEN SUMMARY

Compliance Officer________________________
__________ Division

(distribution)
Exhibit 5-7 NOTIFICATION OF NON-PROSECUTION

Dear __________________________:

Pursuant to 21 CFR 7.85(h), this is to advise you of the decision not to proceed with criminal prosecution of (firm name and/or individual name or names) based on the charges set forth in the Section 305 Notice dated ___.

This decision is based on the evidence we have at this time and does not preclude the initiation of criminal prosecution, based in whole or in part on any or all of the charges set forth in the Notice, should new evidence or subsequent violations of the law reveal the need for such action. In such case, a new Section 305 Notice will issue except as provided in 21 CFR 7.84(a)(2) and (3)

____________________________________
Division Director
## EXHIBIT 5-8 DEADLINES FOR ADMINISTRATIVE DETENTION OF FOOD

### Appellant’s Deadlines

<table>
<thead>
<tr>
<th>Action</th>
<th>Perishable Food</th>
<th>Non-perishable Food</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requesting a Hearing</td>
<td>Two (2) calendar days Request for hearing must be included in request for appeal.</td>
<td>Four (4) calendar days Notice of intent to request a hearing must be filed within four (4) calendar days of receipt of detention order—or FDA will not grant the hearing. Request for hearing must be filed within ten (10) calendar days from receipt of detention order.</td>
</tr>
<tr>
<td>Filing an Appeal</td>
<td>Two (2) calendar days Appeal must be filed within two (2) calendar days of receipt of detention order (the appeal may or may not include a request for a hearing)</td>
<td>Ten (10) calendar days Appeal must be filed within ten (10) calendar days of receipt of detention order.</td>
</tr>
</tbody>
</table>
**EXHIBIT 5-9 TIMEFRAMES FOR ADMINISTRATIVE DETENTION OF FOOD**

<table>
<thead>
<tr>
<th>FDA’s Deadlines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Holding a Hearing</strong></td>
</tr>
<tr>
<td>Two 2 calendar days</td>
</tr>
<tr>
<td>If the Appeal includes a request for a hearing, and FDA grants the request,</td>
</tr>
<tr>
<td>the hearing must be held within two (2) calendar days after the date the appeal</td>
</tr>
<tr>
<td>is filed.</td>
</tr>
<tr>
<td><strong>Written Report of the Hearing</strong></td>
</tr>
<tr>
<td>Noon of the fifth (5th) calendar day</td>
</tr>
<tr>
<td>The presiding officer must issue a written report that includes a proposed</td>
</tr>
<tr>
<td>decision confirming or revoking the detention by noon on the fifth (5th)</td>
</tr>
<tr>
<td>calendar day after the appeal is filed. The hearing participants have four (4)</td>
</tr>
<tr>
<td>hours to submit comments. The presiding officer must issue a decision on the</td>
</tr>
<tr>
<td>appeal within five (5) calendar days after the appeal is filed. [See “Decision</td>
</tr>
<tr>
<td>on an Appeal (with or without a hearing)” below]</td>
</tr>
<tr>
<td><strong>Decision on an Appeal (with or without a hearing)</strong></td>
</tr>
<tr>
<td>Five (5) calendar days</td>
</tr>
<tr>
<td>If a detention order is appealed, the presiding officer must issue a decision on</td>
</tr>
<tr>
<td>the appeal confirming or revoking the detention within (five) 5 calendar days</td>
</tr>
<tr>
<td>after the appeal is filed. If the presiding officer fails to confirm or terminate</td>
</tr>
<tr>
<td>the detention order within this time frame, the detention is deemed terminated.</td>
</tr>
<tr>
<td><strong>Seizure of Perishable Foods</strong></td>
</tr>
<tr>
<td>Four (4) calendar days to send recommendation to DOJ</td>
</tr>
<tr>
<td>If FDA initiates a seizure action against Perishable Food, FDA will send the</td>
</tr>
<tr>
<td>seizure recommendation to the Department of Justice within four (4) calendar</td>
</tr>
<tr>
<td>days after the detention order is issued, unless extenuating circumstances</td>
</tr>
<tr>
<td>exist. If the fourth (4th) calendar day is not a working day, OCC must advise</td>
</tr>
<tr>
<td>DOJ on the last working day before the deadline of its plans to recommend a</td>
</tr>
<tr>
<td>seizure and will send the seizure as soon as practicable on the first working</td>
</tr>
<tr>
<td>day after the non-work day.</td>
</tr>
</tbody>
</table>
Exhibit 5-10  MODEL GENERAL SUMMARY OF INFORMATION – Administrative Detention of Food*

[Division Letterhead]

Date
Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, MS

RE: Administrative Detention Order DO [insert #]

Dear Mr. Smith:

Pursuant to section 16.24(f) of Title 21 of the Code of Federal Regulations (21 CFR 16.24(f)), this letter provides notice of matters to be considered at the hearing requested as part of your appeal of administrative detention order DO [insert #]. As authorized under section 304(h) of the Federal Food, Drug, and Cosmetic Act (Act), the U.S. Food and Drug Administration (FDA) administratively detained [insert description of food] located at [insert location] on [insert date] because the Agency has reason to believe that the food is [adulterated or misbranded]. You may find the Act and its implementing regulations through links on FDA's home page at www.fda.gov.

[If the administrative detention is based, in whole or in part on CLASSIFIED information, consult with OCC on the classified information and insert the following:

FDA’s decision to administratively detain the food is based [in whole or in part] on classified information. In accordance with 21 CFR 1.406, FDA will not provide you with this information. [Insert a statement about the general nature of our basis for the detention, if the classified information and its source can be safeguarded.]

[If the administrative detention is not based on CLASSIFIED information, insert the following:

FDA’s decision to administratively detain your food is based on the following information:

[Insert a comprehensive statement of the basis for the administrative detention, including applicable misbranding or adulteration charges. Also provide a general summary of the information that FDA will present at the hearing in support of the administrative detention.

Examples of sources of supporting information for the summary include, but are not limited to:
1. Form FDA 483 Inspectional Observations that documents objectionable conditions or practices
2. Establishment Inspection Report (EIR) including Exhibits, which describe, in detail, objectionable conditions or practices observed, including product manufacturing information, responsible individuals, and documents collected
3. Sample information including Collection Reports and analytical results or data analysis
4. The food label and labeling
5. Affidavits relating to the adulteration or misbranding
6. Records (e.g., supplier, manufacturer, and distribution records)
7. Epidemiological data from Centers for Disease Control and Prevention or other public health officials that establishes an association between the detained food with foodborne illness
8. Reportable food reports

If you have any questions regarding information in this letter, you may contact me at [Division Director’s phone number] prior to the hearing.

Sincerely yours,

Division Director
Exhibit 5-11  MODEL LETTER GRANTING HEARING – Administrative Detention of Food

[Division/OE Letterhead]

Date
Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, MS

RE: Administrative Detention Order DO [insert #]

Dear Mr. Smith:

I am confirming the information discussed during our telephone conversation today regarding the hearing you requested in your appeal of the administrative detention of [insert description of food] located at [insert location].

I am granting your request for a hearing and providing additional information about the hearing. The hearing you requested will be held on [insert date] at [insert time] at the [insert Division Office, street address, city, state, and Zip Code].

The hearing will be a closed hearing because the proceedings constitute an open investigatory record (21 CFR 16.60(a)). This means that only you, your counsel, witnesses, and employees as well as FDA representatives will be allowed to attend.

Under 21 CFR 1.403 a hearing on appeal of a detention order shall be conducted in accordance with 21 CFR part 16 – Regulatory Hearing Before the Food and Drug Administration with the following exceptions:

1. The detention order under 21 CFR 1.393, rather than the notice under 21 CFR 16.22(a), provides notice of opportunity for the hearing and is part of the administrative record of the regulatory hearing under 21 CFR 16.80(a).

2. A request for a hearing must be addressed to the FDA Division Director in whose division the article of food involved is located.

3. The provision in 21 CFR 16.22(b), providing that a person not be given less than three (3) working days after receipt of notice to request a hearing, does not apply.

4. The provision in 21 CFR 16.24(e), stating that a hearing may not be required to be held at a time less than two (2) working days after receipt of the request for a hearing, does not apply.

5. 21 CFR 1.406, rather than 21 CFR 16.24(f), describes the statement that will be provided to an appellant where a detention order is based on classified information.
6. 21 CFR 1.404, rather than 21 CFR 16.42(a), describes the FDA employees, e.g., Division Directors or other officials senior to a Division Director, who preside at hearings.

7. The presiding officer may require that the hearing be completed within one (1) calendar day, as appropriate.

8. 21 CFR 16.60(e) and (f) do not apply to the hearing. The presiding officer must prepare a written report of the hearing. All written material presented at the hearing will be attached to the report. The presiding officer must include as part of the report of the hearing a finding on the credibility of witnesses (other than expert witnesses) whenever credibility is a material issue, and must include a proposed decision, with a statement of reasons. The hearing participant may review and comment on the presiding officer's report within 4 hours of issuance of the report. The presiding officer will then issue the final Agency decision.

9. 21 CFR 16.80(a)(4) does not apply to the hearing. The presiding officer's report of the hearing, and any comments on the report by the hearing participant under 21 CFR 1.403(h), are part of the administrative record.

10. No party shall have the right under 21 CFR 16.119 to petition the Commissioner of Food and Drugs for reconsideration or a stay of the presiding officer's final Agency decision.

11. If FDA grants a request for an informal hearing on an appeal of a detention order, the hearing must be conducted as a regulatory hearing pursuant to regulation in accordance with 21 CFR part 16, except that 21 CFR 16.95(b) does not apply to the hearing. With respect to the regulatory hearing on an appeal of a detention order, the administrative record of the hearing specified in 21 CFR 16.80(a)(1), (a)(2), (a)(3), and (a)(5), and 1.403(i) constitutes the exclusive record for the presiding officer's final decision on an administrative detention. For purposes of judicial review under 21 CFR 10.45, the record of the administrative proceeding consists of the record of the hearing and the presiding officer's final decision.

I am authorized by 21 CFR 10.19 and 21 CFR 16.60(h) to waive, modify, or suspend any provision under 21 CFR part 16. I am modifying 21 CFR 16.60(b), which provides that all parties may confront and conduct reasonable cross-examination of any person (except for the presiding officer and counsel for the parties) who makes any statement on the matter at the hearing. Reasonable questioning will be allowed instead.

If feasible, at least one (1) day before the hearing, you are to provide the Division Director with written notice of, or a copy of, if the Division Director could not reasonably be expected to obtain a copy, any published articles or written information that you intend to present or rely upon at the hearing, as required by 21 CFR 16.24(g). You may provide this information by facsimile: [insert number], electronically: [insert e-mail], or courier: [insert name and address of Division Director].
Any written communication you forward or present to me must be sent by you to all other participants to the hearing as required by 21 CFR 16.44(c).

You are requested to provide at the hearing a brief summary of any lengthy documents you intend to present at the hearing.

If you have any additional questions on the procedures I will follow at the hearing, you may contact me at [insert phone number] prior to the hearing.

Sincerely yours,

[Presiding Officer]
Exhibit 5-12  MODEL LETTER DENYING HEARING – Administrative Detention of Food

(Division/OE Letterhead)

Date

Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, USA

RE: Administrative Detention Order DO [insert #]

Dear Mr. Smith:

This is a follow-up to our telephone conversation today regarding the hearing you requested as part of your appeal of the administrative detention of [insert description of food] located at [insert location].

I am denying your request for a hearing because you have not raised a genuine and substantial issue of fact (21 CFR 16.26(a)). Specifically, [insert reason why no genuine and substantial issue of fact was raised by the appellant].

Sincerely yours, Presiding Officer
Exhibit 5-13A

MODEL LETTER – FINAL DECISION ON APPEAL OF ADMINISTRATIVE DETENTION ORDER – CONFIRMATION

Administrative Detention of Food

[Division/OE Letterhead]

Date

Decision on Appeal – Confirmation

Administrative Detention Order DO [insert #]

Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, MS

Dear Mr. Smith:

I am confirming the administrative detention order for [insert description of food] located at [insert location] because [insert reason why confirming detention].

[If information that supports the administrative detention is, in whole or in part, CLASSIFIED information, insert the following:]

My decision is based [in whole or in part] on classified information.

[If information that supports the administrative detention is not CLASSIFIED information, insert the following:]

My decision is based on information you submitted in your appeal [and information presented by all parties at the hearing on the appeal].

The administrative detention is effective until [insert date], unless FDA issues a detention termination notice prior to that date. It is a prohibited act under section 301(bb) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 331(bb), to move an article of food that is subject to administrative detention or to alter or remove any mark or label that identifies the article of food as administratively detained.

Sincerely yours,

[Presiding Officer]
Exhibit 5-13B

MODEL LETTER – FINAL DECISION ON APPEAL OF ADMINISTRATIVE DETENTION ORDER – REVOCATION

Administrative Detention of Food

[Division/OE Letterhead]

Date

Decision on Appeal – Revocation

Administrative Detention Order DO [insert #]

Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, MS

Dear Mr. Smith:

I am revoking the administrative detention order for [insert description of food] located at [insert location] because [insert why the order is being revoked]. The administrative detention is terminated as of this date and the food is released. You may remove the labels and tags relating to the detention and return the tags to the Division Director.

[If information utilized to support the administrative detention is, in whole or in part, CLASSIFIED information, insert the following:]

My decision is based [in whole or in part] on classified information.

[If information utilized to support the administrative detention is not CLASSIFIED information, insert the following:]

My decision is based on information you submitted in your appeal [and at the hearing on the appeal]. Thus, FDA no longer has reason to believe the food is adulterated or misbranded.

Sincerely,

[Presiding Officer]
Exhibit 5-13C

MODEL LETTER TERMINATING APPEAL – Administrative Detention of Food
[Division/OE Letterhead]

Date

Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, USA

RE: Administrative Detention Order DO [insert #]

Dear Mr. Smith:

Your appeal of the administrative detention of [insert description of food] located at [insert location] has been terminated because a [seizure action under section 304(a) of the Federal Food, Drug, and Cosmetic Act or an injunction under section 302 of the Federal Food, Drug, and Cosmetic Act] has been filed in court regarding the article of food involved in the detention order (21 CFR 1.402(c)) ([name of case]). If you have any questions on this termination of your appeal, you may contact the Division at [insert phone number].

Sincerely yours,
[Presiding Officer]
Exhibit 5-14  
MODEL GENERAL SUMMARY OF INFORMATION Administrative Detention of Devices

Division Director Letterhead

Date

Ace Plastic Company  
11124 Railroad Street  
Ogallala, Nebraska 69158

Dear Sir:

This is a General Summary of Information in Support of Detention DN 60011. We intend to present the following information to support our action:
1. Form FDA 483 list of observations issued to Albert C. Edwards, owner of Ace Plastic Company.
5. Testimony of Sidney H. Rogers, Investigator, reporting his observations and his discussion with Mr. Edwards.

Sincerely yours, Division Director
Exhibit 5-15
MODEL COMPREHENSIVE STATEMENT* Administrative Detention of Devices

Date

Ace Plastic Co.
11124 Railroad Street
Ogallala, Nebraska 69150

Dear Sir:

The following is a Comprehensive Statement of the Basis for Detention Order DN 60011. FDA Investigator _______ observations:

Black unidentified spots on the needles and holes in the individual protective packaging of the sterile 2cc syringe led him/her to believe that the devices are adulterated and misbranded resulting in issuing Detention Order number DN 60011 made these observations during his/her (date) inspection of your establishment.

The black spots on the needles and holes in the packages lead us to believe the product is adulterated within the meaning of (1) Section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (the Act) in that the device has been prepared, packed, or held under insanitary conditions whereby it may have been rendered injurious to health; and (2) within the meaning of Section 501(c) of the Act in that its quality falls below that which it purports or is represented to possess. Further, these same observations lead us to believe that the product is misbranded per Section 502(a) of the Act because the label states the product to be sterile and the holes in the protective wrapper allow the product to be exposed to contamination.

*To be used when the detention order (FDA 2289 Detention Notice) may not serve as the Comprehensive Statement because the "reason for detention" is not described in sufficient detail. When the detention order may serve as the Comprehensive Statement, the letter need only include a copy of the detention order and reference the "reason for detention" as the Comprehensive Statement.
Exhibit 5-16
EXAMPLES OF DETAILED STATEMENTS Administrative Detention of Devices

EXAMPLES OF STATEMENTS UNDER ITEM #15, "REASON FOR DETENTION" THAT PROVIDE SUFFICIENT DETAIL FOR THE FDA 2289 ORDER TO SERVE AS A COMPREHENSIVE STATEMENT:

1. 21 USC Section 351(c) charge.

- Detention order cites adulteration within the meaning of Section 351(c) because the quality of the device falls below that which it claims to possess.

- Comprehensive statement expands upon the charge in the detention order by adding: "...because the labeling specifies that the device measures "x" within ± 3 percent but tests conducted by FDA show that the device only measures "x" within ± 25 percent."

2. 21 USC Section 351(h) charge.

- Detention order cites adulteration within the meaning of Section 351(h) in that the methods used in, etc. (tracking in plain language the applicable portion of the statute) are not in conformity with GMP requirements under 21 USC Section 360j(f) as set forth in 21 CFR Part 820.

- Comprehensive Statement expands upon the charge in the detention order by adding: "...because (citing applicable sections of the GMP regulations and deviations from them, working directly from the FDA 483 but using common, non-statutory language."

3. 21 USC Section 352(a) charge.

- Detention order cites misbranding within the meaning of Section 352(a) in that the labeling for the device, which states that the device will cure the common cold, is false or misleading.

- Comprehensive statements expand upon the charge in the detention order by adding: "... because..."

The same approach should be followed in comprehensive statements where the detention order cites misbranding within the meaning of 21 USC Sections 352(f), (j), etc. The comprehensive statement simply summarizes the factual basis of division's case. If this kind of format is used for a comprehensive statement, the general summary of the information which the division will present in support of the detention (21 USC Section 321(x)(3)) need not consist of anything more than a list of documents (FDA 483, EIR, CR, Analyst Worksheet), including affidavits (for example, where the charge is based on the absence of an approved PMA or an IDE — see 21 USC Section 351(f)).
Exhibit 5-17
MODEL HEARING CONFIRMATION LETTER Administrative Detention of Devices

Division Letterhead

Date

Mr. Albert C. Edwards  
President  
Ace Plastic Company  
11124 Railroad Street  
Ogallala, Nebraska 69158

Dear Mr. Edwards:

I am confirming the information listed below discussed during our telephone conversation of today.

The hearing you requested on the appeal of the administrative detention of your devices will be held on _____ at the Kansas City division office, 1009 Cherry Street, Kansas City, MO at 9:00 a.m.

The hearing will be a closed hearing because the proceedings constitute an open investigatory record. This means that only you, your counsel, witnesses, and employees as well as FDA representatives will be allowed to attend.

The regulations on administrative detention 21 CFR 800.55 states that 21 CFR Part 16 will be followed in conducting the hearing, however, the regulations make the following exceptions to Part 16:

1. 21 CFR 16.22(a), concerning the issuance of a separate notice of opportunity for a hearing, is not applicable since the Detention Notice also serves as that notice.

2. 21 CFR 16.22(b), concerning the appeal being sent to the Presiding Officer, is not applicable since the regulations require the appeal to be sent to the Division Director of the division where the devices are located.

3. 21 CFR 16.24(e), concerning not holding the hearing within two (2) days of the appeal, is not applicable because of the short time frames involved. We can hold the hearing within two (2) days of your appeal.

4. 21 CFR 16.42(a), concerning those persons who may act as the Presiding Officer, is not applicable because I have been designated by regulations as the Presiding and Deciding Official.
I am authorized by 21 CFR 10.19 and 21 CFR 16.60(h) to waive, modify, or suspend any provision under 21 CFR Part 16. I am waiving or modifying the following provisions:

1. 21 CFR 16.60(f), which requires the presiding officer to make a recommended decision with statements of reasons to the deciding official, is not applicable because I am the Deciding Official as well as the Presiding Officer in this instance.

2. 21 CFR 16.95(b)(1) and (2) which state that the Administrative Record of a Regulatory Hearing (21 CFR 16.80(a)) is the exclusive record and basis respectively for the decision. The decision will not be based on any material that is not part of the administrative record.

   I am modifying 21 CFR 16.95(b)(1) and (2), however, because the decision will be based in most cases, on all information presented to me prior to or during the hearing. The decision will not be based on the following information or documents if they are not received or completed by me within the time period necessary for me to review or complete them prior to making a decision as required by the Act or regulation:

   a. Information and views I have permitted to be submitted after the hearing, are not part of the official record unless the post hearing submissions and information is submitted within the time specified by me.

   b. Any transcript of the hearing.


3. That part of 21 CFR 16.60(b) is waived which provides that all parties may confront and conduct reasonable cross-examination of any person (except for the presiding officer and counsel for the parties) who makes any statement on the matter at the hearing. Reasonable questioning will be allowed instead. Reference congressional intent: House of Representatives Report no. 94-853 and 21 CFR 16.5 and 16.60(h).

If feasible, at least one (1) day before the hearing, you are to provide the Division Director with written notice of, or a copy of if the Director could not reasonably be expected to obtain a copy, any published articles or written information you intend to present or rely upon at the hearing as required by 21 CFR 16.24(g).

Any written communication you forward or present to me must be sent by you to all other participants to the hearing as required by 21 CFR 16.44(c).

You are requested to provide at the hearing a brief summary of any lengthy documents you intend to present at the hearing.

If you have any additional questions on the procedures I will follow at the hearing, you may contact me prior to the hearing.

Sincerely yours,

MAN-00000#  Page 154 of 172  Revision ##
Exhibit 5-18
MODEL ORDER 1/
Administrative Detention of Devices

Division Letterhead

Date

Order

Ace Plastic Company
11124 Railroad Street
Ogallala, Nebraska 69158

Dear Sir:

Based on my review of the material (make brief reference to the documents used by the presiding officer, (e.g. FDA 483, analyst worksheet, published article, CR, EIR, etc. and testimony) presented in the appeal of Detention Order number ________________, I hereby order that the Detention Order be confirmed (revoked) because there is (insufficient) reason to believe that the devices are adulterated (misbranded) within the meaning of Section _____________ of the Federal Food, Drug, and Cosmetic Act in that _____________________________________________.

Albert Smith
Division Director

1/ Short Form: To be used when separate written decision/report of the hearing must be prepared later, due to short time frame for the order.

2/ Delete "of section ", and "in that _____" if the detention is revoked.
EXHIBIT 5-19
MODEL ORDER OF RETENTION, RECALL, AND/OR DESTRUCTION
ORDER OF RETENTION, RECALL, AND/OR DESTRUCTION

Date Issued: MMM DD, YYYY
Issued To: Name of Responsible Individual
Title
Establishment Name
Address
CITY, ST, ZIP CODE

Dear [NAME],

The Food and Drug Administration (FDA) conducted an inspection of your facility at [ADDRESS if different than above] on [MM DD, YYYY], covering the manufacture of human cell, tissue, and cellular and tissue based products (HCT/Ps) subject to Title 21, Code of Federal Regulations, Part 1271 (21 CFR Part 1271). Our review of the information and records examined and collected during the inspection show that certain HCT/Ps received and distributed by your organization may be in violation of 21 CFR Part 1271, as indicated below:

[List Violations]

- Between [DATE] and [DATE], [QUANTITY/TYPE] HCT/Ps from NNN donors were distributed which were repeatedly reactive for HBsAg/HIV by EIA (21 CFR 1271.85). (Example)

Pursuant to 21 CFR 1271.440, the above referenced HCT/Ps must be:

- Recalled (if distributed), within five (5) working days of receipt of this order, under the supervision of an authorized official of the FDA, and/or
- Destroyed by an acceptable method of disposition, within five (5) working days of receipt of this order, under the supervision of an authorized official of the FDA, or
- Retained until it is recalled, destroyed, the safety of the HCT/P is confirmed, or an agreement is reached with the FDA for its proper disposition under the supervision of an authorized official of the FDA.

[NAME OF FIRM], its owners, employees, and agents shall not distribute or dispose of the HCT/P in any manner except to recall and destroy it consistent with the provisions of the Order. Any other arrangements for ensuring the proper disposition of the HCT/Ps must be agreed upon in writing by [NAME OF FIRM] and an authorized official of the FDA. Such arrangements may include assurance that the HCT/P has been recovered, processed, stored, and distributed in conformance with the attached regulations (21 CFR Part 1271).

All actions taken pursuant to this Order, or otherwise related to the products subject to this Order, shall be taken under the supervision of an authorized Official of the FDA.
Within five (5) working days from the receipt of this Order, the recipient of the written Order or prior possessor of such HCT/P may appeal the Order to the Division Director, [NAME], Division, Food and Drug Administration, [ADDRESS, CITY, STATE, ZIP CODE] and request a hearing on the matter in accordance with 21 CFR Part 16 (copy attached). Such manner of appeal is described in 21 CFR 1271.440(e) of the attached regulations. Failure to request a hearing within the specified time period constitutes a waiver of the right to a hearing.

Please contact [NAME], Compliance Officer, at [TELEPHONE NUMBER], to arrange for supervision of the disposition of the products.

[SIGNATURE BLOCK] Division Director

Attachments (2)
21 CFR Part 1271
21 CFR Part 16

cc: Name and Address of any other HCT/P manufacturer or organization with interest in/jurisdiction over this HCT/P.
HFM-360
HFM-100
HFC-210
HFC-230
GCF-1
Exhibit 5-20: Disqualification Proceedings Flowchart
Exhibit 5-21

Sample NIDPOE

[Date]

CERTIFIED MAIL - RETURN RECEIPT REQUESTED

[Clinical Investigator’s Name and Address]

NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN

Dear [Clinical Investigator’s Name]:

Between [inspection start date] and [inspection ending date], Food and Drug Administration (FDA) (hereafter referred to as the “Agency”) investigators conducted an inspection of the following clinical study in which you participated: [title of clinical study]. This inspection was conducted as part of the FDA’s Bioresearch Monitoring Program that includes inspections designed to monitor the conduct of research involving investigational products.

[For drugs, biologics, devices] Based on our evaluation of information obtained by the Agency, we believe that you have [repeatedly and/or deliberately violated regulations governing the proper conduct] [and] [repeated and/or deliberately submitted false information in a required report] of clinical studies involving [an investigational new drug] [an investigational device] as published under Title 21, Code of Federal Regulations (CFR), Part 312, 812 (copy enclosed).

[For new animal drugs] Based on our evaluation of information obtained by the Agency, we believe that you have [repeatedly and/or deliberately failed to comply with the conditions of the exempting regulations] [and] [repeated and/or deliberately submitted false information in a required report], as published under Title 21, Code of Federal Regulations (CFR), Part 511.1(b) (copy enclosed).

This letter provides you with written notice of the matters complained of and initiates an administrative proceeding, described below, to determine whether you should be disqualified from eligibility to receive test articles as set forth under 21 CFR [312.70, 812.119, 511.1(c)], and disqualified from eligibility to conduct any clinical investigation that supports an application for a research or marketing permit for products regulated by FDA including drugs, biologics, devices, new animal drugs, food, including dietary supplements, that bear a nutrient content claim or a health claim, infant formulas, food and color additives, and tobacco products.
A listing of the violations follows. The applicable provisions of the CFR are cited for each violation.

[Insert List of Violations]

This letter is not intended to be an all-inclusive list of deficiencies with your clinical studies of investigational [name of investigational product]. It is your responsibility to ensure adherence to each requirement of the law and relevant regulations.

On the basis of the above listed violations, FDA asserts that you have [repeatedly and/or deliberately failed to comply with the cited regulations] [for new animal drugs: failed to comply with the conditions of the exempting regulations] [and] [repeatedly and/or deliberately submitted false information] and it proposes that you be disqualified as a clinical investigator.

You may reply to the above stated findings, including an explanation of why you should remain eligible to receive test articles and not be disqualified as a clinical investigator, in a written response or at an informal conference in my office. This procedure is provided for by regulation 21 CFR [312.70, 812.119, 511.1(c)].

Within fifteen (15) working days of receipt of this letter, write or call me at [Center contact phone number] to arrange a conference time or to indicate your intent to respond in writing. Your written response will need to be forwarded within thirty (30) working days of receipt of this letter. Your reply should be sent to [Center contact].

Should you request an informal conference, we ask that you provide us with a full and complete explanation of the violations listed above. You should bring with you all pertinent documents. A representative of your choosing may accompany you. Although the conference is informal, a transcript of the conference will be prepared. If you choose to proceed in this manner, we plan to hold such a conference within thirty (30) days of your request.

At any time during this administrative process, you may enter into a consent agreement with FDA regarding your future use of test articles. Such an agreement would terminate this disqualification proceeding. Enclosed you will find a proposed agreement between you and FDA.

The [center name] (“the Center”) will carefully consider any oral or written response. If your explanation is accepted by the Center, the disqualification proceeding will be terminated. If your written or oral responses to our allegations are unsatisfactory, or we cannot come to terms on a consent agreement, or you do not respond to this notice, you will be offered a regulatory hearing before FDA, pursuant to 21 CFR Part 16 (enclosed) and 21 CFR Part [312, 812, 511.1]. Before such a hearing, FDA will provide you notice of the matters to be considered, including a comprehensive statement of the basis for the decision or action taken or proposed, and a general summary of the information that will be presented by FDA in support of the decision or action. A presiding officer who has not participated in this matter
will conduct the hearing. The Commissioner will determine whether you will remain entitled to receive test articles. You should be aware that neither entry into a consent agreement nor pursuit of a hearing precludes the possibility of a corollary judicial proceeding or administrative remedy concerning these violations.

Sincerely yours,

[Designated Center Signatory + title] Enclosures (2)

[To blind copy electronically, send to the relevant party at firstname.lastname@fda.hhs.gov; for hardcopy distribution at the White Oak (WO) campus, include the building and room numbers]

OCC; WO31/WO32
DFOI; ELEM-1029
OGCP; WO32-5129
ORA, Division of Enforcement; WO32
[Originating Center- Center files and distribution]
[Relevant Division Office- Division Personnel, including the Division Director; Director, Investigations Branch; and the Division Investigator(s)] CDER, OSI; WO51
CBER, BIMO group; HFM-664
CVM, BIMO group; HFV-234
CDRH, BIMO group; WO66, BIMO@cdrh.fda.gov
CFSAN, BIMO group; HFS-205
Exhibit 5-22

Sample Consent Agreement

Agreement with Respect to Use of Investigational Products

The [Center name] (“the Center”) of the United States Food and Drug Administration (FDA) and [clinical investigator’s name] hereby agree as follows:

1. [Clinical investigator’s name] conducted investigational clinical studies, including the following:

2. Between [inspection start date] and [inspection ending date], FDA conducted an investigation of the [number or identify] clinical studies performed by [clinical investigator’s name]. As a result of the investigation, FDA determined that these studies contained sufficiently serious deficiencies to warrant the initiation of proceedings to have [clinical investigator’s name] declared ineligible to receive investigational [article(s)], pursuant to 21 U.S.C. [appropriate section]. Specifically, FDA concluded that [clinical investigator’s name] has:

3. By letter dated [date of NIDPOE letter], the Center provided [clinical investigator’s name] with written notice pursuant to 21 CFR [312.70, 812.119, 511.1(c)], of the foregoing violations and the information which led the Center to believe that [clinical investigator’s name] [violated FDA regulations governing the use of investigational [article]] [has submitted false information in a required report].

4. In the written notice, the Center also invited [Clinical investigator’s name] to attend an informal conference to respond to the allegations or to provide a written response to the allegations.

5. [Clinical investigator’s name] does not wish to contest the above allegations.

6. Beginning on the date this agreement is executed by the parties, [clinical investigator’s name] is not eligible to receive investigational drugs, animal drugs, biologics, devices, or food additives, and is not entitled to conduct any further studies, intended or required for submission to FDA, of investigational articles regulated by FDA. [Clinical investigator’s name] agrees to return to the sponsors of the investigational clinical studies in which [he] [she] participated, any and all remaining investigational articles in [his] [her] possession, custody, or control.

7. [Clinical investigator’s name] waives [his] [her] opportunity to provide a written explanation and [his] [her] opportunity to attend an informal conference, and to any regulatory hearing pursuant to 21 CFR Part 16 and 21 CFR [312.70, 812.119, 511.1(c)].
8. This consent agreement terminates the administrative proceeding in this present matter, which included the opportunity for an informal conference or a written explanation and a regulatory hearing pursuant to 21 CFR Part 16 and 21 CFR [312.70, 812.119, 511.1(c)].

9. This agreement does not preclude the United States or any other Agency or private entity or person from bringing other proceedings relating to the matters underlying this agreement, and FDA’s acceptance of the terms of this agreement may not serve as a defense in any proceedings that the United States or any other Agency or private entity or person may initiate against [clinical investigator’s name].

10. [Clinical investigator’s name] acknowledges that double jeopardy would not attach should the United States bring any criminal charges against [him] [her] in connection with any matter relating to the agreement.

11. By this agreement, [clinical investigator’s name] is disqualified as a clinical investigator. Disqualification pursuant to this agreement has the same legal effect as being disqualified pursuant to 21 CFR [312.70, 812.119, 511.1(c)] after a Part 16 hearing.

12. FDA is authorized to and will notify the sponsors of the investigational clinical studies in which [clinical investigator’s name] has participated as an investigator. FDA also will notify the Institutional Review Board (IRB) with authority to oversee clinical studies performed by [clinical investigator’s name] that [clinical investigator’s name] has entered into this consent agreement. The notifications may contain a statement of the basis for [clinical investigator’s name] not being eligible to receive or study investigational articles and the subsequent steps the sponsors and IRB should take.

13. FDA may make copies of this agreement available to the sponsors, IRBs and other interested parties.

14. With respect to this agreement, [clinical investigator’s name] shall abide by the decisions of FDA; these decisions shall be considered the final decisions by FDA in this matter. FDA’s decisions under this agreement shall be reviewed by any reviewing court, if necessary, under the standards set forth in 5 USC 706(2)(A).

15. [Clinical investigator’s name] name will be added to the list of clinical investigators’ entitled “Clinical Investigators- Disqualification Proceedings”, which is available to the public on the web pursuant to the Freedom of Information Act (5 USC 552).

Agreed to:

[clinical investigator’s name]  Date

[Designated Center signatory + title]  Date
Exhibit 5-23

Sample Notice of Opportunity for Hearing (NOOH)

[Date]

CERTIFIED MAIL- RETURN RECEIPT REQUESTED

[Clinical Investigator’s and/or his/her counsel’s Name & Address]

NOTICE OF OPPORTUNITY FOR HEARING

Dear [Clinical Investigator and/or his/her counsel]:

The [Center name] (“the Center”), Food and Drug Administration (FDA) has information indicating that you [repeatedly and/or deliberately violated Federal regulations] [and] [repeatedly and/or deliberately submitted false information in a required report] in your capacity as an investigator in clinical trials with [an investigational new drug] [investigational new animal drug] [an investigational device]. The [violations] [and] [submission of false information] provide(s) the basis for withdrawal of your eligibility as a clinical investigator to receive [investigational new drugs] [investigational new animal drugs] [investigational devices].

Pursuant to section [312.70, 812.119, 511.1(c)] of Title 21, Code of Federal Regulations (CFR), the Center informed you, by letter dated [date of NIDPOE letter], of the specific matters complained of and offered you an opportunity to respond to them in writing or at an informal conference. That same letter gave you the option of entering into a consent agreement with the Agency, thereby terminating any administrative proceedings against you. [State how the investigator responded to this offer whether by not responding, responding in writing, or attending an informal conference]. [The Center has concluded that your [written explanation] [explanation offered at your informal conference] is unacceptable because it fails to adequately address the violations set forth below. [By failing to respond to the letter of [date of NIDPOE letter], you waived your opportunity to provide a written response or for an informal conference.]

Accordingly, you are being offered an opportunity for a regulatory hearing pursuant to 21 CFR Part 16 and [312.70, 812.119, 511.1(c)], on the question of whether you are eligible to receive [investigational new drugs] [investigational new animal drugs] [investigational devices]. You have the right to be advised and represented by counsel at all times. Any regulatory hearing on this matter will be governed by the regulations in 21 CFR Part 16 and the Agency's guidelines on electronic media coverage of administrative proceedings, 21 CFR Part 10, Subpart C. Enclosed you will find copies of these regulations.

A listing of the specific violations follows. These are the matters that will be considered at the regulatory hearing. Applicable provisions of the CFR are cited for each violation.

[Set out violations in numbered paragraphs. Cite CFR provision for each violation.]
Your request for a hearing should be made, in writing, within ten (10) working days of receipt of this letter and should be directed to [name of DE director], Director, Division of Enforcement, ORA, Telephone [DE phone number], Fax [DE fax number]. If no response to this letter is received by that time, you will be deemed to have waived any right to a regulatory hearing, and a decision in this matter will be made based on the facts available to the Agency. No hearing will be held.

A request for a hearing may not rest upon mere allegations or denials but must present specific facts showing that there is a genuine and substantial issue of fact that warrants a hearing. Pursuant to 21 CFR 16.26, a request for a hearing may be denied, in whole or in part, if the Commissioner or his delegate determines that no genuine and substantial issue of fact had been raised by the material submitted. A hearing will not be granted on issues of policy or law. Written notice of a determination of summary judgment will be provided, explaining the reasons for denial of the hearing.

If you wish to respond but do not desire a hearing, you should contact [Name of DE director] within the time period specified above and send a written response containing your reply. The letter should state that you waive your right to a hearing and that you want a decision on the matter to be based on your written response and other information available to the Agency.

The Agency's offer to enter into a consent agreement attached to the Notice of Initiation of Disqualification Proceedings and Opportunity to Explain letter dated [date of NIDPOE letter] remains available. Entering into a consent agreement would terminate the administrative proceedings, but would not preclude the possibility of a corollary judicial proceeding.

No final decision by FDA has been made at this time on your eligibility to continue to use [investigational new drugs] [investigational new animal drugs] [investigational devices]. Moreover, there will be no prejudgment of this matter if you decline to enter into a consent agreement and decide instead either to request a regulatory hearing or to request that the decision be based on information currently available to the Agency.

Please inform [name of DE director] within ten (10) working days of whether you wish to request a hearing or to have this matter resolved by consent agreement or information available to the Agency.

Sincerely,

[Name]  
Associate Commissioner for Regulatory Affairs

Enclosures (3)
[To blind copy electronically, send to the relevant party at firstname.lastname@fda.hhs.gov;
for hardcopy distribution at the White Oak (WO) campus, include the building and room
numbers] OCC; WO31/WO32
DFOI; ELEM-1029

OGCP; WO32-5129
ORA, Division of Enforcement; WO32
[Originating Center- Center files and distribution]
[Relevant Division Office- Division Personnel, including the Division Director; Director,
Investigations Branch; and the Division Investigator(s)]
CDER, OSI; WO51
CBER, BIMO group; HFM-664
CVM, BIMO group; HFV-234
CDRH, BIMO group; WO66, BIMO@cdrh.fda.gov
CFSAN, BIMO group; HFS-205
Exhibit 5-24

MODEL LETTER GRANTING HEARING – Administrative Detention of Drugs

[Division/DE Letterhead]

Date
Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, MS

RE: Administrative Detention Order DO [insert #]

Dear Mr. Smith:

I am confirming the information discussed during our telephone conversation today regarding the hearing you requested in your appeal of the administrative detention of [insert description of drug] located at [insert location].

I am granting your request for a hearing and providing additional information about the hearing. The hearing you requested will be held on [insert date] at [insert time] at the [insert Division Office, street address, city, state, and Zip Code].

The hearing will be a closed hearing because the proceedings constitute an open investigatory record (21 CFR 16.60(a)). This means that only you, your counsel, witnesses, and employees as well as FDA representatives will be allowed to attend.

I am authorized by 21 CFR 10.19 and 21 CFR 16.60(h) to waive, modify, or suspend any provision under 21 CFR part 16. I am modifying 21 CFR 16.60(b), which provides that all parties may confront and conduct reasonable cross-examination of any person (except for the presiding officer and counsel for the parties) who makes any statement on the matter at the hearing. Reasonable questioning will be allowed instead.

If feasible, at least one (1) day before the hearing, you are to provide the Division Director with written notice of, or a copy of, if the Division Director could not reasonably be expected to obtain a copy, any published articles or written information that you intend to present or rely upon at the hearing, as required by 21 CFR 16.24(g). You may provide this information by facsimile: [insert number], electronically: [insert e-mail], or courier: [insert name and address of Division Director].

Any written communication you forward or present to me must be sent by you to all other participants to the hearing as required by 21 CFR 16.44(c).
You are requested to provide at the hearing a brief summary of any lengthy documents you intend to present at the hearing.

If you have any additional questions on the procedures I will follow at the hearing, you may contact me at [insert phone number] prior to the hearing.

Sincerely yours,

[Presiding Officer]
Exhibit 5-25

MODEL LETTER DENYING HEARING – Administrative Detention of Drugs

(Division/OE Letterhead)

Date

Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, USA

RE: Administrative Detention Order DO [insert #]

Dear Mr. Smith:

This is a follow-up to our telephone conversation today regarding the hearing you requested as part of your appeal of the administrative detention of [insert description of drug] located at [insert location].

I am denying your request for a hearing because you have not raised a genuine and substantial issue of fact (21 CFR 16.26(a)). Specifically, [insert reason why no genuine and substantial issue of fact was raised by the appellant].

Sincerely yours,

Presiding Officer
Exhibit 5-26

MODEL LETTER – FINAL DECISION ON APPEAL OF ADMINISTRATIVE DETENTION ORDER – CONFIRMATION

Administrative Detention of Drugs

[Division/OE Letterhead]

Date

Decision on Appeal – Confirmation

Administrative Detention Order DO [insert #]

Mr. John E. Smith
XYZ, Inc.
123 Smith Lane
Anywhere, MS

Dear Mr. Smith:

I am confirming the administrative detention order for [insert description of drug] located at [insert location] because [insert reason why confirming detention].

[If information that supports the administrative detention is, in whole or in part, CLASSIFIED information, insert the following:]
   My decision is based [in whole or in part] on classified information.

[If information that supports the administrative detention is not CLASSIFIED information, insert the following:]
   My decision is based on information you submitted in your appeal [and information presented by all parties at the hearing on the appeal].

The administrative detention is effective until [insert date], unless FDA issues a detention termination notice prior to that date. It is a prohibited act under section 301(r) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 331(r), to move a detained drug in violation of a detention order under section 304(g).

Sincerely yours,

[Presiding Officer]
Exhibit 5-27

MODEL LETTER – FINAL DECISION ON APPEAL OF ADMINISTRATIVE DETENTION ORDER – REVOCATION

Administrative Detention of Drugs [Division/OE Letterhead]

Date

Decision on Appeal – Revocation Administrative Detention Order DO [insert #]

Mr. John E. Smith XYZ, Inc.
123 Smith Lane
Anywhere, MS

Dear Mr. Smith:

I am revoking the administrative detention order for [insert description of drug] located at [insert location] because [insert why the order is being revoked]. The administrative detention is terminated as of this date and the drug is released. You may remove the labels and tags relating to the detention and return the tags to the Division Director.

[If information utilized to support the administrative detention is, in whole or in part, CLASSIFIED information, insert the following:] My decision is based [in whole or in part] on classified information.

[If information utilized to support the administrative detention is not CLASSIFIED information, insert the following:] My decision is based on information you submitted in your appeal [and at the hearing on the appeal]. Thus, FDA no longer has reason to believe the drug is adulterated or misbranded.

Sincerely,

[Presiding Officer]

MAN-00000# Page 172 of 172 Revision ##